BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dörner T, Doria A. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771-1782. [PMID: 22851469 DOI: 10.1136/annrheumdis-2012-201940] [Cited by in Crossref: 694] [Cited by in F6Publishing: 726] [Article Influence: 69.4] [Reference Citation Analysis]
Number Citing Articles
1 Chen YY, Sun X, Huang W, He FF, Zhang C. Therapeutic apheresis in kidney diseases: an updated review. Ren Fail 2022;44:842-57. [PMID: 35723077 DOI: 10.1080/0886022X.2022.2073892] [Reference Citation Analysis]
2 Sakamoto AP, Silva CA, Islabão AG, Novak GV, Molinari B, Nogueira PK, Pereira RMR, Saad-magalhães C, Clemente G, Piotto DP, Aikawa NE, Pitta AC, Trindade VC, Appenzeller S, Carvalho LM, Rabelo-junior CN, Fonseca AR, Sztajnbok FR, Santos MC, Bica BE, Sena EG, Moraes AJ, Fraga MM, Robazzi TC, Spelling PF, Scheibel IM, Cavalcanti AS, Matos EN, Guimarães LJ, Santos FP, Mota LMH, Bonfá E, Terreri MT, for the Brazilian Childhood-onset Systemic Lupus Erythematosus Registry Group. Chronic kidney disease in patients with childhood-onset systemic lupus erythematosus. Pediatr Nephrol 2022. [DOI: 10.1007/s00467-022-05811-y] [Reference Citation Analysis]
3 Han Y, Lu X, Xiao S, Qin J, Zheng L, Feng Y, Cai Y, Qiu R, Huang Q, Yang M. Association between serum uric acid level and systemic lupus erythematosus kidney outcome: An observational study in Southern Chinese population and a meta-analysis. Lupus 2022. [DOI: 10.1177/09612033221140267] [Reference Citation Analysis]
4 Cai T, Zhao J, Yang Y, Jiang Y, Zhang J. Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: A systematic review and meta-analysis of cohort studies. Lupus 2022. [DOI: 10.1177/09612033221129774] [Reference Citation Analysis]
5 Balevic SJ, Randell R, Weiner D, Beard C, Schanberg LE, Hornik CP, Cohen-wolkowiez M, Gonzalez D. Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial. Lupus Sci Med 2022;9:e000811. [DOI: 10.1136/lupus-2022-000811] [Reference Citation Analysis]
6 Bobot M, Jourde-chiche N. Lupus nephritis: Is it necessary to systematically repeat kidney biopsy? La Revue de Médecine Interne 2022. [DOI: 10.1016/j.revmed.2022.11.002] [Reference Citation Analysis]
7 Khandelwal P, Govindarajan S, Bagga A. Management and outcomes in children with lupus nephritis in the developing countries. Pediatr Nephrol 2022. [PMID: 36255555 DOI: 10.1007/s00467-022-05769-x] [Reference Citation Analysis]
8 Lu W, Tian F, Ma J, Zhong Y, Liu Z, Xue L. Diagnostic accuracy of the European League against rheumatism/American College of Rheumatology-2019 versus the Systemic Lupus International Collaborating Clinics-2012 versus the ACR-1997 classification criteria in adult systemic lupus erythematosus: A systematic review and meta-analysis. Front Immunol 2022;13:1023451. [DOI: 10.3389/fimmu.2022.1023451] [Reference Citation Analysis]
9 Concannon A, Wong W, Han DY. The long-term outcome of New Zealand Maori and Pacific Island children diagnosed with childhood onset lupus nephritis. Lupus 2022;:9612033221128437. [PMID: 36168149 DOI: 10.1177/09612033221128437] [Reference Citation Analysis]
10 Yang L, Ren G, Chen W, Zhao L, Guo J, Ge Y, Zeng C, Hu W, Huang X, Zhang H. Long-term follow-up of autologous peripheral blood hematopoietic stem cell transplantation for refractory lupus nephritis—a series study of 20 patients. Lupus. [DOI: 10.1177/09612033221126848] [Reference Citation Analysis]
11 Sada K, Kurita N, Noma H, Matsuki T, Quasny H, Levy RA, Jones-leone AR, Gairy K, Yajima N. MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT. Lupus Sci Med 2022;9:e000746. [DOI: 10.1136/lupus-2022-000746] [Reference Citation Analysis]
12 Kapsia E, Marinaki S, Michelakis I, Liapis G, Sfikakis PP, Boletis J, Tektonidou MG. Predictors of Early Response, Flares, and Long-Term Adverse Renal Outcomes in Proliferative Lupus Nephritis: A 100-Month Median Follow-Up of an Inception Cohort. JCM 2022;11:5017. [DOI: 10.3390/jcm11175017] [Reference Citation Analysis]
13 Cajamarca-Barón J, Buitrago-Bohórquez J, Orozco JEM, Segura O, Guavita-Navarro D, Gallego-Cardona L, Cubides H, Arredondo AM, Escobar A, Rojas-Villarraga A. Efficacy and safety of intravenous immunoglobulin in patients with lupus nephritis: A systematic review of the literature. Autoimmun Rev 2022;:103182. [PMID: 36028194 DOI: 10.1016/j.autrev.2022.103182] [Reference Citation Analysis]
14 Yu C, Li P, Dang X, Zhang X, Mao Y, Chen X. Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun 2022;:102871. [PMID: 35999111 DOI: 10.1016/j.jaut.2022.102871] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Ozdemir A, Baran E, Kutu M, Celik S, Yılmaz M. Could systemic immune inflammation index be a new parameter for diagnosis and disease activity assessment in systemic lupus erythematosus? Int Urol Nephrol 2022. [PMID: 35918626 DOI: 10.1007/s11255-022-03320-3] [Reference Citation Analysis]
16 Du K, Zhang X, Feng J, Zhong S, Qi J, Lin Z. Renal response and its predictive factors of lupus nephritis: a 2-year real-world study of 56 hospital-based patients. Clin Rheumatol 2022. [PMID: 35854166 DOI: 10.1007/s10067-022-06258-0] [Reference Citation Analysis]
17 Wakiya R, Ueeda K, Shimada H, Nakashima S, Kameda T, Miyatake N, Kato M, Miyagi T, Sugihara K, Mizusaki M, Mino R, Kadowaki N, Dobashi H. Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease. Clin Rheumatol 2022. [PMID: 35849246 DOI: 10.1007/s10067-022-06282-0] [Reference Citation Analysis]
18 Mao Z, Tan Y, Tao J, Li L, Yu F, Zhao M. mTORC1 activation induced proximal tubular damage via the pentose phosphate pathway in lupus nephritis. Free Radic Biol Med 2022:S0891-5849(22)00492-0. [PMID: 35863688 DOI: 10.1016/j.freeradbiomed.2022.07.010] [Reference Citation Analysis]
19 Bertsias G. Recommendations for Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America 2022. [DOI: 10.1016/j.rdc.2022.05.001] [Reference Citation Analysis]
20 Ogbu EA, Brunner HI. Treatment Guidelines in Pediatric Rheumatic Diseases. Rheumatic Disease Clinics of North America 2022. [DOI: 10.1016/j.rdc.2022.03.007] [Reference Citation Analysis]
21 Jourde-Chiche N, Costedoat-Chalumeau N, Baumstarck K, Loundou A, Bouillet L, Burtey S, Caudwell V, Chiche L, Couzi L, Daniel L, Deligny C, Dussol B, Faguer S, Gobert P, Gondran G, Huart A, Hummel A, Kalbacher E, Karras A, Lambert M, Le Guern V, Lebourg L, Loubière S, Maillard-Lefebvre H, Maurier F, Pha M, Queyrel V, Remy P, Sarrot-Reynauld F, Verhelst D, Hachulla E, Amoura Z, Daugas E; WIN-Lupus study group. Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. Ann Rheum Dis 2022:annrheumdis-2022-222435. [PMID: 35725295 DOI: 10.1136/annrheumdis-2022-222435] [Reference Citation Analysis]
22 Wakiya R, Ueeda K, Nakashima S, Shimada H, Kameda T, Mansour MMF, Kato M, Miyagi T, Sugihara K, Mizusaki M, Mino R, Kadowaki N, Dobashi H. Effect of add-on hydroxychloroquine therapy on serum proinflammatory cytokine levels in patients with systemic lupus erythematosus. Sci Rep 2022;12:10175. [PMID: 35715525 DOI: 10.1038/s41598-022-14571-6] [Reference Citation Analysis]
23 Duran E, Yıldırım T, Taghiyeva A, Bilgin E, Arıcı M, Sağlam EA, Özen S, Üner M, Erdem Y, Kalyoncu U, Ertenli AI. Differences and similarities of proliferative and non-proliferative forms of biopsy-proven lupus nephritis: Single centre, cross-disciplinary experience. Lupus 2022;:9612033221106305. [PMID: 35658643 DOI: 10.1177/09612033221106305] [Reference Citation Analysis]
24 Sciascia S, Barinotti A, Radin M, Cecchi I, Menegatti E, Terzolo E, Rossi D, Baldovino S, Fenoglio R, Roccatello D. Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience. JCM 2022;11:2977. [DOI: 10.3390/jcm11112977] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Molina-ríos S, Quintana-lópez G, Aroca G, Egea E, Iglesias-gamarra A. Association of anti-C1q antibodies, adiponectin and HLA II genotype in Colombian patients with systemic lupus erythematosus with lupus nephritis. Revista Colombiana de Reumatología 2022. [DOI: 10.1016/j.rcreu.2022.03.004] [Reference Citation Analysis]
26 Vollbach K, Schuetz C, Hedrich CM, Speth F, Mönkemöller K, Brunner J, Neudorf U, Rietschel C, Hospach A, Kallinich T, Hinze C, Wagner N, Tönshoff B, Weber LT, Latta K, Thumfart J, Bald M, Wiemann D, Zappel H, Tenbrock K, Haffner D. Working Towards a Treat-to-Target Protocol in Juvenile Proliferative Lupus Nephritis – A Survey of Pediatric Rheumatologists and Nephrologists in Germany and Austria. Front Pediatr 2022;10:851998. [DOI: 10.3389/fped.2022.851998] [Reference Citation Analysis]
27 Gallagher KL, Patel P, Beresford MW, Smith EMD. What Have We Learnt About the Treatment of Juvenile-Onset Systemic Lupus Erythematous Since Development of the SHARE Recommendations 2012? Front Pediatr 2022;10:884634. [DOI: 10.3389/fped.2022.884634] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Kapsia E, Marinaki S, Michelakis I, Liapis G, Sfikakis PP, Tektonidou MG, Boletis J. New Insights Into an Overlooked Entity: Long-Term Outcomes of Membranous Lupus Nephritis From a Single Institution Inception Cohort. Front Med 2022;9:809533. [DOI: 10.3389/fmed.2022.809533] [Reference Citation Analysis]
29 Huang F, Huang J, Liu Y, Li J, Rajakani K. Effect of Rituximab on 24-Hour Urine Protein and Albumin or Renal Function in Patients with Glomerulonephritis. Journal of Healthcare Engineering 2022;2022:1-8. [DOI: 10.1155/2022/6412740] [Reference Citation Analysis]
30 Murphy L. Systemic lupus erythematosus: overview, management and COVID-19. Br J Nurs 2022;31:348-355. [DOI: 10.12968/bjon.2022.31.7.348] [Reference Citation Analysis]
31 Ngamjanyaporn P, Worawichawong S, Pisitkun P, Khiewngam K, Kantachuvesiri S, Nongnuch A, Assanatham M, Sathirapongsasuti N, Kitiyakara C. Predicting treatment response and clinicopathological findings in lupus nephritis with urine epidermal growth factor, monocyte chemoattractant protein-1 or their ratios. PLoS ONE 2022;17:e0263778. [DOI: 10.1371/journal.pone.0263778] [Reference Citation Analysis]
32 Jeon H, Lee J, Ju JH, Kim WU, Park SH, Moon SJ, Kwok SK. Chronic kidney disease in Korean patients with lupus nephritis: over a 35-year period at a single center. Clin Rheumatol 2022. [PMID: 35178647 DOI: 10.1007/s10067-021-06030-w] [Reference Citation Analysis]
33 Tanaka Y, Nakayamada S, Yamaoka K, Ohmura K, Yasuda S. Rituximab in the Real-World Treatment of Lupus Nephritis: A Retrospective Cohort Study in Japan. Mod Rheumatol 2022:roac007. [PMID: 35165714 DOI: 10.1093/mr/roac007] [Reference Citation Analysis]
34 Huang T, Xie S, Ding L, Zeng X, Luo H. Identification of novel classes for patients with lupus nephritis using two-step cluster model. Wien Klin Wochenschr 2022. [PMID: 35038004 DOI: 10.1007/s00508-021-02001-y] [Reference Citation Analysis]
35 Islam M, Ali A, Ahmed M. Efficacy and short term outcome of intravenous cyclophosphamide therapy in children with lupus nephritis: A tertiary hospital study of Bangladesh. Paediatr Nephrol J Bangladesh 2022;7:53. [DOI: 10.4103/pnjb.pnjb_18_22] [Reference Citation Analysis]
36 de Jesús NR, Lacerda MI, dos Santos FC, Levy RA, de Jesús GR. Rheumatological Diseases. Perinatology 2022. [DOI: 10.1007/978-3-030-83434-0_28] [Reference Citation Analysis]
37 Chowdhary P, Kale S, Sharma R. To study the efficacy and safety of tacrolimus and azathioprine combination as an induction therapy for proliferative lupus nephritis. J Nephrol Soc 2022;1:19. [DOI: 10.4103/jtns.jtns_18_22] [Reference Citation Analysis]
38 Miller-hodges E, Bellamy COC, Kluth DC, Dhaun N. Systemic Lupus Erythematosus, Antiphospholipid Syndrome and the Kidney. Primer on Nephrology 2022. [DOI: 10.1007/978-3-030-76419-7_28] [Reference Citation Analysis]
39 Choi SJ, Ahn SM, Oh JS, Hong S, Lee C, Yoo B, Kim Y. Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea. J Rheum Dis 2022;29:22-32. [DOI: 10.4078/jrd.2022.29.1.22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 da Silva AQB, de Almeida JB, Kirsztajn GM. Artificial Intelligence in Nephrology. Innovations in Nephrology 2022. [DOI: 10.1007/978-3-031-11570-7_15] [Reference Citation Analysis]
41 Bandhan IH, Islam MN, Ahmad HI, Ahmedullah AK. Outcome of low-dose prednisolone use for the induction of remission in lupus nephritis patients. Int J Rheum Dis 2021. [PMID: 34894070 DOI: 10.1111/1756-185X.14265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Chi S, Xue J, Chen X, Liu X, Ji Y. Correlation of plasma and urine Wnt5A with the disease activity and cutaneous lesion severity in patients with systemic lupus erythematosus. Immunol Res 2021. [PMID: 34860323 DOI: 10.1007/s12026-021-09253-w] [Reference Citation Analysis]
43 Santacruz JC, Mantilla MJ, Ballesteros JG, Bello JM, Londoño J. Actualización de las terapias disponibles para la nefritis lúpica refractaria. Revista Colombiana de Reumatología 2021. [DOI: 10.1016/j.rcreu.2021.10.004] [Reference Citation Analysis]
44 Yap DY, Li PH, Tang C, So BY, Kwan LP, Chan GC, Lau CS, Chan TM. Long-Term Results of Triple Immunosuppression With Tacrolimus Added to Mycophenolate and Corticosteroids in the Treatment of Lupus Nephritis. Kidney International Reports 2021. [DOI: 10.1016/j.ekir.2021.12.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
45 Shabaka A, Landaluce-triska E, Sánchez-álvarez JE, Fernández-juárez G. Changing trends in presentation and indications of biopsy in lupus nephritis: data from the Spanish Registry of Glomerulonephritis. Clinical Kidney Journal 2021. [DOI: 10.1093/ckj/sfab236] [Reference Citation Analysis]
46 Jeon H, Lee J, Ju JH, Kim WU, Park SH, Moon SJ, Kwok SK. Renal function deterioration is an independent mortality determinant in Koreans diagnosed with lupus nephritis. Lupus 2021;30:1896-905. [PMID: 34809514 DOI: 10.1177/09612033211038823] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Teng S, Tian Y, Luo N, Zheng Q, Shao M, Li L. Efficacy and safety of an anti-CD20 monoclonal antibody, rituximab, for lupus nephritis: A meta-analysis. Int J Rheum Dis 2021. [PMID: 34811947 DOI: 10.1111/1756-185X.14240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Villa P, Márquez-hernández JD, Duque V, Muñoz-grajales C, Pinto-peñaranda LF, Mesa-navas MA, Velásquez-franco CJ. Hydroxychloroquine use and blood pressure below 130/80 are associated with remission in lupus nephritis: A cohort study. Revista Colombiana de Reumatología 2021;28:109-115. [DOI: 10.1016/j.rcreu.2021.03.010] [Reference Citation Analysis]
49 Zhao Z, Xu X, Jiang H, Foster KW, Jia Z, Wei X, Chen N, Goldring SR, Crow MK, Wang D. Preclinical Dose-Escalation Study of ZSJ-0228, a Polymeric Dexamethasone Prodrug, in the Treatment of Murine Lupus Nephritis. Mol Pharm 2021;18:4188-97. [PMID: 34569234 DOI: 10.1021/acs.molpharmaceut.1c00567] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Zheng Z, Zhang X, Ding J, Zhang D, Cui J, Fu X, Han J, Zhu P. Deep Learning-Based Artificial Intelligence System for Automatic Assessment of Glomerular Pathological Findings in Lupus Nephritis. Diagnostics (Basel) 2021;11:1983. [PMID: 34829330 DOI: 10.3390/diagnostics11111983] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
51 Zhai P, Huang Y, Yue S, Yang X, Luo J, Zhang Y, Mei X, Bi L, Zhai W, Ren X, Yang Y, Zheng X, Yamamoto T. Diagnostic efficacy and influence factors of urinary protein/creatinine ratio replacing 24-h urine protein as an evaluator of proteinuria in children. Int Urol Nephrol 2021. [PMID: 34668110 DOI: 10.1007/s11255-021-03021-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Takeuchi T, Hashimoto H, Matsumoto M. Long-term safety and effectiveness of mycophenolate mofetil in adults with lupus nephritis: a real-world study in Japan. Mod Rheumatol 2021:roab076. [PMID: 34897492 DOI: 10.1093/mr/roab076] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Suzuki E, Yashiro-Furuya M, Temmoku J, Fujita Y, Matsuoka N, Hazama M, Asano T, Sato S, Kobayashi H, Watanabe H, Kanno T, Migita K. Comparison of renal remission and relapse-free rate in initial- and delayed-onset lupus nephritis. Int J Rheum Dis 2021;24:1500-9. [PMID: 34636151 DOI: 10.1111/1756-185X.14228] [Reference Citation Analysis]
54 Martínez Ávila MC, Almanza Hurtado AJ, Rodríguez Blanco JD, Rodríguez Yánez T, Daza Arnedo R, Aroca Martínez G. Nefropatía lúpica: una puesta al día. Revista Colombiana de Reumatología 2021. [DOI: 10.1016/j.rcreu.2021.06.008] [Reference Citation Analysis]
55 Wang Y, Xiao S, Xia Y, Wang H. The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies. Clin Rev Allergy Immunol 2021. [PMID: 34542806 DOI: 10.1007/s12016-021-08898-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Gilbert M, Goilav B, Hsu JJ, Nietert PJ, Meidan E, Chua A, Ardoin SP, Wenderfer SE, von Scheven E, Ruth NM; Pediatric Nephrology and Rheumatology Collaborative Group, the Childhood Arthritis and Rheumatology Research Alliance, and the American Society for Pediatric Nephrology. Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE. Pediatr Rheumatol Online J 2021;19:137. [PMID: 34461932 DOI: 10.1186/s12969-021-00627-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
57 Gupta L, Aggarwal R, Naveen R, Lawrence A, Zanwar A, Misra DP, Agarwal V, Misra R, Aggarwal A. High Prevalence of Active Tuberculosis in Adults and Children with Idiopathic Inflammatory Myositis as Compared with Systemic Lupus Erythematosus in a Tuberculosis Endemic Country: Retrospective Data Review from a Tertiary Care Centre in India. Mediterr J Rheumatol 2021;32:134-42. [PMID: 34447909 DOI: 10.31138/mjr.32.2.134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
58 Zickert A, Lannfelt K, Schmidt Mende J, Sundelin B, Gunnarsson I. Resorption of immune deposits in membranous lupus nephritis following rituximab vs conventional immunosuppressive treatment. Rheumatology (Oxford) 2021;60:3443-50. [PMID: 33367774 DOI: 10.1093/rheumatology/keaa788] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
59 Faustini F, Dunn N, Kharlamova N, Ryner M, Bruchfeld A, Malmström V, Fogdell-Hahn A, Gunnarsson I. First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis. Arthritis Res Ther 2021;23:211. [PMID: 34389040 DOI: 10.1186/s13075-021-02589-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
60 Sawhney S, Agarwal M. Rituximab use in pediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort. Lupus 2021;:9612033211034567. [PMID: 34315295 DOI: 10.1177/09612033211034567] [Reference Citation Analysis]
61 Gururani S, Devarasetti PK, Uppin M, Rajasekhar L. Treatment outcomes in refractory lupus nephritis: Data from an observational study. Lupus 2021;:9612033211033980. [PMID: 34304627 DOI: 10.1177/09612033211033980] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Nosadini M, Thomas T, Eyre M, Anlar B, Armangue T, Benseler SM, Cellucci T, Deiva K, Gallentine W, Gombolay G, Gorman MP, Hacohen Y, Jiang Y, Lim BC, Muscal E, Ndondo A, Neuteboom R, Rostásy K, Sakuma H, Sharma S, Tenembaum SN, Van Mater HA, Wells E, Wickstrom R, Yeshokumar AK, Irani SR, Dalmau J, Lim M, Dale RC. International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm 2021;8:e1052. [PMID: 34301820 DOI: 10.1212/NXI.0000000000001052] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 22.0] [Reference Citation Analysis]
63 Nguyen Thi N, Tran Minh D, Nguyen Thu H, Luong Thi P, Thai Thien N, Pho Hong D, Nguyen Trung K, Tran Viet T, Do Q, Le Viet T. Association Between Hypoalbuminemia, Degree of Proteinuria, and Lupus Nephritis Class: A Single-Center Cross-sectional Biopsy Study. Nephro-Urol Mon 2021;13. [DOI: 10.5812/numonthly.112883] [Reference Citation Analysis]
64 Morell M, Pérez-Cózar F, Marañón C. Immune-Related Urine Biomarkers for the Diagnosis of Lupus Nephritis. Int J Mol Sci 2021;22:7143. [PMID: 34281193 DOI: 10.3390/ijms22137143] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
65 Okamoto M, Kitamura M, Sato S, Fujikawa K, Horai Y, Matsuoka N, Tsuboi M, Nonaka F, Shimizu T, Koga T, Kawashiri SY, Iwamoto N, Tamai M, Nakamura H, Origuchi T, Nishino T, Kawakami A, Ichinose K. Life prognosis and renal relapse after induction therapy in Japanese patients with proliferative and pure membranous lupus nephritis. Rheumatology (Oxford) 2021;60:2333-41. [PMID: 33166998 DOI: 10.1093/rheumatology/keaa599] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
66 Gisca E, Duarte L, Farinha F, Isenberg DA. Assessing outcomes in a lupus nephritis cohort over a 40-year period. Rheumatology (Oxford) 2021;60:1814-22. [PMID: 33111137 DOI: 10.1093/rheumatology/keaa491] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
67 Oishi Y, Ikeuchi H, Hamatani H, Nakasatomi M, Sakairi T, Kaneko Y, Maeshima A, Iwase A, Hiromura K. Pregnancy outcomes in patients with systemic lupus erythematosus with or without a history of lupus nephritis. Clin Exp Nephrol 2021;25:835-43. [PMID: 34165663 DOI: 10.1007/s10157-020-02017-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Kostopoulou M, Fanouriakis A, Cheema K, Boletis J, Bertsias G, Jayne D, Boumpas DT. Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations. RMD Open 2020;6:e001263. [PMID: 32699043 DOI: 10.1136/rmdopen-2020-001263] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
69 Sánchez-cubías SM, Guaracha-basañez GA, Sandoval-flores MG, Domínguez-quintana M, Romero-díaz J. The value of repeat kidney biopsy in lupus nephritis. A systematic review. Revista Colombiana de Reumatología 2021;28:44-52. [DOI: 10.1016/j.rcreu.2021.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Fayed A, Soliman A, Elgohary R. Measuring Serum Sclerostin in Egyptian Patients With Systemic Lupus Erythematosus and Evaluating Its Effect on Disease Activity: A Case-Control Study. J Clin Rheumatol 2021;27:161-7. [PMID: 31895114 DOI: 10.1097/RHU.0000000000001256] [Reference Citation Analysis]
71 Nie P, Hu L, Li B, Lou Y, Luo M, Wang Y, Lu X, Luo P. Relationship between hyperuricemia and serositis in patients with lupus nephritis. Int Urol Nephrol 2021. [PMID: 33970417 DOI: 10.1007/s11255-021-02873-z] [Reference Citation Analysis]
72 Roccatello D, Sciascia S, Fenoglio R, Rossi D. A new challenge for lupus nephritis management: Induction therapy without immunosuppressive maintenance regimen. Autoimmun Rev 2021;20:102844. [PMID: 33971336 DOI: 10.1016/j.autrev.2021.102844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
73 Aringer M, Petri M. New classification criteria for systemic lupus erythematosus. Curr Opin Rheumatol 2020;32:590-6. [PMID: 32925250 DOI: 10.1097/BOR.0000000000000740] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
74 Sandri G, Manzini CU, Salvarani C. On- and off-label use of rituximab in rheumatic diseases. Beyond Rheumatol 2021;3. [DOI: 10.4081/br.2021.56] [Reference Citation Analysis]
75 Tailliar M, Schanstra JP, Dierckx T, Breuil B, Hanouna G, Charles N, Bascands JL, Dussol B, Vazi A, Chiche L, Siwy J, Faguer S, Daniel L, Daugas E, Jourde-Chiche N, On Behalf Of The Groupe Coopératif Sur le Lupus Rénal Gclr. Urinary Peptides as Potential Non-Invasive Biomarkers for Lupus Nephritis: Results of the Peptidu-LUP Study. J Clin Med 2021;10:1690. [PMID: 33920017 DOI: 10.3390/jcm10081690] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
76 Li Y, Xu S, Xu G. Comparison of Different Uses of Cyclophosphamide in Lupus Nephritis: A Meta-Analysis of Randomized Controlled Trials. Endocr Metab Immune Disord Drug Targets 2020;20:687-702. [PMID: 31702519 DOI: 10.2174/1871530319666191107110420] [Reference Citation Analysis]
77 Jin Z, Wang F, Pan W, Liu L, Wu M, Hu H, Ding X, Wei H, Zou Y, Qian X, Wang M, Wu J, Tao J, Tan J, Da Z, Zhang M, Li J, Feng X, Sun L. Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus. Rheumatology (Oxford) 2021;60:1774-83. [PMID: 33099642 DOI: 10.1093/rheumatology/keaa485] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
78 Sato R, Imaizumi T, Aizawa T, Watanabe S, Tsugawa K, Kawaguchi S, Seya K, Matsumiya T, Tanaka H. Inhibitory effect of anti-malarial agents on the expression of proinflammatory chemokines via Toll-like receptor 3 signaling in human glomerular endothelial cells. Ren Fail 2021;43:643-50. [PMID: 33820486 DOI: 10.1080/0886022X.2021.1908901] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
79 Campos LMDA, Carvalho LMD, Brufatto MZ. Atualização terapêutica no LES juvenil – nefrite. Rev Paul Reumatol 2021. [DOI: 10.46833/reumatologiasp.2021.20.1.6-15] [Reference Citation Analysis]
80 Park J, Jang W, Park HS, Park KH, Kwok SK, Park SH, Oh EJ. Cytokine clusters as potential diagnostic markers of disease activity and renal involvement in systemic lupus erythematosus. J Int Med Res 2020;48:300060520926882. [PMID: 32489126 DOI: 10.1177/0300060520926882] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
81 Gomes MF, Mardones C, Xipell M, Blasco M, Solé M, Espinosa G, García-Herrera A, Cervera R, Quintana LF. The extent of tubulointerstitial inflammation is an independent predictor of renal survival in lupus nephritis. J Nephrol 2021. [PMID: 33721269 DOI: 10.1007/s40620-021-01007-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
82 Lebreton V, Bourcier B, Cosson K, Lagarce F, Spiesser-robelet L, Vrignaud S. New liquid oral formulations of hydroxychloroquine: a physicochemical stability study. Pharmaceutical Technology in Hospital Pharmacy 2021;6:20200013. [DOI: 10.1515/pthp-2020-0013] [Reference Citation Analysis]
83 Sun K, Corneli AL, Dombeck C, Swezey T, Rogers JL, Criscione-Schreiber LG, Sadun RE, Eudy AM, Doss J, Bosworth HB, Clowse M. Barriers to taking medications for systemic lupus erythematosus: a qualitative study of racial minority patients, lupus providers, and clinic staff. Arthritis Care Res (Hoboken) 2021. [PMID: 33662174 DOI: 10.1002/acr.24591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Szymanik-Grzelak H, Barabasz M, Wikiera-Magott I, Banaszak B, Wieczorkiewicz-Płaza A, Bieniaś B, Drożynska-Duklas M, Tkaczyk M, Pańczyk-Tomaszewska M. Retrospective analysis of clinical and pathomorphological features of lupus nephritis in children. Adv Med Sci 2021;66:128-37. [PMID: 33545446 DOI: 10.1016/j.advms.2021.01.004] [Reference Citation Analysis]
85 Das U, Patel R, Guditi S, Taduri G. Correlation between the clinical remission and histological remission in repeat biopsy findings of quiescent proliferative lupus nephritis. Lupus 2021;30:876-83. [PMID: 33611965 DOI: 10.1177/0961203321995251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
86 Kozlovskaya NL, Solovyev SK, Aseeva EA, Popkova TV, Panafidina TA, Nasonov EL, Lila AM, Mesnyankina AA, Nikishina NY. The 2019 updated EULAR/ERA-EDTA guidelines for the management of lupus nephritis. Expert comments. Part II. Sovremennaâ revmatologiâ 2021;15:9-14. [DOI: 10.14412/1996-7012-2021-1-9-14] [Reference Citation Analysis]
87 Roldan CA, Sibbitt WL Jr, Greene ER, Qualls CR, Jung RE. Libman-Sacks endocarditis and associated cerebrovascular disease: The role of medical therapy. PLoS One 2021;16:e0247052. [PMID: 33592060 DOI: 10.1371/journal.pone.0247052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
88 Nie Y, Zhao L, Zhang X. B Cell Aberrance in Lupus: the Ringleader and the Solution. Clin Rev Allergy Immunol 2021. [PMID: 33534064 DOI: 10.1007/s12016-020-08820-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
89 Roccatello D, Sciascia S, Naretto C, Alpa M, Fenoglio R, Ferro M, Quattrocchio G, Rubini E, Rahbani E, Rossi D. A Prospective Study on Long-Term Clinical Outcomes of Patients With Lupus Nephritis Treated With an Intensified B-Cell Depletion Protocol Without Maintenance Therapy. Kidney Int Rep 2021;6:1081-7. [PMID: 33912758 DOI: 10.1016/j.ekir.2021.01.027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
90 Rong Y, Jun H, Kiang TKL. Population pharmacokinetics of mycophenolic acid in paediatric patients. Br J Clin Pharmacol 2021;87:1730-57. [PMID: 33118201 DOI: 10.1111/bcp.14590] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
91 Parodis I, Adamichou C, Aydin S, Gomez A, Demoulin N, Weinmann-Menke J, Houssiau FA, Tamirou F. Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. Rheumatology (Oxford) 2020;59:3424-34. [PMID: 32353879 DOI: 10.1093/rheumatology/keaa129] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 20.0] [Reference Citation Analysis]
92 Wang S, Wang F, Wang X, Zhang Y, Song L. Elevated Creatinine Clearance in Lupus Nephritis patients with Normal Creatinine. Int J Med Sci 2021;18:1449-55. [PMID: 33628102 DOI: 10.7150/ijms.51117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford) 2020;59:v69-81. [PMID: 33280011 DOI: 10.1093/rheumatology/keaa403] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 25.0] [Reference Citation Analysis]
94 Gasparotto M, Gatto M, Binda V, Doria A, Moroni G. Lupus nephritis: clinical presentations and outcomes in the 21st century. Rheumatology (Oxford) 2020;59:v39-51. [PMID: 33280015 DOI: 10.1093/rheumatology/keaa381] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 39.0] [Reference Citation Analysis]
95 Aringer M, Johnson SR. Classifying and diagnosing systemic lupus erythematosus in the 21st century. Rheumatology (Oxford) 2020;59:v4-v11. [PMID: 33280013 DOI: 10.1093/rheumatology/keaa379] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 25.0] [Reference Citation Analysis]
96 Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology (Oxford) 2020;59:v29-38. [PMID: 33280012 DOI: 10.1093/rheumatology/keaa382] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 31.0] [Reference Citation Analysis]
97 Abe Y, Tada K, Yamaji K, Tamura N. Real-World Experience of Safety of Mycophenolate Mofetil in 119 Japanese Patients with Systemic Lupus Erythematosus: A Retrospective Single-Center Study. Biomed Res Int 2021;2021:8630596. [PMID: 33564682 DOI: 10.1155/2021/8630596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
98 Leandro M, Isenberg DA. Rituximab - The first twenty years. Lupus 2021;30:371-7. [PMID: 33459161 DOI: 10.1177/0961203320982668] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
99 Wang G, Wu L, Su H, Feng X, Shi M, Jin L, Yang M, Zhou Z, Su C, Yang B, Li Y, Cao W. Association of Urinary Matrix Metalloproteinase 7 Levels With Incident Renal Flare in Lupus Nephritis. Arthritis Rheumatol 2021;73:265-75. [PMID: 32892475 DOI: 10.1002/art.41506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
100 Nielly H, Mathian A, Cazenave M, Izzedine H, Haroche J, Cohen-Aubart F, Hie M, Miyara M, Pineton de Chambrun M, Benameur N, Hausfater P, Pha M, Boutin-Lê Thi Huong D, Rouvier P, Brocheriou I, Cluzel P, Amoura Z. Safety and effectiveness of transjugular renal biopsy for systemic lupus erythematosus and antiphospholipid antibody syndrome patients taking antithrombotics. Nephrol Dial Transplant 2020;35:1721-9. [PMID: 31157889 DOI: 10.1093/ndt/gfz085] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
101 Berthelsen DB, Woodworth TG, Goel N, Ioannidis JPA, Tugwell P, Devoe D, Williamson P, Terwee CB, Suarez-Almazor ME, Strand V, Leong AL, Conaghan PG, Boers M, Shea BJ, Brooks PM, Simon LS, Furst DE, Christensen R; OMERACT Safety Working Group. Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group. Semin Arthritis Rheum 2021;51:607-17. [PMID: 33483129 DOI: 10.1016/j.semarthrit.2020.09.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Pleyer U, Becker MD, Chronopoulos A, Kötter I, Salchow DJ, Thurau S, Szentmáry N, Seitz B, Walscheid K, Tappeiner C, Heiligenhaus A. Hintergrund/therapeutische Grundrezepte. Entzündliche Augenerkrankungen 2021. [DOI: 10.1007/978-3-662-60399-4_21] [Reference Citation Analysis]
103 Almaani SJ, Mejia-vilet J, Rovin BH. Kidney disease. Lahita's Systemic Lupus Erythematosus 2021. [DOI: 10.1016/b978-0-12-820583-9.00011-7] [Reference Citation Analysis]
104 Mbengue M, Mezouari M, Diagne S, Niang A. Infectious Complications in Lupus Nephritis and Associated Factors: A Multicenter Study. OJNeph 2021;11:506-515. [DOI: 10.4236/ojneph.2021.114043] [Reference Citation Analysis]
105 Kyttaris VC. New treatments of systemic lupus erythematosus. Systemic Lupus Erythematosus 2021. [DOI: 10.1016/b978-0-12-814551-7.00066-0] [Reference Citation Analysis]
106 Rosalia R. Perspectives on Repurposed Drugs Based on Globally Accepted Therapeutic Guidelines to Combat SARS-CoV-2 Infection. DHPS 2021;Volume 13:11-18. [DOI: 10.2147/dhps.s272411] [Reference Citation Analysis]
107 Avar-aydin PO, Schultz K, Brunner HI. Metrics and Outcome Measures of Disease Activity and Damage in Childhood-Onset Systemic Lupus Erythematosus. Outcome Measures and Metrics in Systemic Lupus Erythematosus 2021. [DOI: 10.1007/978-3-030-73303-2_8] [Reference Citation Analysis]
108 Wise L, Stohl W. Immunosuppressive therapy in SLE. Lahita's Systemic Lupus Erythematosus 2021. [DOI: 10.1016/b978-0-12-820583-9.00044-0] [Reference Citation Analysis]
109 Frangou EA, Bertsias G, Boumpas DT. Cytotoxic drug treatment. Systemic Lupus Erythematosus 2021. [DOI: 10.1016/b978-0-12-814551-7.00064-7] [Reference Citation Analysis]
110 Shah K, Cragg M, Leandro M, Reddy V. Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus. Biologicals 2021;69:1-14. [PMID: 33288390 DOI: 10.1016/j.biologicals.2020.11.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
111 Gasparin AA, de Andrade NPB, Hax V, Palominos PE, Siebert M, Marx R, Schaefer PG, Veronese FV, Monticielo OA. Urinary soluble VCAM-1 is a useful biomarker of disease activity and treatment response in lupus nephritis. BMC Rheumatol 2020;4:67. [PMID: 33292825 DOI: 10.1186/s41927-020-00162-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
112 Lamba P, Nam KH, Contractor J, Kim A. Nephritic Syndrome. Primary Care: Clinics in Office Practice 2020;47:615-629. [DOI: 10.1016/j.pop.2020.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Ciang NCO, Mok CC. Glucocorticoid Withdrawal in Lupus Nephritis: A Study Protocol and Literature Review. Journal of Clinical Rheumatology and Immunology 2020;20:47-55. [DOI: 10.1142/s2661341720300049] [Reference Citation Analysis]
114 Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, Barry WT, Gao W, Ryker K, Tosta P, Askanase AD, Boackle SA, Chatham WW, Kamen DL, Karp DR, Kirou KA, Sam Lim S, Marder B, McMahon M, Parikh SV, Pendergraft WF 3rd, Podoll AS, Saxena A, Wofsy D, Diamond B, Smilek DE, Aranow C, Dall'Era M. Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis Rheumatol 2021;73:121-31. [PMID: 32755035 DOI: 10.1002/art.41466] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 26.0] [Reference Citation Analysis]
115 Kozlovskaya NL, Solovyev SK, Aseeva EA, Popkova TV, Panafidina TA, Nasonov EL, Lila AM, Mesnyankina AA, Nikishina NY. The 2019 updated EULAR/ERA-EDTA guidelines for the management of lupus nephritis. Expert comments. Part I. Sovremennaâ revmatologiâ 2020;14:7-15. [DOI: 10.14412/1996-7012-2020-4-7-15] [Reference Citation Analysis]
116 Petricca L, Gigante MR, Paglionico A, Costanzi S, Vischini G, Di Mario C, Varriano V, Tanti G, Tolusso B, Alivernini S, Grandaliano G, Ferraccioli G, Gremese E. Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies. Front Med (Lausanne) 2020;7:553075. [PMID: 33195302 DOI: 10.3389/fmed.2020.553075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
117 Yang H, Liu H, Zhou Z, Zhao L, Fei Y, Chen H, Zhang F, Zhang X. Management of Severe Refractory Systemic Lupus Erythematosus: Real-World Experience and Literature Review. Clin Rev Allergy Immunol 2021;60:17-30. [PMID: 33159635 DOI: 10.1007/s12016-020-08817-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
118 Kwon OC, Park JH, Lee SW, Song JJ, Park YB, Park MC. Worse Renal Presentation and Prognosis in Initial-Onset Lupus Nephritis than Early-Onset Lupus Nephritis. Yonsei Med J 2020;61:951-7. [PMID: 33107238 DOI: 10.3349/ymj.2020.61.11.951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
119 Umeda R, Ogata S, Hara S, Takahashi K, Inaguma D, Hasegawa M, Yasuoka H, Yuzawa Y, Hayashi H, Tsuboi N. Comparison of the 2018 and 2003 International Society of Nephrology/Renal Pathology Society classification in terms of renal prognosis in patients of lupus nephritis: a retrospective cohort study. Arthritis Res Ther 2020;22:260. [PMID: 33148339 DOI: 10.1186/s13075-020-02358-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
120 Salgado Guerrero M, Londono Jimenez A, Dobrowolski C, Mowrey WB, Goilav B, Wang S, Broder A. Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease. BMC Nephrol 2020;21:450. [PMID: 33115441 DOI: 10.1186/s12882-020-02083-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
121 Morales E, Trujillo H, Bada T, Alonso M, Gutiérrez E, Rodríguez E, Gutiérrez E, Galindo M, Praga M. What is the value of repeat kidney biopsies in patients with lupus nephritis? Lupus 2021;30:25-34. [PMID: 33081588 DOI: 10.1177/0961203320965703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
122 Jiang YP, Zhao XX, Chen RR, Xu ZH, Wen CP, Yu J. Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: A systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e22328. [PMID: 32957400 DOI: 10.1097/MD.0000000000022328] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
123 Chedid A, Rossi GM, Peyronel F, Menez S, Atta MG, Bagnasco SM, Arend LJ, Rosenberg AZ, Fine DM. Low-Level Proteinuria in Systemic Lupus Erythematosus. Kidney Int Rep 2020;5:2333-40. [PMID: 33305127 DOI: 10.1016/j.ekir.2020.09.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
124 Zhang H, Zhou M, Han X, Yang Y, Yu X. Mycophenolate mofetil in the treatment of Chinese patients with lupus nephritis: A PRISMA-compliant meta-analysis. Medicine (Baltimore) 2020;99:e21121. [PMID: 32871981 DOI: 10.1097/MD.0000000000021121] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
125 Sutherland LJ, Talreja H. C3-glomerulonephritis in New Zealand - a case series. BMC Nephrol 2020;21:399. [PMID: 32943008 DOI: 10.1186/s12882-020-02056-5] [Reference Citation Analysis]
126 Ramanujam M, Steffgen J, Visvanathan S, Mohan C, Fine JS, Putterman C. Phoenix from the flames: Rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis. Autoimmun Rev 2020;19:102668. [PMID: 32942031 DOI: 10.1016/j.autrev.2020.102668] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
127 Hammond ER, Tummala R, Berglind A, Syed F, Wang X, Desta B, Nab H. Study protocol for the international Systemic Lupus Erythematosus Prospective Observational Cohort Study (SPOCS): understanding lupus and the role of type I interferon gene signature. BMJ Open 2020;10:e036563. [PMID: 32873668 DOI: 10.1136/bmjopen-2019-036563] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
128 Matta EG, Rubini DA, Araújo NC. Effect of systemic arterial hypertension and use of antiproteinuric drug in induction therapy for lupus nephritis. Einstein (São Paulo) 2020;18. [DOI: 10.31744/einstein_journal/2020ao5322] [Reference Citation Analysis]
129 Ranganathan D, Abdul-Aziz MH, John GT, McWhinney BC, Fassett RG, Healy H, Kubler P, Lim A, Lipman J, Purvey M, Roberts M, Reyaldeen R, Ungerer J, Roberts JA. Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN). Ther Drug Monit 2019;41:703-13. [PMID: 31219949 DOI: 10.1097/FTD.0000000000000658] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
130 Porta S, Danza A, Arias Saavedra M, Carlomagno A, Goizueta MC, Vivero F, Ruiz-Irastorza G. Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues. J Clin Med 2020;9:E2709. [PMID: 32839376 DOI: 10.3390/jcm9092709] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 11.5] [Reference Citation Analysis]
131 Laucekova Z, Bodova KB, Nachajova M, Kudela E, Fiolka R, Pridavkova D, Staskova K, Biringer K. Systemic Lupus Erythematosus Treatment in Pregnancy: Case Study. Acta Medica Martiniana 2020;20:80-9. [DOI: 10.2478/acm-2020-0010] [Reference Citation Analysis]
132 Tocut M, Shoenfeld Y, Zandman-Goddard G. Systemic lupus erythematosus: an expert insight into emerging therapy agents in preclinical and early clinical development. Expert Opin Investig Drugs 2020;29:1151-62. [PMID: 32755494 DOI: 10.1080/13543784.2020.1807004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
133 Albirdisi MR, Al-Homood IA. Characteristics of lupus nephritis in Saudi lupus patients: A retrospective observational study. Lupus 2020;29:1638-43. [PMID: 32741304 DOI: 10.1177/0961203320947151] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
134 Teng Q, Ma L, Ma Y, Zhang Y, Kang N, Hu Y, Zhang S. The challenge of managing comorbidities: a case report of primary Sjogren's syndrome in a patient with acute intermittent porphyria. Intractable Rare Dis Res 2020;9:137-40. [PMID: 32844069 DOI: 10.5582/irdr.2020.03064] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
135 Chen X, Wang DD, Xu H, Li ZP. Population pharmacokinetics model and initial dose optimization of tacrolimus in children and adolescents with lupus nephritis based on real-world data. Exp Ther Med 2020;20:1423-30. [PMID: 32765671 DOI: 10.3892/etm.2020.8821] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
136 Oni L, Wright RD, Marks S, Beresford MW, Tullus K. Kidney outcomes for children with lupus nephritis. Pediatr Nephrol 2021;36:1377-85. [PMID: 32725543 DOI: 10.1007/s00467-020-04686-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 27] [Article Influence: 9.5] [Reference Citation Analysis]
137 Zhang L, Zhang K, Dong W, Li R, Huang R, Zhang H, Shi W, Liu S, Li Z, Chen Y, Ye Z, Liang X, Yu X. Raised Plasma Levels of Asymmetric Dimethylarginine Are Associated with Pathological Type and Predict the Therapeutic Effect in Lupus Nephritis Patients Treated with Cyclophosphamide. Kidney Dis (Basel) 2020;6:355-63. [PMID: 33490115 DOI: 10.1159/000509767] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
138 Foster HE, Scott C, Tiderius CJ, Dobbs MB; Members of the Paediatric Global Musculoskeletal Task Force. Improving musculoskeletal health for children and young people - A 'call to action'. Best Pract Res Clin Rheumatol 2020;34:101566. [PMID: 32727697 DOI: 10.1016/j.berh.2020.101566] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
139 Davis A, Chang J, Shapiro S, Klein-Gitelman M, Faerber J, Katcoff H, Cidav Z, Mandell DS, Knight A. Immunomodulatory Medication Use in Newly Diagnosed Youth With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 2021;73:1672-7. [PMID: 32702144 DOI: 10.1002/acr.24392] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
140 Ichinose K, Kitamura M, Sato S, Fujikawa K, Horai Y, Matsuoka N, Tsuboi M, Nonaka F, Shimizu T, Sumiyoshi R, Koga T, Kawashiri SY, Iwamoto N, Igawa T, Tamai M, Nakamura H, Origuchi T, Nishino T, Kawakami A. Comparison of complete renal response and mortality in early- and late-onset lupus nephritis: a multicenter retrospective study of a Japanese cohort. Arthritis Res Ther 2020;22:175. [PMID: 32698892 DOI: 10.1186/s13075-020-02271-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
141 Xourgia E, Tektonidou MG. Management of Non-criteria Manifestations in Antiphospholipid Syndrome. Curr Rheumatol Rep 2020;22:51. [PMID: 32699944 DOI: 10.1007/s11926-020-00935-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
142 Чиж К, Тушина А. Updated European Guidelines for the Management of Lupus Nephritis Patients. Рецепт 2020. [DOI: 10.34883/pi.2020.2.2.049] [Reference Citation Analysis]
143 Kim J, Lee JS, Go H, Lim JS, Oh JS, Kim YG, Lee CK, Yoo B, Hong S. Clinical and histological significance of urinary CD11c+ macrophages in lupus nephritis. Arthritis Res Ther 2020;22:173. [PMID: 32680578 DOI: 10.1186/s13075-020-02265-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
144 Bartels-Peculis L, Sharma A, Edwards AM, Sanyal A, Connolly-Strong E, Nelson WW. Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population. Open Access Rheumatol 2020;12:117-24. [PMID: 32607019 DOI: 10.2147/OARRR.S248750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
145 Soliman WM, Sherif NM, Ghanima IM, El-badawy MA. Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios in Systemic Lupus Erythematosus: Relation With Disease Activity and Lupus Nephritis. Reumatología Clínica (English Edition) 2020;16:255-261. [DOI: 10.1016/j.reumae.2018.07.014] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
146 Ho RTC, Leung MH. Factors Associated with Renal Outcomes in an Inception Cohort of Biopsy-proven Lupus Nephritis Patients. Journal of Clinical Rheumatology and Immunology 2020;20:9-20. [DOI: 10.1142/s2661341720500029] [Reference Citation Analysis]
147 Wright RD, Bannerman F, Beresford MW, Oni L. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy. BMC Nephrol 2020;21:245. [PMID: 32605540 DOI: 10.1186/s12882-020-01888-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
148 Gatto M, Saccon F, Zen M, Regola F, Fredi M, Andreoli L, Tincani A, Urban ML, Emmi G, Ceccarelli F, Conti F, Bortoluzzi A, Govoni M, Tani C, Mosca M, Ubiali T, Gerosa M, Bozzolo E, Canti V, Cardinaletti P, Gabrielli A, Tanti G, Gremese E, De Marchi G, De Vita S, Fasano S, Ciccia F, Pazzola G, Salvarani C, Negrini S, Puppo F, Di Matteo A, De Angelis R, Orsolini G, Rossini M, Faggioli P, Laria A, Piga M, Mathieu A, Scarpato S, Rossi FW, Paulis A, Brunetta E, Ceribelli A, Selmi C, Prete M, Racanelli V, Vacca A, Bartoloni E, Gerli R, Larosa M, Iaccarino L, Doria A. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real‐Life Setting. Arthritis Rheumatol 2020;72:1314-24. [DOI: 10.1002/art.41253] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
149 Kwon OC, Park JH, Park HC, Jung SM, Lee SW, Song JJ, Park YB, Park MC. Non-histologic factors discriminating proliferative lupus nephritis from membranous lupus nephritis. Arthritis Res Ther 2020;22:138. [PMID: 32517774 DOI: 10.1186/s13075-020-02223-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
150 Moroni G, Gatto M, Tamborini F, Quaglini S, Radice F, Saccon F, Frontini G, Alberici F, Sacchi L, Binda V, Trezzi B, Vaglio A, Messa P, Sinico RA, Doria A. Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. Ann Rheum Dis 2020;79:1077-83. [PMID: 32503858 DOI: 10.1136/annrheumdis-2020-216965] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
151 Batu ED, Özen S. Implications of COVID-19 in pediatric rheumatology. Rheumatol Int 2020;40:1193-213. [PMID: 32500409 DOI: 10.1007/s00296-020-04612-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
152 Kostopoulou M, Adamichou C, Bertsias G. An Update on the Diagnosis and Management of Lupus Nephritis. Curr Rheumatol Rep 2020;22:30. [PMID: 32500443 DOI: 10.1007/s11926-020-00906-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
153 Stolyar L, Lahita RG, Panush RS. Rituximab use as induction therapy for lupus nephritis: a systematic review. Lupus 2020;29:892-912. [PMID: 32486934 DOI: 10.1177/0961203320928412] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
154 Lorenzo-Vizcaya A, Fasano S, Isenberg DA. Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE? Immunotargets Ther 2020;9:105-10. [PMID: 32582577 DOI: 10.2147/ITT.S240874] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
155 Ding H, Lin C, Cai J, Guo Q, Dai M, Mohan C, Shen N. Urinary activated leukocyte cell adhesion molecule as a novel biomarker of lupus nephritis histology. Arthritis Res Ther 2020;22:122. [PMID: 32460901 DOI: 10.1186/s13075-020-02209-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
156 Argolini LM, Frontini G, Elefante E, Saccon F, Binda V, Tani C, Scotti I, Carli L, Gatto M, Esposito C, Gerosa M, Caporali R, Doria A, Messa P, Mosca M, Moroni G. Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up. J Nephrol 2021;34:389-98. [PMID: 32462476 DOI: 10.1007/s40620-020-00753-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
157 Mok CC, Ho LY, Ying SKY, Leung MC, To CH, Ng WL. Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann Rheum Dis 2020;79:1070-6. [PMID: 32448782 DOI: 10.1136/annrheumdis-2020-217178] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
158 Terzioğlu Bebitoğlu B, Oğuz E, Hodzic A, Hatiboğlu N, Kam Ö. Chloroquine / Hydroxychloroquine: Pharmacological view of an old drug currently used in COVID-19 treatment. Anadolu Kliniği Tıp Bilimleri Dergisi 2020. [DOI: 10.21673/anadoluklin.735826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
159 Scobell R, Pradhan M. Management of Lupus Nephritis in Children. Indian Pediatr 2020;57:401-6. [DOI: 10.1007/s13312-020-1811-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
160 Prasad N, Kurian J, Agarwal V, Bhadauria D, Behera M, Yacha M, Kushwaha R, Agrawal V, Jain M, Gupta A. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil. Lupus 2020;29:845-53. [PMID: 32437258 DOI: 10.1177/0961203320926256] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
161 Mirouse A, Parrot A, Audigier V, Demoule A, Mayaux J, Géri G, Mariotte E, Bréchot N, de Prost N, Vautier M, Neuville M, Bigé N, de Montmollin E, Cacoub P, Resche-Rigon M, Cadranel J, Saadoun D. Severe diffuse alveolar hemorrhage related to autoimmune disease: a multicenter study. Crit Care 2020;24:231. [PMID: 32423434 DOI: 10.1186/s13054-020-02936-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
162 Dos Santos M, Veronese FV, Moresco RN. Uric acid and kidney damage in systemic lupus erythematosus. Clin Chim Acta 2020;508:197-205. [PMID: 32428504 DOI: 10.1016/j.cca.2020.05.034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
163 Kim H, Kim T, Kim M, Lee HY, Kim Y, Kang MS, Kim J. Activation of the alternative complement pathway predicts renal outcome in patients with lupus nephritis. Lupus 2020;29:862-71. [PMID: 32408850 DOI: 10.1177/0961203320925165] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
164 Jiang Y, Zhang Q, Wang H, Tang D, Zhang Y, Yimo, Zhang, Yu L. Expressions of IFN-γ and IL-4 before and after Treatment of Lupus Nephritis with Traditional Chinese Medicine Combined with Cyclophosphamide and Their Values for Efficacy Prediction and Evaluation. Iran J Public Health 2020;49:886-95. [PMID: 32953676] [Reference Citation Analysis]
165 Becker JU, Mayerich D, Padmanabhan M, Barratt J, Ernst A, Boor P, Cicalese PA, Mohan C, Nguyen HV, Roysam B. Artificial intelligence and machine learning in nephropathology. Kidney Int 2020;98:65-75. [PMID: 32475607 DOI: 10.1016/j.kint.2020.02.027] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 16.0] [Reference Citation Analysis]
166 Abdulrahman MA, Afifi N, El-ashry M. Neutrophil/lymphocyte and platelet/lymphocyte ratios are useful predictors comparable to serum IL6 for disease activity and damage in naive and relapsing patients with lupus nephritis. The Egyptian Rheumatologist 2020;42:107-112. [DOI: 10.1016/j.ejr.2019.08.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
167 Dierckx T, Chiche L, Daniel L, Lauwerys B, Weyenbergh JV, Jourde-Chiche N. Serum GlycA Level is Elevated in Active Systemic Lupus Erythematosus and Correlates to Disease Activity and Lupus Nephritis Severity. J Clin Med 2020;9:E970. [PMID: 32244481 DOI: 10.3390/jcm9040970] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
168 Kang Y, Yan Q, Fu Q, Wang R, Dai M, Du F, Dai Q, Ye P, Wu C, Lu L, Bao C. Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study. Arthritis Res Ther 2020;22:65. [PMID: 32228698 DOI: 10.1186/s13075-020-02154-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
169 Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, Boletis J, Frangou E, Houssiau FA, Hollis J, Karras A, Marchiori F, Marks SD, Moroni G, Mosca M, Parodis I, Praga M, Schneider M, Smolen JS, Tesar V, Trachana M, van Vollenhoven RF, Voskuyl AE, Teng YKO, van Leew B, Bertsias G, Jayne D, Boumpas DT. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020;79:713-23. [PMID: 32220834 DOI: 10.1136/annrheumdis-2020-216924] [Cited by in Crossref: 234] [Cited by in F6Publishing: 250] [Article Influence: 117.0] [Reference Citation Analysis]
170 Kinloch AJ, Cascino MD, Dai J, Bermea RS, Ko K, Vesselits M, Dragone LL, Mor Vaknin N, Legendre M, Markovitz DM, Okoreeh MK, Townsend MJ, Clark MR. Anti-vimentin antibodies: a unique antibody class associated with therapy-resistant lupus nephritis. Lupus 2020;29:569-77. [PMID: 32216516 DOI: 10.1177/0961203320913606] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
171 Wang A, Xu Y, Fei Y, Wang M. The role of immunosuppressive agents in the management of severe and refractory immune-related adverse events. Asia Pac J Clin Oncol 2020;16:201-10. [PMID: 32212243 DOI: 10.1111/ajco.13332] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
172 Bertolo M, Baumgart S, Durek P, Peddinghaus A, Mei H, Rose T, Enghard P, Grützkau A. Deep Phenotyping of Urinary Leukocytes by Mass Cytometry Reveals a Leukocyte Signature for Early and Non-Invasive Prediction of Response to Treatment in Active Lupus Nephritis. Front Immunol 2020;11:256. [PMID: 32265898 DOI: 10.3389/fimmu.2020.00256] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
173 Aringer M, Leuchten N, Dörner T. Biologika und „small molecules“ beim systemischen Lupus erythematodes. Z Rheumatol 2020;79:232-40. [DOI: 10.1007/s00393-020-00767-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
174 Thimm MA, Rositch AF, VandenBussche C, McDonald L, Garonzik Wang JM, Levinson K. Lower Genital Tract Dysplasia in Female Solid Organ Transplant Recipients. Obstet Gynecol 2019;134:385-94. [PMID: 31306332 DOI: 10.1097/AOG.0000000000003378] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
175 Solovyev SK, Aseeva EA, Nasonov EL, Lila AM, Koilubaeva GM. Possibilities and prospects for glucocorticoid withdrawal in systemic lupus erythematosus. Sovremennaâ revmatologiâ 2020;14:6-11. [DOI: 10.14412/1996-7012-2020-1-6-11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
176 Suhlrie A, Hennies I, Gellermann J, Büscher A, Hoyer P, Waldegger S, Wygoda S, Beetz R, Lange-Sperandio B, Klaus G, Konrad M, Holder M, Staude H, Rascher W, Oh J, Pape L, Tönshoff B, Haffner D; German Society of Paediatric Nephrology. Twelve-month outcome in juvenile proliferative lupus nephritis: results of the German registry study. Pediatr Nephrol 2020;35:1235-46. [PMID: 32193650 DOI: 10.1007/s00467-020-04501-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
177 Mejia-Vilet JM, Parikh SV, Song H, Fadda P, Shapiro JP, Ayoub I, Yu L, Zhang J, Uribe-Uribe N, Rovin BH. Immune gene expression in kidney biopsies of lupus nephritis patients at diagnosis and at renal flare. Nephrol Dial Transplant 2019;34:1197-206. [PMID: 29800348 DOI: 10.1093/ndt/gfy125] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
178 Tanaka Y. State-of-the-art treatment of systemic lupus erythematosus. Int J Rheum Dis 2020;23:465-71. [PMID: 32134201 DOI: 10.1111/1756-185X.13817] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 20.0] [Reference Citation Analysis]
179 Murphy G, Isenberg DA. New therapies for systemic lupus erythematosus - past imperfect, future tense. Nat Rev Rheumatol. 2019;15:403-412. [PMID: 31165780 DOI: 10.1038/s41584-019-0235-5] [Cited by in Crossref: 87] [Cited by in F6Publishing: 90] [Article Influence: 43.5] [Reference Citation Analysis]
180 Parodis I, Lopez Benavides AH, Zickert A, Pettersson S, Möller S, Welin Henriksson E, Voss A, Gunnarsson I. The Impact of Belimumab and Rituximab on Health-Related Quality of Life in Patients With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 2019;71:811-21. [PMID: 30055091 DOI: 10.1002/acr.23718] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
181 Solovyev SK, Aseeva EA, Popkova TV, Lila AM, Mazurov VI, Nasonov EL. Systemic lupus erythematosus: new horizons for diagnosis and therapy. Naučno-praktičeskaâ revmatologiâ 2020;58:5-14. [DOI: 10.14412/1995-4484-2020-5-14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
182 Parodis I, Tamirou F, Houssiau FA. Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med 2020;7:e000389. [PMID: 32153796 DOI: 10.1136/lupus-2020-000389] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 14.5] [Reference Citation Analysis]
183 Kamińska J, Dymicka-Piekarska V, Tomaszewska J, Matowicka-Karna J, Koper-Lenkiewicz OM. Diagnostic utility of protein to creatinine ratio (P/C ratio) in spot urine sample within routine clinical practice. Crit Rev Clin Lab Sci 2020;57:345-64. [PMID: 32058809 DOI: 10.1080/10408363.2020.1723487] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
184 Gupta KL, Bharati J, Anakutti H, Pattanashetti N, Rathi M, Ramachandran R, Nada R. Contribution of Clinically Indicated Repeat Renal Biopsy in Indian Patients with Lupus Nephritis. Indian J Nephrol 2020;30:377-81. [PMID: 33840956 DOI: 10.4103/ijn.IJN_166_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
185 Zoshima T, Hara S, Mizushima I, Nishioka R, Ito K, Fujii H, Yamada K, Nomura H, Kawano M. Wire-loop lesion is associated with serological immune abnormality, but not renal prognosis, in lupus nephritis. Lupus 2020;29:407-12. [PMID: 32041502 DOI: 10.1177/0961203320905652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
186 Lever E, Alves MR, Isenberg DA. Towards Precision Medicine in Systemic Lupus Erythematosus. Pharmgenomics Pers Med 2020;13:39-49. [PMID: 32099443 DOI: 10.2147/PGPM.S205079] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
187 Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers 2020;6:7. [PMID: 31974366 DOI: 10.1038/s41572-019-0141-9] [Cited by in Crossref: 179] [Cited by in F6Publishing: 196] [Article Influence: 89.5] [Reference Citation Analysis]
188 Hao GX, Song LL, Zhang DF, Su LQ, Jacqz-Aigrain E, Zhao W. Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics. Br J Clin Pharmacol 2020;86:274-84. [PMID: 31725919 DOI: 10.1111/bcp.14174] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
189 Chen T, Zhou Y, Zhang J, Chen C, Pan J. Long-term predictive value of acute kidney injury classification in diffuse proliferative lupus nephritis with acute kidney injury. BMC Nephrol 2020;21:13. [PMID: 31931741 DOI: 10.1186/s12882-019-1676-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
190 Lan-Ting H, You-Ming C, Li-Xin W, Chen W, Xiao-Yan Z, Hong-Yan H. Clinicopathological factors for tubulointerstitial injury in lupus nephritis. Clin Rheumatol 2020;39:1617-26. [PMID: 31902029 DOI: 10.1007/s10067-019-04909-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
191 Delfino J, Dos Santos TAFG, Skare TL. Comparison of lupus patients with early and late onset nephritis: a study in 71 patients from a single referral center. Adv Rheumatol 2020;60:5. [PMID: 31900216 DOI: 10.1186/s42358-019-0105-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
192 Narayan B, Nelson-piercy C. Physiological Changes of the Immune System During Pregnancy. Principles and Practice of Maternal Critical Care 2020. [DOI: 10.1007/978-3-030-43477-9_15] [Reference Citation Analysis]
193 Jung N, Mayet W, Mertens P, Meyer (federführend) J, Müller O, Pfeifer M, Schellinger P, Weiss N, Wendtner C. RHEUMATISCHE ERKRANKUNGEN. Rationelle Diagnostik und Therapie in der Inneren Medizin 2020. [DOI: 10.1016/b978-3-437-06282-7.50016-4] [Reference Citation Analysis]
194 Aringer M, Leuchten N, Schneider M. Treat-to-Target bei systemischem Lupus erythematodes. Kompass Autoimmun 2020;2:45-52. [DOI: 10.1159/000507644] [Reference Citation Analysis]
195 Haffner D. Vaskulitiden mit renaler Beteiligung. Pädiatrie 2020. [DOI: 10.1007/978-3-662-60300-0_241] [Reference Citation Analysis]
196 Maynard SE, Thadhani R. Pregnancy and Kidney Disease. Chronic Renal Disease 2020. [DOI: 10.1016/b978-0-12-815876-0.00074-7] [Reference Citation Analysis]
197 Mleeh NT, Alzahrani NA, Hariri JO, Mortada HH, Algethami MR. Dermatologists' Adherence to the Latest Recommendations for Screening of Hydroxychloroquine Retinopathy in Saudi Arabia: Cross-Sectional Study. Interact J Med Res 2019;8:e15218. [PMID: 31855186 DOI: 10.2196/15218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
198 Mathian A, Pha M, Haroche J, Cohen-Aubart F, Hié M, Pineton de Chambrun M, Boutin THD, Miyara M, Gorochov G, Yssel H, Cherin P, Devilliers H, Amoura Z. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. Ann Rheum Dis 2020;79:339-46. [PMID: 31852672 DOI: 10.1136/annrheumdis-2019-216303] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 18.0] [Reference Citation Analysis]
199 Mejia-Vilet JM, López-Hernández YJ, Trujeque-Matos M, Santander-Velez JI, Cano-Verduzco ML, Cruz C, Morales-Buenrostro LE. High frequency of nocturnal hypertension in lupus nephritis: should ABPM be implemented in usual practice? Clin Rheumatol 2020;39:1147-55. [PMID: 31838636 DOI: 10.1007/s10067-019-04830-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
200 Yap DYH, Chan TM. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments. Int J Mol Sci 2019;20:E6231. [PMID: 31835612 DOI: 10.3390/ijms20246231] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 13.0] [Reference Citation Analysis]
201 Aringer M. Inflammatory markers in systemic lupus erythematosus. J Autoimmun 2020;110:102374. [PMID: 31812331 DOI: 10.1016/j.jaut.2019.102374] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 17.7] [Reference Citation Analysis]
202 Hernández Cruz B, Alonso F, Calvo Alén J, Pego-reigosa JM, López-longo FJ, Galindo-izquierdo M, Olivé A, Tomero E, Horcada L, Uriarte E, Erausquin C, Sánchez-atrio A, Montilla C, Santos Soler G, Fernández-nebro A, Blanco R, Rodríguez-gómez M, Vela P, Freire M, Díez-álvarez E, Boteanu AL, Narváez J, Martínez Taboada V, Ruiz-lucea E, Andreu J, Fernández-berrizbeitia O, Hernández-beriain J, Gantes M, Pérez-venegas JJ, Ibáñez-barceló M, Pecondón-español Á, Marras C, Bonilla G, Castellví I, Moreno M, Raya E, Quevedo Vila VE, Vázquez T, Ruán JI, Muñoz S, Rúa-figueroa Í; on behalf of RELESSER (Spanish Society of Rheumatology Systemic Lupus Erythematosus register) group. Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry). Lupus 2020;29:27-36. [DOI: 10.1177/0961203319889667] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
203 Lee JS, Oh JS, Kim Y, Lee C, Yoo B, Hong S. Recovery of renal function in patients with lupus nephritis and reduced renal function: the beneficial effect of hydroxychloroquine. Lupus 2020;29:52-7. [DOI: 10.1177/0961203319890007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
204 Cervera R, Mosca M, Ríos-garcés R, Espinosa G, Trujillo H, Bada T, Praga M. Treatment for refractory lupus nephritis: Rituximab vs triple target therapy. Autoimmunity Reviews 2019;18:102406. [DOI: 10.1016/j.autrev.2019.102406] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
205 Popkova TV, Panafidina TA, Solovyev SK. According to the 2019 updated European League Against Rheumatism (EULAR) recommendations for the treatment of systemic lupus erythematosus: debatable issues and comments. Naučno-praktičeskaâ revmatologiâ 2019;57:496-510. [DOI: 10.14412/1995-4484-2019-496-510] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
206 Kandane-rathnayake R, Kent JR, Louthrenoo W, Luo S-, Wu Y-, Lateef A, Golder V, Sockalingam S, Navarra SA, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O’neill S, Goldblatt F, Lau CS, Hoi A, Nikpour M, Morand E. Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus. Lupus 2019;28:1669-77. [DOI: 10.1177/0961203319887799] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
207 Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171-354. [PMID: 31180581 DOI: 10.1002/jca.21705] [Cited by in Crossref: 539] [Cited by in F6Publishing: 565] [Article Influence: 179.7] [Reference Citation Analysis]
208 Felten R, Scher F, Sibilia J, Chasset F, Arnaud L. Les traitements du lupus systémique : retour vers le futur. Revue du Rhumatisme 2019;86:573-581. [DOI: 10.1016/j.rhum.2019.08.005] [Reference Citation Analysis]
209 Aringer M, Leuchten N, Schneider M. Treat to Target in Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America 2019;45:537-48. [DOI: 10.1016/j.rdc.2019.07.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
210 Smith EMD, Lythgoe H, Midgley A, Beresford MW, Hedrich CM. Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clin Immunol 2019;209:108274. [PMID: 31678365 DOI: 10.1016/j.clim.2019.108274] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 15.3] [Reference Citation Analysis]
211 Almutairi A, Aljammz H, Al-Hussain T, Al-Mayouf SM. Stand-alone renal SLICC criterion with full house glomerular deposits: is it enough for childhood lupus nephritis? Clin Rheumatol 2020;39:401-5. [PMID: 31637610 DOI: 10.1007/s10067-019-04789-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
212 Zen M, Saccon F, Gatto M, Montesso G, Larosa M, Benvenuti F, Iaccarino L, Doria A. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission. Rheumatology 2020;59:1591-8. [DOI: 10.1093/rheumatology/kez422] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
213 Schreiber J, Eisenberger U, de Groot K. [Lupus nephritis]. Internist (Berl) 2019;60:468-77. [PMID: 30840107 DOI: 10.1007/s00108-019-0574-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
214 Kim S, Reen Ooi AY, Stephens T, Jiang H. Cost-effectiveness of tacrolimus for the treatment of moderate-to-severe lupus nephritis in China. J Comp Eff Res 2019;8:1125-41. [PMID: 31580156 DOI: 10.2217/cer-2018-0111] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
215 Won J, Lee JS, Oh JS, Kim Y, Lee C, Yoo B, Hong S. Impact of stringent response in proteinuria on long-term renal outcomes in proliferative lupus nephritis. Lupus 2019;28:1294-301. [DOI: 10.1177/0961203319876695] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
216 Magro R. Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus. Ther Adv Musculoskelet Dis 2019;11:1759720X19874309. [PMID: 31565077 DOI: 10.1177/1759720X19874309] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
217 Torres-Salido MT, Sanchis M, Solé C, Moliné T, Vidal M, Vidal X, Solà A, Hotter G, Ordi-Ros J, Cortés-Hernández J. Urinary Neuropilin-1: A Predictive Biomarker for Renal Outcome in Lupus Nephritis. Int J Mol Sci 2019;20:E4601. [PMID: 31533337 DOI: 10.3390/ijms20184601] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
218 Stokes MB, D'Agati VD. Classification of Lupus Nephritis; Time for a Change? Adv Chronic Kidney Dis 2019;26:323-9. [PMID: 31733716 DOI: 10.1053/j.ackd.2019.06.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
219 Adamichou C, Georgakis S, Bertsias G. Cytokine targets in lupus nephritis: Current and future prospects. Clinical Immunology 2019;206:42-52. [DOI: 10.1016/j.clim.2018.08.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
220 Ruiz-irastorza G, Ruiz-estevez B, Lazaro E, Ruiz-arruza I, Duffau P, Martin-cascon M, Richez C, Ugarte A, Blanco P. Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts. Autoimmunity Reviews 2019;18:102359. [DOI: 10.1016/j.autrev.2019.102359] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
221 Maynard S, Guerrier G, Duffy M. Pregnancy in Women With Systemic Lupus and Lupus Nephritis. Adv Chronic Kidney Dis 2019;26:330-7. [PMID: 31733717 DOI: 10.1053/j.ackd.2019.08.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
222 Jorge A, Ung C, Young LH, Melles RB, Choi HK. Hydroxychloroquine retinopathy - implications of research advances for rheumatology care. Nat Rev Rheumatol 2018;14:693-703. [PMID: 30401979 DOI: 10.1038/s41584-018-0111-8] [Cited by in Crossref: 111] [Cited by in F6Publishing: 116] [Article Influence: 37.0] [Reference Citation Analysis]
223 Pakozdi A, Pyne D, Sheaff M, Rajakariar R. Utility of a repeat renal biopsy in lupus nephritis: a single centre experience. Nephrol Dial Transplant 2018;33:507-13. [PMID: 28444337 DOI: 10.1093/ndt/gfx019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
224 Chalmers C. Applied Anatomy and Physiology and the Renal Disease Process. Renal Nursing 2019. [DOI: 10.1002/9781119413172.ch2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
225 Berghen N, Vulsteke JB, Westhovens R, Lenaerts J, De Langhe E. Rituximab in systemic autoimmune rheumatic diseases: indications and practical use. Acta Clin Belg 2019;74:272-9. [PMID: 30253707 DOI: 10.1080/17843286.2018.1521904] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
226 Shi M, Luo W, Feng X, Jin L, Yang M, Wu L, Yang Z, Su C, Li Y, Su H, Wang G, Cao W. Urinary Angiotensinogen Predicts Renal Disease Activity in Lupus Nephritis. Antioxid Redox Signal 2019;31:1289-301. [PMID: 31264479 DOI: 10.1089/ars.2019.7782] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
227 Yo JH, Barbour TD, Nicholls K. Management of refractory lupus nephritis: challenges and solutions. Open Access Rheumatol 2019;11:179-88. [PMID: 31372070 DOI: 10.2147/OARRR.S166303] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
228 Nakano M, Kubo K, Shirota Y, Iwasaki Y, Takahashi Y, Igari T, Inaba Y, Takeshima Y, Tateishi S, Yamashita H, Miyazaki M, Sato H, Kanda H, Kaneko H, Ishii T, Fujio K, Tanaka N, Mimori A. Delayed lupus nephritis in the course of systemic lupus erythematosus is associated with a poorer treatment response: a multicentre, retrospective cohort study in Japan. Lupus 2019;28:1062-73. [PMID: 31296139 DOI: 10.1177/0961203319860200] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
229 Kwon OC, Cho YM, Oh JS, Hong S, Lee C, Yoo B, Kim Y. Renal flare in class V lupus nephritis: increased risk in patients with tubulointerstitial lesions. Rheumatol Int 2019;39:2061-7. [DOI: 10.1007/s00296-019-04369-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
230 Yajima N, Tsujimoto Y, Fukuma S, Sada KE, Shimizu S, Niihata K, Takahashi R, Asano Y, Azuma T, Kameda H, Kuwana M, Kohsaka H, Sugiura-Ogasawara M, Suzuki K, Takeuchi T, Tanaka Y, Tamura N, Matsui T, Mimori T, Fukuhara S, Atsumi T. The development of quality indicators for systemic lupus erythematosus using electronic health data: A modified RAND appropriateness method. Mod Rheumatol 2020;30:525-31. [PMID: 31111758 DOI: 10.1080/14397595.2019.1621419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
231 Dasari S, Chakraborty A, Truong L, Mohan C. A Systematic Review of Interpathologist Agreement in Histologic Classification of Lupus Nephritis. Kidney Int Rep 2019;4:1420-5. [PMID: 31701051 DOI: 10.1016/j.ekir.2019.06.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
232 Jesus D, Matos A, Henriques C, Zen M, Doria A, Inês LS. Response to: 'SLE-DAS: ready for routine use' by Mathew et al. Ann Rheum Dis 2020;79:e117. [PMID: 31201172 DOI: 10.1136/annrheumdis-2019-215794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
233 Kiyokawa T, Hanaoka H, Iida H, Ishimori K, Takakuwa Y, Okazaki T, Ozaki S, Kawahata K. High plasma mycophenolate acid concentration in the early phase of induction therapy predicts good renal outcome in lupus nephritis. Mod Rheumatol 2020;30:517-24. [PMID: 31135249 DOI: 10.1080/14397595.2019.1623435] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
234 Tani C, Elefante E, Signorini V, Zucchi D, Lorenzoni V, Carli L, Stagnaro C, Ferro F, Mosca M. Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience. RMD Open 2019;5:e000916. [PMID: 31275608 DOI: 10.1136/rmdopen-2019-000916] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 10.7] [Reference Citation Analysis]
235 Durcan L, O'Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393:2332-2343. [PMID: 31180030 DOI: 10.1016/s0140-6736(19)30237-5] [Cited by in Crossref: 161] [Cited by in F6Publishing: 132] [Article Influence: 53.7] [Reference Citation Analysis]
236 Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet 2019;393:2344-58. [PMID: 31180031 DOI: 10.1016/S0140-6736(19)30546-X] [Cited by in Crossref: 208] [Cited by in F6Publishing: 216] [Article Influence: 69.3] [Reference Citation Analysis]
237 Raimbourg Q, Daugas É. [Lupus nephritis]. Nephrol Ther 2019;15:174-89. [PMID: 30738732 DOI: 10.1016/j.nephro.2018.11.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
238 Mok CC. Metabolic syndrome and systemic lupus erythematosus: the connection. Expert Rev Clin Immunol 2019;15:765-75. [PMID: 31094570 DOI: 10.1080/1744666X.2019.1620601] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
239 Korsten P, Tampe B, Konig MF, Nikiphorou E. Sarcoidosis and autoimmune diseases: differences, similarities and overlaps. Curr Opin Pulm Med 2018;24:504-12. [PMID: 29985181 DOI: 10.1097/MCP.0000000000000500] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
240 Liu B, Ou Q, Tang Y, Fu S, Liang P, Yu Y, Xu Z, Chen Y, Xu A. Corticosteroids combined with doublet or single-agent immunosuppressive therapy for active proliferative lupus nephritis. Clin Rheumatol 2019;38:2519-28. [PMID: 31081535 DOI: 10.1007/s10067-019-04596-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
241 Berlit P, Krämer M; Consensus Group. Cerebral involvement in systemic vasculitides: Extracts from the guideline of the German neurological society. Neurol Res Pract 2019;1:13. [PMID: 33324879 DOI: 10.1186/s42466-019-0016-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
242 Aseeva EA, Soloviev SK, Popkova TV, Nikishina NY, Mesnyankina AA. Management of patients with systemic lupus erythematosus in real clinical practice. Naučno-praktičeskaâ revmatologiâ 2019;57:191-196. [DOI: 10.14412/1995-4484-2019-191-196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
243 Reppe Moe SE, Molberg Ø, Strøm EH, Lerang K. Assessing the relative impact of lupus nephritis on mortality in a population-based systemic lupus erythematosus cohort. Lupus 2019;28:818-25. [PMID: 31072277 DOI: 10.1177/0961203319847275] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
244 Anders HJ, Hiepe F. Treatment Options for Refractory Lupus Nephritis. Clin J Am Soc Nephrol 2019;14:653-5. [PMID: 30979714 DOI: 10.2215/CJN.03230319] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
245 Chen YM, Hung WT, Liao YW, Hsu CY, Hsieh TY, Chen HH, Hsieh CW, Lin CT, Lai KL, Tang KT, Tseng CW, Huang WN, Chen YH. Combination immunosuppressant therapy and lupus nephritis outcome: a hospital-based study. Lupus 2019;28:658-66. [PMID: 30971165 DOI: 10.1177/0961203319842663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
246 Huang X, Chen W, Ren G, Zhao L, Guo J, Gong D, Zeng C, Hu W, Liu Z. Autologous Hematopoietic Stem Cell Transplantation for Refractory Lupus Nephritis. Clin J Am Soc Nephrol. 2019;14:719-727. [PMID: 30979713 DOI: 10.2215/cjn.10570918] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
247 Petta I, Peene I, Elewaut D, Vereecke L, De Bosscher K. Risks and benefits of corticosteroids in arthritic diseases in the clinic. Biochem Pharmacol 2019;165:112-25. [PMID: 30978323 DOI: 10.1016/j.bcp.2019.04.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
248 Zhang CX, Cai L, Zhou ZY, Mao YY, Huang H, Yin L, Chen TX, Zhou W. Clinical manifestations, immunological features and prognosis of Chinese pediatric systemic lupus erythematosus: A single-center study. Int J Rheum Dis 2019;22:1070-6. [PMID: 30957986 DOI: 10.1111/1756-185X.13547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
249 Sumethkul K, Kitumnuaypong T, Angthararak S, Pichaiwong W. Low-dose cyclosporine for active lupus nephritis: a dose titration approach. Clin Rheumatol 2019;38:2151-9. [PMID: 30937637 DOI: 10.1007/s10067-019-04469-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
250 Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, Houssiau F, Jayne D, Kouloumas M, Kuhn A, Larsen JL, Lerstrøm K, Moroni G, Mosca M, Schneider M, Smolen JS, Svenungsson E, Tesar V, Tincani A, Troldborg A, van Vollenhoven R, Wenzel J, Bertsias G, Boumpas DT. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019;78:736-45. [DOI: 10.1136/annrheumdis-2019-215089] [Cited by in Crossref: 749] [Cited by in F6Publishing: 780] [Article Influence: 249.7] [Reference Citation Analysis]
251 Mesnyankina AA, Solovyev SK, Aseeva EA, Aleksankin AP, Aleksandrova EN, Nasonov EL. Effect of biological agents on B-lymphocyte subpopulations in patients with systemic lupus erythematosus. Sovremennaâ revmatologiâ 2019;13:35-43. [DOI: 10.14412/1996-7012-2019-1-35-43] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
252 Aljaberi N, Bennett M, Brunner HI, Devarajan P. Proteomic profiling of urine: implications for lupus nephritis. Expert Rev Proteomics 2019;16:303-13. [PMID: 30855196 DOI: 10.1080/14789450.2019.1592681] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
253 Smith E, Al-abadi E, Armon K, Bailey K, Ciurtin C, Davidson J, Gardner-medwin J, Haslam K, Hawley D, Leahy A, Leone V, Mcerlane F, Mewar D, Modgil G, Moots R, Pilkington C, Ramanan A, Rangaraj S, Riley P, Sridhar A, Wilkinson N, Beresford MW, Hedrich CM. Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis. Lupus 2019;28:613-20. [DOI: 10.1177/0961203319836712] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
254 Zhou T, Lin S, Yang S, Lin W. Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis. Drug Des Devel Ther 2019;13:857-69. [PMID: 30880918 DOI: 10.2147/DDDT.S189156] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
255 Kronbichler A, Brezina B, Gauckler P, Quintana LF, Jayne DRW. Refractory lupus nephritis: When, why and how to treat. Autoimmun Rev 2019;18:510-8. [PMID: 30844548 DOI: 10.1016/j.autrev.2019.03.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
256 Sakkas LI, Tronzas P. The Greek (Hellenic) rheumatology over the years: from ancient to modern times. Rheumatol Int 2019;39:947-55. [PMID: 30805680 DOI: 10.1007/s00296-019-04261-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
257 Kawazoe M, Kaneko K, Yamada Z, Masuoka S, Mizutani S, Yamada S, Shikano K, Sato H, Kaburaki M, Muraoka S, Kawai S, Nanki T. Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus. Clin Rheumatol 2019;38:1571-8. [PMID: 30778862 DOI: 10.1007/s10067-019-04473-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
258 Weidenbusch M, Bai Y, Eder J, Anders HJ; for the Lupus Nephritis Trials Network. Refractory lupus nephritis: a survey. Lupus 2019;28:455-64. [DOI: 10.1177/0961203319828516] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
259 Ichinose K, Kitamura M, Sato S, Eguchi M, Okamoto M, Endo Y, Tsuji S, Takatani A, Shimizu T, Umeda M, Fukui S, Sumiyoshi R, Koga T, Kawashiri S, Iwamoto N, Igawa T, Tamai M, Nakamura H, Origuchi T, Nishino T, Kawakami A. Complete renal response at 12 months after induction therapy is associated with renal relapse-free rate in lupus nephritis: a single-center, retrospective cohort study. Lupus 2019;28:501-9. [DOI: 10.1177/0961203319829827] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
260 Nagafuchi Y, Shoda H, Fujio K. Immune Profiling and Precision Medicine in Systemic Lupus Erythematosus. Cells 2019;8:E140. [PMID: 30744169 DOI: 10.3390/cells8020140] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
261 Condello M, Pellegrini E, Caraglia M, Meschini S. Targeting Autophagy to Overcome Human Diseases. Int J Mol Sci 2019;20:E725. [PMID: 30744021 DOI: 10.3390/ijms20030725] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 18.3] [Reference Citation Analysis]
262 Fanouriakis A, Bertsias G. Changing paradigms in the treatment of systemic lupus erythematosus. Lupus Sci Med 2019;6:e000310. [PMID: 31168398 DOI: 10.1136/lupus-2018-000310] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
263 Marticorena Garcia SR, Grossmann M, Bruns A, Dürr M, Tzschätzsch H, Hamm B, Braun J, Sack I, Guo J. Tomoelastography Paired With T2* Magnetic Resonance Imaging Detects Lupus Nephritis With Normal Renal Function: . Investigative Radiology 2019;54:89-97. [DOI: 10.1097/rli.0000000000000511] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
264 Kronbichler A, Jayne D. Response to: 'Prevention of infections in patients with antineutrophil cytoplasm antibody-associated vasculitis: potential role of hydroxychloroquine' by Novikov et al. Ann Rheum Dis 2020;79:e20. [PMID: 30700426 DOI: 10.1136/annrheumdis-2018-214735] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
265 Kitagawa A, Tsuboi N, Yokoe Y, Katsuno T, Ikeuchi H, Kajiyama H, Endo N, Sawa Y, Suwa J, Sugiyama Y, Hachiya A, Mimura T, Hiromura K, Maruyama S. Urinary levels of the leukocyte surface molecule CD11b associate with glomerular inflammation in lupus nephritis. Kidney Int 2019;95:680-92. [PMID: 30712924 DOI: 10.1016/j.kint.2018.10.025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
266 Ichinose K, Kitamura M, Sato S, Fujikawa K, Horai Y, Matsuoka N, Tsuboi M, Nonaka F, Shimizu T, Fukui S, Umeda M, Koga T, Kawashiri S, Iwamoto N, Tamai M, Nakamura H, Origuchi T, Nishino T, Kawakami A. Factors predictive of long-term mortality in lupus nephritis: a multicenter retrospective study of a Japanese cohort. Lupus 2019;28:295-303. [DOI: 10.1177/0961203319826690] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
267 Yap DY, Yung S, Chan TM. Lupus nephritis: An update on treatments and pathogenesis. Nephrology (Carlton) 2018;23 Suppl 4:80-3. [PMID: 30298658 DOI: 10.1111/nep.13469] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
268 Schneider M. Target Therapy in SLE. Autoimmunity Reviews 2019;18:21-4. [DOI: 10.1016/j.autrev.2018.07.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
269 Waldman M, Austin HA, Balow JE. Immunological Renal Diseases. Clinical Immunology 2019. [DOI: 10.1016/b978-0-7020-6896-6.00068-5] [Reference Citation Analysis]
270 Hoyer BF, Dörner T. Targeted Therapies in SLE. Dubois' Lupus Erythematosus and Related Syndromes 2019. [DOI: 10.1016/b978-0-323-47927-1.00057-8] [Reference Citation Analysis]
271 Haffner D. Vaskulitiden mit renaler Beteiligung bei Kindern und Jugendlichen. Pädiatrie 2019. [DOI: 10.1007/978-3-642-54671-6_241-2] [Reference Citation Analysis]
272 Restrepo-escobar M, Granda-carvajal PA, Jaimes F. Development and Internal Validation of a Prediction Model to Estimate the Probability of Needing Aggressive Immunosuppressive Therapy With Cytostatics in de Novo Lupus Nephritis Patients. Reumatología Clínica 2019;15:27-33. [DOI: 10.1016/j.reuma.2017.05.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
273 Anvari E, Ferreira Provenzano L, Nevares A, Herlitz LC, Smith H. Lupus Nephritis (Including Antiphospholipid Antibody Syndrome), Adult. Glomerulonephritis 2019. [DOI: 10.1007/978-3-319-49379-4_14] [Reference Citation Analysis]
274 Milić B, Ilić T, Popović M. New recommendations for the classification and management of systemic lupus erythematosus. Timočki medicinski glasnik 2019;44:164-169. [DOI: 10.5937/tmg1904164m] [Reference Citation Analysis]
275 Yeoh S, Hua H, Yepes JF, Peterson DE. Oral Manifestations of Systemic Diseases and Their Treatments. Contemporary Oral Medicine 2019. [DOI: 10.1007/978-3-319-72303-7_18] [Reference Citation Analysis]
276 Restrepo-escobar M, Granda-carvajal PA, Jaimes F. Development and Internal Validation of a Prediction Model to Estimate the Probability of Needing Aggressive Immunosuppressive Therapy With Cytostatics in de Novo Lupus Nephritis Patients. Reumatología Clínica (English Edition) 2019;15:27-33. [DOI: 10.1016/j.reumae.2017.05.010] [Reference Citation Analysis]
277 Xibillé-friedmann D, Pérez-rodríguez M, Carrillo-vázquez S, Álvarez-hernández E, Aceves FJ, Ocampo-torres MC, García-garcía C, García-figueroa JL, Merayo-chalico J, Barrera-vargas A, Portela-hernández M, Sicsik S, Andrade-ortega L, Rosales-don Pablo VM, Martínez A, Prieto-seyffert P, Pérez-cristóbal M, Saavedra MÁ, Castro-colín Z, Ramos A, Huerta-sil G, Hernández-cabrera MF, Jara LJ, Limón-camacho L, Tinajero-nieto L, Barile-fabris LA. Clinical Practice Guidelines for the Treatment of Systemic Lupus Erythematosus by the Mexican College of Rheumatology. Reumatología Clínica (English Edition) 2019;15:3-20. [DOI: 10.1016/j.reumae.2018.03.003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
278 Xibillé-friedmann D, Pérez-rodríguez M, Carrillo-vázquez S, Álvarez-hernández E, Aceves FJ, Ocampo-torres MC, García-garcía C, García-figueroa JL, Merayo-chalico J, Barrera-vargas A, Portela-hernández M, Sicsik S, Andrade-ortega L, Rosales-don Pablo VM, Martínez A, Prieto-seyffert P, Pérez-cristóbal M, Saavedra MÁ, Castro-colín Z, Ramos A, Huerta-sil G, Hernández-cabrera MF, Jara LJ, Limón-camacho L, Tinajero-nieto L, Barile-fabris LA. Guía de práctica clínica para el manejo del lupus eritematoso sistémico propuesta por el Colegio Mexicano de Reumatología. Reumatología Clínica 2019;15:3-20. [DOI: 10.1016/j.reuma.2018.03.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
279 Mitoma H, Manto M, Gandini J. Central Nervous System Vasculitis and Related Diseases. Contemporary Clinical Neuroscience 2019. [DOI: 10.1007/978-3-030-19515-1_21] [Reference Citation Analysis]
280 Chung MK, Kang Y, Lee J. Severe Hypogammaglobulinemia Associated with Active Lupus Nephritis Treatment Resulting in Cytomegalovirus Infection. J Rheum Dis 2019;26:273. [DOI: 10.4078/jrd.2019.26.4.273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
281 Goswami RP, Sircar G, Sit H, Ghosh A, Ghosh P. Cyclophosphamide Versus Mycophenolate Versus Rituximab in Lupus Nephritis Remission Induction: A Historical Head-to-Head Comparative Study. JCR: Journal of Clinical Rheumatology 2019;25:28-35. [DOI: 10.1097/rhu.0000000000000760] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
282 Choi S, Park D, Kang J, Lee K, Xu H, Lee JS, Choi Y, Lee S. Comparison of Renal Responses to Cyclophosphamide and Mycophenolate Mofetil used as Induction Therapies in Korean Patients with Lupus Nephritis. J Rheum Dis 2019;26:57. [DOI: 10.4078/jrd.2019.26.1.57] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
283 Mejia-vilet JM, Rovin BH. Epidemiology and Management of Lupus Nephritis. Dubois' Lupus Erythematosus and Related Syndromes 2019. [DOI: 10.1016/b978-0-323-47927-1.00059-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
284 Quittnat-pelletier FS, Bhasin A, Hladunewich MA. Glomerular Diseases in Pregnancy. Glomerulonephritis 2019. [DOI: 10.1007/978-3-319-49379-4_49] [Reference Citation Analysis]
285 Khan S, Dar SA, Mandal RK, Jawed A, Wahid M, Panda AK, Lohani M, Mishra BN, Akhter N, Haque S. Angiotensin-Converting Enzyme Gene I/D Polymorphism Is Associated With Systemic Lupus Erythematosus Susceptibility: An Updated Meta-Analysis and Trial Sequential Analysis.Front Physiol. 2018;9:1793. [PMID: 30618805 DOI: 10.3389/fphys.2018.01793] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
286 Mok CC. Is Treat-to-target in Lupus Nephritis Realistic in Clinical Practice? CRR 2018;15:2-6. [DOI: 10.2174/1573397114666180406100857] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
287 Gatto M, Zen M, Iaccarino L, Doria A. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol 2019;15:30-48. [DOI: 10.1038/s41584-018-0133-2] [Cited by in Crossref: 73] [Cited by in F6Publishing: 77] [Article Influence: 18.3] [Reference Citation Analysis]
288 Panafidina ТA, Popkova ТV. General principles in the treatment of lupus nephritis with the prevention of cardiovascular events. Sovremennaâ revmatologiâ 2018;12:4-8. [DOI: 10.14412/1996-7012-2018-4-4-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
289 Gauckler P, Shin JI, Mayer G, Kronbichler A. Eosinophilia and Kidney Disease: More than Just an Incidental Finding? J Clin Med 2018;7:E529. [PMID: 30544782 DOI: 10.3390/jcm7120529] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
290 Goswami RP, Sit H, Ghosh P, Sircar G, Ghosh A. Steroid-free remission in lupus: myth or reality; an observational study from a tertiary referral centre. Clin Rheumatol 2019;38:1089-97. [DOI: 10.1007/s10067-018-4377-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
291 An Y, Zhou Y, Bi L, Liu B, Wang H, Lin J, Xu D, Wang M, Zhang J, Wang Y, An Y, Zhu P, Xie R, Zhang Z, Mei Y, Liu X, Deng X, Yao Z, Zhang Z, Wang Y, Xiao W, Shen H, Yang X, Xu H, Yu F, Wang G, Lu X, Li Y, Li Y, Zuo X, Li Y, Liu Y, Zhao Y, Guo J, Sun L, Zhao M, Li Z. Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study. Clin Rheumatol 2019;38:1047-54. [PMID: 30488367 DOI: 10.1007/s10067-018-4368-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
292 Tamirou F, Arnaud L, Talarico R, Scirè CA, Alexander T, Amoura Z, Avcin T, Bortoluzzi A, Cervera R, Conti F, Cornet A, Devilliers H, Doria A, Frassi M, Fredi M, Govoni M, Houssiau F, Lladò A, Macieira C, Martin T, Massaro L, Moraes-Fontes MF, Pamfil C, Paolino S, Tani C, Tas SW, Tektonidou M, Tincani A, Van Vollenhoven RF, Bombardieri S, Burmester G, Eurico FJ, Galetti I, Hachulla E, Mueller-Ladner U, Schneider M, Smith V, Cutolo M, Mosca M, Costedoat-Chalumeau N. Systemic lupus erythematosus: state of the art on clinical practice guidelines. RMD Open 2018;4:e000793. [PMID: 30564454 DOI: 10.1136/rmdopen-2018-000793] [Cited by in Crossref: 39] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
293 McClure M, Jones R. Update on Lupus Nephritis for GPs. Lupus 2018;27:11-4. [PMID: 30452323 DOI: 10.1177/0961203318801687] [Reference Citation Analysis]
294 Vukelic M, Li Y, Kyttaris VC. Novel Treatments in Lupus. Front Immunol 2018;9:2658. [PMID: 30524430 DOI: 10.3389/fimmu.2018.02658] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
295 Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun. 2019;96:1-13. [PMID: 30448290 DOI: 10.1016/j.jaut.2018.11.001] [Cited by in Crossref: 212] [Cited by in F6Publishing: 173] [Article Influence: 53.0] [Reference Citation Analysis]
296 Łuszczyńska P, Pawiński T, Kunicki PK, Durlik M, Augustyniak-Bartosik H, Hurkacz M. Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients-implications for therapeutic drug monitoring. Eur J Clin Pharmacol 2019;75:371-9. [PMID: 30430214 DOI: 10.1007/s00228-018-2599-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
297 Georgiev T, Stoilov R. Bulgarian rheumatology: science and practice in a cost-constrained environment. Rheumatol Int 2019;39:417-29. [PMID: 30413925 DOI: 10.1007/s00296-018-4202-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
298 Oku K, Atsumi T. Systemic lupus erythematosus: nothing stale her infinite variety. Mod Rheumatol 2018;28:758-65. [PMID: 29947275 DOI: 10.1080/14397595.2018.1494239] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
299 Castro M, Ugolini-Lopes M, Borba EF, Bonfá E, Seguro LPC. Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression. Lupus 2018;27:2215-9. [PMID: 30394834 DOI: 10.1177/0961203318809883] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
300 Tani C, Elefante E, Martin-Cascón M, Belhocine M, Lavilla Olleros C, Vagelli R, Stagnaro C, Costedoat-Chalumeau N, Ruiz-Irastorza G, Mosca M. Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres. Lupus Sci Med 2018;5:e000274. [PMID: 30538815 DOI: 10.1136/lupus-2018-000274] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
301 Anders HJ. Re-biopsy in lupus nephritis. Ann Transl Med 2018;6:S41. [PMID: 30613616 DOI: 10.21037/atm.2018.09.47] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
302 Teng YKO, Bredewold EOW, Rabelink TJ, Huizinga TWJ, Eikenboom HCJ, Limper M, Fritsch-Stork RDE, Bloemenkamp KWM, Sueters M. An evidence-based approach to pre-pregnancy counselling for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2018;57:1707-20. [PMID: 29165607 DOI: 10.1093/rheumatology/kex374] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
303 Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K. A positive direct Coombs’ test in the absence of hemolytic anemia predicts high disease activity and poor renal response in systemic lupus erythematosus. Lupus 2018;27:2274-8. [DOI: 10.1177/0961203318809182] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
304 Aizawa T, Imaizumi T, Hirono K, Watanabe S, Tsugawa K, Tanaka H. Chloroquine attenuates TLR3-mediated plasminogen activator inhibitor-1 expression in cultured human glomerular endothelial cells. Clin Exp Nephrol 2019;23:448-54. [PMID: 30341573 DOI: 10.1007/s10157-018-1659-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
305 Fang J, Li W, Tan M, Peng X, Tan Z, Wang W. Effect of different hepatitis B infection status on the prognosis of active lupus nephritis treated with immunosuppression: a retrospective analysis of 177 patients. Int J Rheum Dis 2018;21:1060-7. [PMID: 29878614 DOI: 10.1111/1756-185X.13313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
306 Boumpas DT, Bertsias GK, Fanouriakis A. 2008–2018: a decade of recommendations for systemic lupus erythematosus. Ann Rheum Dis 2018;77:1547-8. [DOI: 10.1136/annrheumdis-2018-214014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
307 Ichinose K, Kitamura M, Sato S, Fujikawa K, Horai Y, Matsuoka N, Tsuboi M, Nonaka F, Shimizu T, Fukui S, Umeda M, Koga T, Kawashiri SY, Iwamoto N, Igawa T, Tamai M, Nakamura H, Origuchi T, Nishino T, Kawakami A. Podocyte foot process width is a prediction marker for complete renal response at 6 and 12 months after induction therapy in lupus nephritis. Clin Immunol 2018;197:161-8. [PMID: 30296591 DOI: 10.1016/j.clim.2018.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
308 Micu M, Ostensen M, Villiger P, Micu R, Ionescu R. Paternal exposure to antirheumatic drugs—What physicians should know: Review of the literature. Seminars in Arthritis and Rheumatism 2018;48:343-55. [DOI: 10.1016/j.semarthrit.2018.01.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
309 Yap DY, Tang C, Chan GC, Kwan LP, Ma MK, Mok MM, Chan TM. Longterm Data on Sirolimus Treatment in Patients with Lupus Nephritis. J Rheumatol 2018;45:1663-70. [DOI: 10.3899/jrheum.180507] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 9.5] [Reference Citation Analysis]
310 Linnemann B. Antiphospholipid syndrome – an update. Vasa 2018;47:451-64. [DOI: 10.1024/0301-1526/a000723] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 11.5] [Reference Citation Analysis]
311 Campbell EJ, Clarke AE, Ramsey-Goldman R. Systemic lupus erythematosus: a case-based presentation of renal, neurologic, and hematologic emergencies. Expert Rev Clin Immunol 2018;14:803-16. [PMID: 30173578 DOI: 10.1080/1744666X.2018.1518132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
312 Felten R, Scher F, Sibilia J, Chasset F, Arnaud L. Advances in the treatment of systemic lupus erythematosus: From back to the future, to the future and beyond. Joint Bone Spine 2019;86:429-36. [PMID: 30243784 DOI: 10.1016/j.jbspin.2018.09.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
313 Sin FE, Isenberg D. An evaluation of voclosporin for the treatment of lupus nephritis. Expert Opinion on Pharmacotherapy 2018;19:1613-21. [DOI: 10.1080/14656566.2018.1516751] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
314 Yap DYH, Tam CH, Yung S, Wong S, Tang CSO, Mok TMY, Yuen CKY, Ma MKM, Lau CS, Chan TM. Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. Nephrology Dialysis Transplantation 2020;35:810-8. [DOI: 10.1093/ndt/gfy284] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
315 Kaleda MI, Nikishina IP. CURRENT INTERNATIONAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS. rsp 2018;56:405-415. [DOI: 10.14412/1995-4484-2018-405-415] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
316 Soliman WM, Sherif NM, Ghanima IM, El-Badawy MA. Neutrophil to lymphocyte and platelet to lymphocyte ratios in systemic lupus erythematosus: Relation with disease activity and lupus nephritis. Reumatol Clin (Engl Ed) 2020;16:255-61. [PMID: 30166230 DOI: 10.1016/j.reuma.2018.07.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
317 Barber MRW, Hanly JG, Su L, Urowitz MB, St Pierre Y, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Fortin PR, Gladman DD, Sanchez-Guerrero J, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Theriault C, Farewell V, Clarke AE. Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care Res (Hoboken) 2018;70:1294-302. [PMID: 29193883 DOI: 10.1002/acr.23480] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
318 Elalouf O, Keeling SO, Touma Z. Subcutaneous belimumab in the treatment of systemic lupus erythematosus. Immunotherapy 2018;10:1163-73. [PMID: 30105936 DOI: 10.2217/imt-2018-0061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
319 Ayoub I, Nelson J, Rovin BH. Induction Therapy for Lupus Nephritis: the Highlights. Curr Rheumatol Rep 2018;20:60. [PMID: 30109511 DOI: 10.1007/s11926-018-0766-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
320 Nossent J, Raymond W, Kang A, Wong D, Ognjenovic M, Chakera A. The current role for clinical and renal histological findings as predictor for outcome in Australian patients with lupus nephritis. Lupus 2018;27:1838-46. [PMID: 30092734 DOI: 10.1177/0961203318792361] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
321 Kwon OC, Park Y, Lee JS, Oh JS, Kim YG, Lee CK, Yoo B, Hong S. Non-albumin proteinuria as a parameter of tubulointerstitial inflammation in lupus nephritis. Clin Rheumatol 2019;38:235-41. [PMID: 30094751 DOI: 10.1007/s10067-018-4256-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
322 Schwenger V. Was der Rheumatologe vom Nephrologen lernen kann. Z Rheumatol 2018;77:452-459. [DOI: 10.1007/s00393-018-0486-6] [Reference Citation Analysis]
323 Pamfil C, Makowska Z, De Groof A, Tilman G, Babaei S, Galant C, Montigny P, Demoulin N, Jadoul M, Aydin S, Lesche R, McDonald F, Houssiau FA, Lauwerys BR. Intrarenal activation of adaptive immune effectors is associated with tubular damage and impaired renal function in lupus nephritis. Ann Rheum Dis 2018;77:1782-9. [PMID: 30065042 DOI: 10.1136/annrheumdis-2018-213485] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
324 Pefanis A, Williams DS, Skrzypek H, Fung A, Paizis K. A case of ANCA-associated vasculitis presenting de novo in pregnancy, successfully treated with rituximab. Obstet Med 2020;13:41-4. [PMID: 32284732 DOI: 10.1177/1753495X18780853] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
325 Charles N, Chemouny JM, Daugas E. Basophil involvement in lupus nephritis: a basis for innovation in daily care. Nephrology Dialysis Transplantation 2019;34:750-6. [DOI: 10.1093/ndt/gfy245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
326 George J, Sankaramangalam KP, Sinha A, Hari P, Dinda AK, Bagga A. Lupus Nephritis in Indian Children: Flares and Refractory Illness. Indian Pediatr 2018;55:478-81. [DOI: 10.1007/s13312-018-1337-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
327 Misra DP, Sharma A, Agarwal V. Rheumatology science and practice in India. Rheumatol Int 2018;38:1587-600. [PMID: 30022301 DOI: 10.1007/s00296-018-4111-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
328 Mesnyankina AA, Solovyev SK, Aseeva EA, Nasonov EL. THE EFFICIENCY OF BIOLOGICAL THERAPY AND THE FEATURES OF HUMORAL IMMUNITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. rsp 2018;56:302-9. [DOI: 10.14412/1995-4484-2018-302-309] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
329 Balbi GGM, Machado-ribeiro F, Marques CD, Signorelli F, Levy RA. The interplay between tuberculosis and systemic lupus erythematosus. Current Opinion in Rheumatology 2018;30:395-402. [DOI: 10.1097/bor.0000000000000493] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
330 Melderis S, Wiech T, Iking-konert C, Steinmetz OM. Lupusnephritis. Z Rheumatol 2018;77:593-608. [DOI: 10.1007/s00393-018-0496-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
331 Wang CR, Liu MF, Weng CT, Lin WC, Li WT, Tsai HW. Systemic lupus erythematosus-associated diffuse alveolar haemorrhage: a single-centre experience in Han Chinese patients. Scand J Rheumatol 2018;47:392-9. [PMID: 29916287 DOI: 10.1080/03009742.2017.1420817] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
332 van Vollenhoven RF. Genotypes, phenotypes and treatment with immunomodulators in the rheumatic diseases. J Intern Med 2018;284:228-39. [PMID: 29908080 DOI: 10.1111/joim.12800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
333 Wang J, Qi YY, Chen XP, Ma L, Zhang LL, Zhao Y, Wang M. Analysis of clinical risk factors in relapsed patients with class IV lupus nephritis. Exp Ther Med 2018;15:5461-8. [PMID: 29904425 DOI: 10.3892/etm.2018.6130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
334 Tang K, Tseng C, Hsieh T, Chen D. Induction therapy for membranous lupus nephritis: a systematic review and network meta-analysis. Int J Rheum Dis 2018;21:1163-72. [DOI: 10.1111/1756-185x.13321] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
335 Koga T, Umeda M, Endo Y, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Fukui S, Nishino A, Kawashiri S, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Murakami N, Kitajima M, Kawakami A. Effect of a gonadotropin-releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study. Int J Rheum Dis 2018;21:1287-92. [DOI: 10.1111/1756-185x.13318] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
336 Talari K, Anandh U, Patrick A. Lupus Nephritis with Coexistent Antiphospholipid Antibodies Associated Nephropathy: A Case Report and Literature Review. Indian J Nephrol 2018;28:164-6. [PMID: 29861569 DOI: 10.4103/ijn.IJN_204_16] [Reference Citation Analysis]
337 Gergianaki I, Bertsias G. Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner. Front Med (Lausanne) 2018;5:161. [PMID: 29896474 DOI: 10.3389/fmed.2018.00161] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
338 Little J, Parker B, Lunt M, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Buyon J, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, Fortin P, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Sam Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN. Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology (Oxford) 2018;57:677-87. [PMID: 29361147 DOI: 10.1093/rheumatology/kex444] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
339 Katsuno T, Ozaki T, Ozeki T, Hachiya A, Kim H, Kato N, Ishimoto T, Kato S, Kosugi T, Tsuboi N, Mizuno M, Ito Y, Maruyama S. Investigation on the benefits of mycophenolate mofetil and therapeutic drug monitoring in the treatment of Japanese patients with lupus nephritis. Clin Exp Nephrol 2018;22:1341-50. [PMID: 29796823 DOI: 10.1007/s10157-018-1590-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
340 Parodis I, Söder F, Faustini F, Kasza Z, Samuelsson I, Zickert A, Svenungsson E, van Vollenhoven RF, Malmström V, Wermeling F, Gunnarsson I. Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus – distinct roles of BAFF and APRIL. Lupus 2018;27:1470-8. [DOI: 10.1177/0961203318777116] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
341 Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D'Cruz D, Empson B, Griffiths B, Jayne D, Khamashta M, Lightstone L, Norton P, Norton Y, Schreiber K, Isenberg D; British Society for Rheumatology Standards, Audit and Guidelines Working Group. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. Rheumatology (Oxford) 2018;57:14-8. [PMID: 29029296 DOI: 10.1093/rheumatology/kex291] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
342 Obrișcă B, Jurubiță R, Andronesi A, Sorohan B, Achim C, Bobeica R, Gherghiceanu M, Mandache E, Ismail G. Histological predictors of renal outcome in lupus nephritis: the importance of tubulointerstitial lesions and scoring of glomerular lesions. Lupus 2018;27:1455-63. [PMID: 29759047 DOI: 10.1177/0961203318776109] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
343 Wu J, Ma J, Zhang WH, Di W. Management and outcomes of pregnancy with or without lupus nephritis: a systematic review and meta-analysis. Ther Clin Risk Manag 2018;14:885-901. [PMID: 29785115 DOI: 10.2147/TCRM.S160760] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
344 Ren Y, Xie J, Lin F, Luo W, Zhang Z, Mao P, Zhong R, Liang Y, Yang Z. Serum human epididymis protein 4 is a predictor for developing nephritis in patients with systemic lupus erythematosus: A prospective cohort study. Int Immunopharmacol 2018;60:189-93. [PMID: 29747124 DOI: 10.1016/j.intimp.2018.04.048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
345 Moroni G, Vercelloni PG, Quaglini S, Gatto M, Gianfreda D, Sacchi L, Raffiotta F, Zen M, Costantini G, Urban ML, Pieruzzi F, Messa P, Vaglio A, Sinico RA, Doria A. Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis 2018;77:1318-25. [PMID: 29730634 DOI: 10.1136/annrheumdis-2017-212732] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 19.3] [Reference Citation Analysis]
346 Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Okazaki T, Yamada H, Ozaki S, Kawahata K. Renal protective effect of antiplatelet therapy in antiphospholipid antibody-positive lupus nephritis patients without antiphospholipid syndrome. PLoS One 2018;13:e0196172. [PMID: 29723256 DOI: 10.1371/journal.pone.0196172] [Reference Citation Analysis]
347 Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K. Early achievement of deep remission predicts low incidence of renal flare in lupus nephritis class III or IV. Arthritis Res Ther 2018;20:86. [PMID: 29720229 DOI: 10.1186/s13075-018-1576-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
348 Mody PG, Mody GM, Assounga A. The clinical manifestations and response to treatment in South Africans with lupus nephritis. Lupus 2018;27:1207-17. [PMID: 29665754 DOI: 10.1177/0961203318770024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
349 Kondo T, Amano K. Era of steroid sparing in the management of immune-mediated inflammatory diseases. Immunol Med 2018;41:6-11. [PMID: 30938261 DOI: 10.1080/09114300.2018.1451593] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
350 Haag H, Liang T, Avina-Zubieta JA, De Vera MA. How do patients with systemic autoimmune rheumatic disease perceive the use of their medications: a systematic review and thematic synthesis of qualitative research. BMC Rheumatol 2018;2:9. [PMID: 30886960 DOI: 10.1186/s41927-018-0017-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
351 Joo YB, Kang YM, Kim H, Suh C, Kim T, Park Y, Lee J, Lee J, Yoo DH, Bae S, Lee H, Bang S. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil. Int J Rheum Dis 2018;21:1031-9. [DOI: 10.1111/1756-185x.13274] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
352 Jaryal A, Vikrant S. Current status of lupus nephritis. Indian J Med Res 2017;145:167-78. [PMID: 28639592 DOI: 10.4103/ijmr.IJMR_163_16] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
353 Habuka M, Wada Y, Kurosawa Y, Yamamoto S, Tani Y, Ohashi R, Ajioka Y, Nakano M, Narita I. Fatal visceral disseminated varicella zoster infection during initial remission induction therapy in a patient with lupus nephritis and rheumatoid arthritis-possible association with mycophenolate mofetil and high-dose glucocorticoid therapy: a case report. BMC Res Notes 2018;11:165. [PMID: 29506558 DOI: 10.1186/s13104-018-3271-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
354 Yap DYH, Kwan LPY, Ma MKM, Mok MMY, Chan GCW, Chan TM. Preemptive immunosuppressive treatment for asymptomatic serological reactivation may reduce renal flares in patients with lupus nephritis: a cohort study. Nephrology Dialysis Transplantation 2019;34:467-73. [DOI: 10.1093/ndt/gfy024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
355 Lee KS, Kronbichler A, Eisenhut M, Lee KH, Shin JI. Cardiovascular involvement in systemic rheumatic diseases: An integrated view for the treating physicians. Autoimmunity Reviews 2018;17:201-14. [DOI: 10.1016/j.autrev.2017.12.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
356 Mousavi Roknabadi RS, Hadi N, Habib Agahi Z, Rezvan B, Mantegh A. The Association Between Erythrocyte Sedimentation Rate, C3, C4, Anti-dsDNA Levels, and Renal Disease Activity, Based on BILAG Index in Females With Lupus Nephritis. Nephro-Urol Mon 2018;10. [DOI: 10.5812/numonthly.63075] [Reference Citation Analysis]
357 Mehra S, Usdadiya JB, Jain VK, Misra DP, Negi VS. Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study. Rheumatol Int 2018;38:557-68. [DOI: 10.1007/s00296-018-3995-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
358 Jesus D, Rodrigues M, da Silva JAP, Inês L. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis. Lupus 2018;27:1358-62. [DOI: 10.1177/0961203318758508] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
359 Misra DP, Sharma A, Agarwal V. Guidelines for management of rheumatic diseases in developing countries from basics to real-world situation: relevance, need, and processes for development. Rheumatol Int 2018;38:549-56. [PMID: 29445869 DOI: 10.1007/s00296-018-3996-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
360 Tian M, Song X, Dong L, Xin X, Dong J. Systematic evaluation of different doses of cyclophosphamide induction therapy for lupus nephritis. Medicine (Baltimore) 2017;96:e9408. [PMID: 29390559 DOI: 10.1097/MD.0000000000009408] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
361 Alexandre AR, Carreira PL, Isenberg DA. Very delayed lupus nephritis: a report of three cases and literature review. Lupus Sci Med 2018;5:e000241. [PMID: 29387436 DOI: 10.1136/lupus-2017-000241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
362 Horák P, Skácelová M, Vymětal J, Schubertová M. Life threatening manifestations of lupus and antiphospholipid syndrome in internal medicine. Vnitr Lek 2018;64:136-145. [DOI: 10.36290/vnl.2018.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
363 Schrezenmeier E, Jayne D, Dörner T. Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives. J Am Soc Nephrol 2018;29:741-58. [PMID: 29326157 DOI: 10.1681/ASN.2017040367] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
364 Iwata S, Saito K, Hirata S, Ohkubo N, Nakayamada S, Nakano K, Hanami K, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Yoshinari H, Tanaka Y. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus 2017;27:802-11. [DOI: 10.1177/0961203317749047] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
365 Liang N, Zhong Y, Zhou J, Liu B, Lu R, Guan Y, Wang Q, Liang C, He Y, Zhou Y, Song J, Zhou J. Immunosuppressive effects of hydroxychloroquine and artemisinin combination therapy via the nuclear factor-κB signaling pathway in lupus nephritis mice. Exp Ther Med 2018;15:2436-42. [PMID: 29456648 DOI: 10.3892/etm.2018.5708] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
366 Park D, Choi S, Xu H, Kang J, Lee K, Lee JS, Choi Y, Lee S. Chronicity index, especially glomerular sclerosis, is the most powerful predictor of renal response following immunosuppressive treatment in patients with lupus nephritis. Int J Rheum Dis 2018;21:458-67. [DOI: 10.1111/1756-185x.13254] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
367 . High-Risk Pregnancy. 2018. [DOI: 10.1017/9781108349185] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
368 Sun YS, Sun IT, Wang HK, Yang AH, Tsai CY, Huang CJ, Huang DF, Lai CC. Risk of complications of ultrasound-guided renal biopsy for adult and pediatric patients with systemic lupus erythematosus. Lupus 2018;27:828-36. [PMID: 29301470 DOI: 10.1177/0961203317751048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
369 Wang CR, Tsai YS, Li WT. Lupus myocarditis receiving the rituximab therapy-a monocentric retrospective study. Clin Rheumatol. 2018;37:1701-1707. [PMID: 29299707 DOI: 10.1007/s10067-017-3971-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
370 Mansour M, Maria F, Moustapha CM, Ahmed LT, Khodia F, Alex K, Moustapha F, Bakary B, Seynabou D, Niakhaleen K, Aw BM, Ameth D, Lot ML, Abdou N, Boucar D, Fary KEH. Prognostic Aspects of Lupus Nephritis at Aristide Le Dantec University Hospital in Dakar. OJNeph 2018;08:124-132. [DOI: 10.4236/ojneph.2018.84014] [Reference Citation Analysis]
371 Arnaud L, van Vollenhoven R. Specific issues. Advanced Handbook of Systemic Lupus Erythematosus 2018. [DOI: 10.1007/978-3-319-43035-5_7] [Reference Citation Analysis]
372 Cadet MJ. Identification and Management of Lupus Nephritis: An Overview. The Journal for Nurse Practitioners 2018;14:1-6. [DOI: 10.1016/j.nurpra.2017.09.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
373 Moroni G, Gatto M, Raffiotta F, Binda V, Frangou E, Lightstone L, Boumpas DT. Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate. Autoimmunity Reviews 2018;17:11-8. [DOI: 10.1016/j.autrev.2017.11.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
374 Yeoh S, Hua H, Yepes JF, Peterson DE. Oral Manifestations of Systemic Diseases and their Treatments. Contemporary Oral Medicine 2018. [DOI: 10.1007/978-3-319-28100-1_18-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
375 Lightstone L, Doria A, Wilson H, Ward FL, Larosa M, Bargman JM. Can we manage lupus nephritis without chronic corticosteroids administration? Autoimmunity Reviews 2018;17:4-10. [DOI: 10.1016/j.autrev.2017.11.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
376 Phang KF, Cho J, Lee W, Mak A. Glucocorticoid-induced osteoporosis in systemic lupus erythematosus. Rheumatology Practice and Research 2018;3:205990211880251. [DOI: 10.1177/2059902118802510] [Reference Citation Analysis]
377 Iaccarino L, Andreoli L, Bocci EB, Bortoluzzi A, Ceccarelli F, Conti F, De Angelis R, De Marchi G, De Vita S, Di Matteo A, Emmi G, Emmi L, Gatto M, Gerli R, Gerosa M, Govoni M, Larosa M, Meroni PL, Mosca M, Pazzola G, Reggia R, Saccon F, Salvarani C, Tani C, Zen M, Frigo AC, Tincani A, Doria A. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. Journal of Autoimmunity 2018;86:1-8. [DOI: 10.1016/j.jaut.2017.09.004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 15.3] [Reference Citation Analysis]
378 Sahay M, Saivani Y, Ismal K, Vali PS. Mycophenolate versus Cyclophosphamide for Lupus Nephritis. Indian J Nephrol 2018;28:35-40. [PMID: 29515299 DOI: 10.4103/ijn.IJN_2_16] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
379 Szymanik-Grzelak H, Przychodzeń J, Stelmaszczyk-Emmel A, Pańczyk-Tomaszewska M. Thrombotic thrombocytopenic purpura in the course of systemic lupus erythematosus in a 15-year-old girl. Cent Eur J Immunol 2017;42:407-8. [PMID: 29472821 DOI: 10.5114/ceji.2017.72822] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
380 Touma Z, Gladman DD. Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. Lupus Sci Med 2017;4:e000239. [PMID: 29344386 DOI: 10.1136/lupus-2017-000239] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 12.6] [Reference Citation Analysis]
381 Tsujimura S, Adachi T, Saito K, Tanaka Y. Role of P-glycoprotein on CD69+CD4+ cells in the pathogenesis of proliferative lupus nephritis and non-responsiveness to immunosuppressive therapy. RMD Open 2017;3:e000423. [PMID: 29225917 DOI: 10.1136/rmdopen-2016-000423] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
382 Jadot V, Krzesinski JM, Von Frenckell C, Bovy C, Bouquegneau A. [Lupus nephropathy: Insight in new treatments]. Nephrol Ther 2018;14:1-12. [PMID: 29191575 DOI: 10.1016/j.nephro.2017.05.002] [Reference Citation Analysis]
383 Shimizu Y, Yasuda S, Kimura T, Nishio S, Kono M, Ohmura K, Shimamura S, Kono M, Fujieda Y, Kato M, Oku K, Bohgaki T, Fukasawa Y, Tanaka S, Atsumi T. Interferon-inducible Mx1 protein is highly expressed in renal tissues from treatment-naïve lupus nephritis, but not in those under immunosuppressive treatment. Mod Rheumatol 2018;28:661-9. [PMID: 29189089 DOI: 10.1080/14397595.2017.1404711] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
384 Piga M, Floris A, Cappellazzo G, Chessa E, Congia M, Mathieu A, Cauli A. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. Arthritis Res Ther 2017;19:247. [PMID: 29126432 DOI: 10.1186/s13075-017-1451-5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 9.4] [Reference Citation Analysis]
385 Zheng Z, Yu R, Gao C, Jian X, Quan S, Xing G, Liu S, Liu Z. Low copy number of FCGR3B is associated with lupus nephritis in a Chinese population. Exp Ther Med 2017;14:4497-502. [PMID: 29104657 DOI: 10.3892/etm.2017.5069] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
386 Liossis SC, Staveri C. B Cell-Based Treatments in SLE: Past Experience and Current Directions. Curr Rheumatol Rep 2017;19. [DOI: 10.1007/s11926-017-0707-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
387 Mok CC, Tse SM, Chan KL, Ho LY. Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort. Lupus 2018;27:722-7. [PMID: 29087260 DOI: 10.1177/0961203317739129] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
388 Devarapu SK, Kumar Vr S, Rupanagudi KV, Kulkarni OP, Eulberg D, Klussmann S, Anders HJ. Reprint of "Dual blockade of the pro-inflammatory chemokine CCL2 and the homeostatic chemokine CXCL12 is as effective as high dose cyclophosphamide in murine proliferative lupus nephritis". Clin Immunol 2017;185:119-27. [PMID: 29111236 DOI: 10.1016/j.clim.2017.10.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
389 Ikuma D, Hiromura K, Kajiyama H, Suwa J, Ikeuchi H, Sakairi T, Kaneko Y, Maeshima A, Kurosawa H, Hirayama Y, Yokota K, Araki Y, Sato K, Asanuma YF, Akiyama Y, Hara M, Nojima Y, Mimura T. The correlation of urinary podocytes and podocalyxin with histological features of lupus nephritis. Lupus 2018;27:484-93. [PMID: 29050536 DOI: 10.1177/0961203317734918] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
390 Kyttaris VC. Novel Treatments in Lupus. Curr Rheumatol Rep 2017;19:10. [PMID: 28265845 DOI: 10.1007/s11926-017-0638-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
391 Mok CC. Calcineurin inhibitors in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2017;31:429-38. [PMID: 29224682 DOI: 10.1016/j.berh.2017.09.010] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 9.8] [Reference Citation Analysis]
392 Gordon C, Amissah-arthur M, Gayed M, Brown S, Bruce IN, D’cruz D, Empson B, Griffiths B, Jayne D, Khamashta M, Lightstone L, Norton P, Norton Y, Schreiber K, Isenberg D; for the British Society for Rheumatology Standards, Audit and Guidelines Working Group. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology 2018;57:e1-e45. [DOI: 10.1093/rheumatology/kex286] [Cited by in Crossref: 161] [Cited by in F6Publishing: 172] [Article Influence: 32.2] [Reference Citation Analysis]
393 Velásquez-franco CJ, Colina Vargas YA, Pérez SC, Ospina FO, Correa MT, Vargas JM, Zapata-castellanos AL, Rodríguez Padilla LM, Pinto Peñaranda LF, Mesa Navas MA. Clinicopathological relationship in Colombian patients with lupus nephritis. Revista Colombiana de Reumatología 2017;24:211-218. [DOI: 10.1016/j.rcreu.2017.10.001] [Reference Citation Analysis]
394 Velásquez-franco CJ, Colina Vargas YA, Pérez SC, Ospina FO, Correa MT, Vargas JM, Zapata-castellanos AL, Rodríguez Padilla LM, Pinto Peñaranda LF, Mesa Navas MA. Clinicopathological relationship in Colombian patients with lupus nephritis. Revista Colombiana de Reumatología (English Edition) 2017;24:211-218. [DOI: 10.1016/j.rcreue.2017.12.004] [Reference Citation Analysis]
395 Waiser J, Duerr M, Budde K, Rudolph B, Wu K, Bachmann F, Halleck F, Schönemann C, Lachmann N. Treatment of Acute Antibody-Mediated Renal Allograft Rejection With Cyclophosphamide. Transplantation 2017;101:2545-52. [DOI: 10.1097/tp.0000000000001617] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
396 Mehat P, Atiquzzaman M, Esdaile JM, Aviña-zubieta A, De Vera MA. Medication Nonadherence in Systemic Lupus Erythematosus: A Systematic Review. Arthritis Care Res 2017;69:1706-13. [DOI: 10.1002/acr.23191] [Cited by in Crossref: 76] [Cited by in F6Publishing: 80] [Article Influence: 15.2] [Reference Citation Analysis]
397 Campbell NKJ, Saadeldin K, De Vera MA. The Duality of Economic Issues With Medication Non-adherence in Patients With Inflammatory Arthritis. Curr Rheumatol Rep 2017;19:66. [PMID: 28921409 DOI: 10.1007/s11926-017-0691-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
398 Boneparth A, Radhakrishna SM, Greenbaum LA, Yen E, Okamura DM, Cooper JC, Mason S, Levy DM, Sule SD, Jensen PT, Yildirim-Toruner C, Ardoin SP, Wenderfer SE. Approach to Membranous Lupus Nephritis: A Survey of Pediatric Nephrologists and Pediatric Rheumatologists. J Rheumatol 2017;44:1619-23. [PMID: 28916546 DOI: 10.3899/jrheum.170502] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
399 Kasitanon N, Boripatkosol P, Louthrenoo W. Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria. Int J Rheum Dis 2018;21:200-7. [PMID: 28901731 DOI: 10.1111/1756-185X.13152] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
400 Doria A, Cervera R, Gatto M, Chehab G, Schneider M. The new targeted therapy in systemic lupus erythematosus: Is the glass half-full or half-empty? Autoimmun Rev 2017;16:1119-24. [PMID: 28899802 DOI: 10.1016/j.autrev.2017.09.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
401 Groot N, de Graeff N, Marks SD, Brogan P, Avcin T, Bader-Meunier B, Dolezalova P, Feldman BM, Kone-Paut I, Lahdenne P, McCann L, Özen S, Pilkington CA, Ravelli A, Royen-Kerkhof AV, Uziel Y, Vastert BJ, Wulffraat NM, Beresford MW, Kamphuis S. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis 2017;76:1965-73. [PMID: 28877866 DOI: 10.1136/annrheumdis-2017-211898] [Cited by in Crossref: 71] [Cited by in F6Publishing: 76] [Article Influence: 14.2] [Reference Citation Analysis]
402 Schneider M, Carnarius H, Schlegl T. Partizipative Entscheidungsfindung auch bei komplexen systemischen Autoimmunerkrankungen wie dem systemischen Lupus erythematodes (SLE)? rheuma plus 2017;16:92-103. [DOI: 10.1007/s12688-016-0093-z] [Reference Citation Analysis]
403 Aringer M, Schneider M. [Management of systemic lupus erythematosus]. Internist (Berl) 2016;57:1052-9. [PMID: 27670650 DOI: 10.1007/s00108-016-0135-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
404 Tannor EK, Bates WD, Moosa MR. The clinical relevance of repeat renal biopsies in the management of lupus nephritis: a South African experience. Lupus 2018;27:525-35. [PMID: 28820361 DOI: 10.1177/0961203317726864] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
405 Medina-Rosas J, Su J, Cook RJ, Sabapathy A, Touma Z. Comparison of Spot Urine Protein to Creatinine Ratio to 24-Hour Proteinuria to Identify Important Change Over Time in Proteinuria in Lupus. J Clin Rheumatol 2017;23:301-7. [PMID: 28816766 DOI: 10.1097/RHU.0000000000000557] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
406 Sha H, Wu Y, Fan Y. Utilization of industrial waste as a novel adsorbent: Mono/competitive adsorption of chromium(VI) and nickel(II) using diatomite waste modified by EDTA. Appl Organometal Chem 2018;32:e3977. [DOI: 10.1002/aoc.3977] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
407 Hogan J, Godron A, Baudouin V, Kwon T, Harambat J, Deschênes G, Niel O. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis. Pediatr Nephrol 2018;33:111-6. [DOI: 10.1007/s00467-017-3767-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
408 Chavarot N, Verhelst D, Pardon A, Caudwell V, Mercadal L, Sacchi A, Leonardi C, Le Guern V, Karras A, Daugas E; Groupe Coopératif sur le Lupus Rénal. Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study. Medicine (Baltimore) 2017;96:e7429. [PMID: 28682905 DOI: 10.1097/MD.0000000000007429] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
409 Trotter K, Clark MR, Liarski VM. Overview of pathophysiology and treatment of human lupus nephritis. Curr Opin Rheumatol 2016;28:460-7. [PMID: 27341623 DOI: 10.1097/BOR.0000000000000319] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
410 Takeuchi T, Okada K, Yoshida H, Yagi N. Post-marketing surveillance study of the long-term use of mizoribine for the treatment of lupus nephritis: 2-Year results. Mod Rheumatol 2018;28:85-94. [PMID: 28722500 DOI: 10.1080/14397595.2017.1349573] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
411 Caliskan Y, Torun ES, Tiryaki TO, Oruc A, Ozluk Y, Akgul SU, Temurhan S, Oztop N, Kilicaslan I, Sever MS. Immunosuppressive Treatment in C3 Glomerulopathy: Is it Really Effective? Am J Nephrol 2017;46:96-107. [PMID: 28700996 DOI: 10.1159/000479012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
412 Tektonidou MG, Dasgupta A, Ward MM. Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis. Arthritis Rheumatol 2016;68:1432-41. [PMID: 26815601 DOI: 10.1002/art.39594] [Cited by in Crossref: 218] [Cited by in F6Publishing: 233] [Article Influence: 43.6] [Reference Citation Analysis]
413 Sakai R, Kurasawa T, Nishi E, Kondo T, Okada Y, Shibata A, Nishimura K, Chino K, Okuyama A, Takei H, Nagasawa H, Amano K. Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan. Lupus 2017;27:273-82. [DOI: 10.1177/0961203317719148] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
414 Dall'Era M. Treatment of lupus nephritis: current paradigms and emerging strategies. Curr Opin Rheumatol 2017;29:241-7. [PMID: 28207493 DOI: 10.1097/BOR.0000000000000381] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
415 Yu F, Haas M, Glassock R, Zhao MH. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13:483-495. [PMID: 28669995 DOI: 10.1038/nrneph.2017.85] [Cited by in Crossref: 154] [Cited by in F6Publishing: 164] [Article Influence: 30.8] [Reference Citation Analysis]
416 Yap DY, Tang C, Ma MK, Mok MM, Chan GC, Kwan LP, Chan TM. Longterm Data on Disease Flares in Patients with Proliferative Lupus Nephritis in Recent Years. J Rheumatol 2017;44:1375-83. [DOI: 10.3899/jrheum.170226] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
417 Ngamjanyaporn P, McCarthy EM, Sergeant JC, Reynolds J, Skeoch S, Parker B, Bruce IN. Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey. Lupus Sci Med 2017;4:e000173. [PMID: 29238601 DOI: 10.1136/lupus-2016-000173] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
418 Jourde-Chiche N, Whalen E, Gondouin B, Speake C, Gersuk V, Dussol B, Burtey S, Pascual V, Chaussabel D, Chiche L. Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis. Rheumatology (Oxford) 2017;56:477-87. [PMID: 28031441 DOI: 10.1093/rheumatology/kew439] [Cited by in Crossref: 10] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
419 Apostolopoulos D, Morand EF. It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford) 2017;56:i114-22. [PMID: 28013208 DOI: 10.1093/rheumatology/kew406] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
420 Groot N, de Graeff N, Avcin T, Bader-Meunier B, Brogan P, Dolezalova P, Feldman B, Kone-Paut I, Lahdenne P, Marks SD, McCann L, Ozen S, Pilkington C, Ravelli A, Royen-Kerkhof AV, Uziel Y, Vastert B, Wulffraat N, Kamphuis S, Beresford MW. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis 2017;76:1788-96. [PMID: 28630236 DOI: 10.1136/annrheumdis-2016-210960] [Cited by in Crossref: 96] [Cited by in F6Publishing: 102] [Article Influence: 19.2] [Reference Citation Analysis]
421 Brunner HI, Bennett MR, Gulati G, Abulaban K, Klein-Gitelman MS, Ardoin SP, Tucker LB, Rouster-Stevens KA, Witte D, Ying J, Devarajan P. Urine Biomarkers to Predict Response to Lupus Nephritis Therapy in Children and Young Adults. J Rheumatol 2017;44:1239-48. [PMID: 28620062 DOI: 10.3899/jrheum.161128] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
422 Yung S, Yap DY, Chan TM. Recent advances in the understanding of renal inflammation and fibrosis in lupus nephritis. F1000Res 2017;6:874. [PMID: 28663794 DOI: 10.12688/f1000research.10445.1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
423 Ugolini-Lopes MR, Seguro LPC, Castro MXF, Daffre D, Lopes AC, Borba EF, Bonfá E. Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis? Lupus Sci Med 2017;4:e000213. [PMID: 29238603 DOI: 10.1136/lupus-2017-000213] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 11.4] [Reference Citation Analysis]
424 Ugolini-lopes MR, Criado PR, Parsi K, Kucukkaya RD, Amigo M, Tektonidou MG, Andrade D. Treatment of Non-criteria Manifestations in Antiphospholipid Syndrome. In: Erkan D, Lockshin MD, editors. Antiphospholipid Syndrome. Cham: Springer International Publishing; 2017. pp. 247-66. [DOI: 10.1007/978-3-319-55442-6_13] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
425 Fischer-betz R, Specker C. Pregnancy in systemic lupus erythematosus and antiphospholipid syndrome. Best Practice & Research Clinical Rheumatology 2017;31:397-414. [DOI: 10.1016/j.berh.2017.09.011] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 10.2] [Reference Citation Analysis]
426 Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C, Lazaro E, Iza A, Couzi L, Saenz R, Richez C, Porta S, Blanco P. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev 2017;16:826-32. [PMID: 28564619 DOI: 10.1016/j.autrev.2017.05.017] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 8.4] [Reference Citation Analysis]
427 Collado MV, Dorado E, Rausch S, Gomez G, Khoury M, Zazzetti F, Gargiulo M, Suarez L, Chaparro R, Paira S, Galvan L, Juarez V, Pisoni C, Garcia M, Martinez L, Alvarez A, Alvarez C, Barreira J, Sarano J. Long-term Outcome of Lupus Nephritis Class II in Argentine Patients: An Open Retrospective Analysis. J Clin Rheumatol 2016;22:299-306. [PMID: 27152693 DOI: 10.1097/RHU.0000000000000395] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
428 Abd Rahman AN, Tett SE, Abdul Gafor HA, Mcwhinney BC, Staatz CE. Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis. Eur J Drug Metab Pharmacokinet 2017;42:993-1004. [DOI: 10.1007/s13318-017-0420-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
429 Chen Y, Sun J, Zou K, Yang Y, Liu G. Treatment for lupus nephritis: an overview of systematic reviews and meta-analyses. Rheumatol Int 2017;37:1089-99. [DOI: 10.1007/s00296-017-3733-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
430 Oni L, Beresford MW, Witte D, Chatzitolios A, Sebire N, Abulaban K, Shukla R, Ying J, Brunner HI. Inter-observer variability of the histological classification of lupus glomerulonephritis in children. Lupus 2017;26:1205-11. [PMID: 28478696 DOI: 10.1177/0961203317706558] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
431 Pirone C, Mendoza-Pinto C, van der Windt DA, Parker B, O Sullivan M, Bruce IN. Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review. Semin Arthritis Rheum 2017;47:384-96. [PMID: 28602359 DOI: 10.1016/j.semarthrit.2017.04.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
432 Rijnink EC, Teng YKO, Wilhelmus S, Almekinders M, Wolterbeek R, Cransberg K, Bruijn JA, Bajema IM. Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis. Clin J Am Soc Nephrol 2017;12:734-43. [PMID: 28473317 DOI: 10.2215/CJN.10601016] [Cited by in Crossref: 78] [Cited by in F6Publishing: 83] [Article Influence: 15.6] [Reference Citation Analysis]
433 Chowdhary VR. Broad Concepts in Management of Systemic Lupus Erythematosus. Mayo Clinic Proceedings 2017;92:744-61. [DOI: 10.1016/j.mayocp.2017.02.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
434 Marinaki S, Skalioti C, Boletis J. Glomerular Diseases and Renal Transplantation: Pathogenic Pathways and Evolution of Therapeutic Interventions. Transplant Proc 2017;49:243-52. [PMID: 28219579 DOI: 10.1016/j.transproceed.2016.11.035] [Reference Citation Analysis]
435 Lazaro E, Scherlinger M, Truchetet M, Chiche L, Schaeverbeke T, Blanco P, Richez C. Biotherapies in systemic lupus erythematosus: New targets. Joint Bone Spine 2017;84:267-74. [DOI: 10.1016/j.jbspin.2016.07.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
436 Restrepo-Escobar M, Granda-Carvajal PA, Jaimes F. Systematic review of the literature on reproducibility of the interpretation of renal biopsy in lupus nephritis. Lupus 2017;26:1502-12. [PMID: 28441914 DOI: 10.1177/0961203317706556] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
437 Kleinmann JF, Tubach F, Le Guern V, Mathian A, Richez C, Saadoun D, Sacre K, Sellam J, Seror R, Amoura Z, Andres E, Audia S, Bader-Meunier B, Blaison G, Bonnotte B, Cacoub P, Caillard S, Chiche L, Chosidow O, Costedoat-Chalumeau N, Daien C, Daugas E, Derdèche N, Doria A, Fain O, Fakhouri F, Farge D, Gabay C, Guillo S, Hachulla E, Hajjaj-Hassouni N, Hamidou M, Houssiau FA, Jourde-Chiche N, Koné-Paut I, Ladjouz-Rezig A, Lambotte O, Lipsker D, Mariette X, Martin-Silva N, Martin T, Maurier F, Meckenstock R, Mékinian A, Meyer O, Mohamed S, Morel J, Moulin B, Mulleman D, Papo T, Poindron V, Puéchal X, Punzi L, Quartier P, Sailler L, Smail A, Soubrier M, Sparsa A, Tazi-Mezalek Z, Zakraoui L, Zuily S, Sibilia J, Gottenberg JE. International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmun Rev 2017;16:650-7. [PMID: 28434948 DOI: 10.1016/j.autrev.2017.04.011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
438 Buyon JP, Kim MY, Guerra MM, Lu S, Reeves E, Petri M, Laskin CA, Lockshin MD, Sammaritano LR, Branch DW, Porter TF, Sawitzke A, Merrill JT, Stephenson MD, Cohn E, Salmon JE. Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus. Clin J Am Soc Nephrol. 2017;12:940-946. [PMID: 28400421 DOI: 10.2215/cjn.11431116] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 10.4] [Reference Citation Analysis]
439 Hanaoka H, Kiyokawa T, Iida H, Ishimori K, Takakuwa Y, Okazaki T, Yamada H, Ichikawa D, Shirai S, Koike J, Ozaki S. Comparison of renal response to four different induction therapies in Japanese patients with lupus nephritis class III or IV: A single-centre retrospective study. PLoS One 2017;12:e0175152. [PMID: 28384208 DOI: 10.1371/journal.pone.0175152] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
440 Adamichou C, Bertsias G. Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies. Mediterr J Rheumatol 2017;28:4-12. [PMID: 32185248 DOI: 10.31138/mjr.28.1.4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
441 Choi MY, Barber MR, Barber CE, Clarke AE, Fritzler MJ. Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care. Lupus 2016;25:838-49. [PMID: 27252260 DOI: 10.1177/0961203316640367] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
442 Aparicio-soto M, Sánchez-hidalgo M, Alarcón-de-la-lastra C. An update on diet and nutritional factors in systemic lupus erythematosus management. Nutr Res Rev 2017;30:118-37. [DOI: 10.1017/s0954422417000026] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
443 Park DJ, Kang JH, Lee JW, Lee KE, Kim TJ, Park YW, Lee JS, Choi YD, Lee SS. Risk factors to predict the development of chronic kidney disease in patients with lupus nephritis. Lupus 2017;26:1139-48. [DOI: 10.1177/0961203317694257] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
444 Lecapitaine A, Bakir R, Delassus J, Gros H, Bouldouyre M. Lupus systémique : quels patients et quelle prise en charge en Centre Hospitalier Général ? Santé Publique 2017;Vol. 29:47-55. [DOI: 10.3917/spub.171.0047] [Reference Citation Analysis]
445 Tanaka H, Joh K, Imaizumi T. Treatment of pediatric-onset lupus nephritis: a proposal of optimal therapy. Clin Exp Nephrol 2017;21:755-63. [PMID: 28258497 DOI: 10.1007/s10157-017-1381-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
446 Ghasemi E, Heydari A, Sillanpää M. Superparamagnetic Fe3O4@EDTA nanoparticles as an efficient adsorbent for simultaneous removal of Ag(I), Hg(II), Mn(II), Zn(II), Pb(II) and Cd(II) from water and soil environmental samples. Microchemical Journal 2017;131:51-6. [DOI: 10.1016/j.microc.2016.11.011] [Cited by in Crossref: 97] [Cited by in F6Publishing: 98] [Article Influence: 19.4] [Reference Citation Analysis]
447 Zampeli E, Klinman DM, Gershwin ME, Moutsopoulos HM. A comprehensive evaluation for the treatment of lupus nephritis. Journal of Autoimmunity 2017;78:1-10. [DOI: 10.1016/j.jaut.2016.12.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
448 Miller-Hodges E, Dominiczak AF, Jennings GL, Oparil S, Batlle DC, Elijovich F, Basile JN, Laffer CL, Oliveras A, Dhaun N. Hypertension and Its Complications in a Young Man With Autoimmune Disease. Hypertension 2017;69:536-44. [PMID: 28242716 DOI: 10.1161/HYPERTENSIONAHA.117.09036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
449 Imaizumi T, Hayakari R, Matsumiya T, Yoshida H, Tsuruga K, Watanabe S, Kawaguchi S, Tanaka H. Chloroquine attenuates TLR3/IFN-β signaling in cultured normal human mesangial cells: A possible protective effect against renal damage in lupus nephritis. Mod Rheumatol 2017;27:1004-9. [PMID: 28150518 DOI: 10.1080/14397595.2017.1289646] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
450 Basu B, Roy B, Babu BG. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatr Nephrol 2017;32:1013-21. [DOI: 10.1007/s00467-017-3583-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
451 Mendoza-Pinto C, Pirone C, van der Windt DA, Parker B, Bruce IN. Can we identify who gets benefit or harm from mycophenolate mofetil in systemic lupus erythematosus? A systematic review. Semin Arthritis Rheum 2017;47:65-78. [PMID: 28325471 DOI: 10.1016/j.semarthrit.2017.01.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
452 Rubio ER, Lozano F, Díaz SM. Mujer de 26 años con lupus eritematoso sistémico y edemas. Medicine - Programa de Formación Médica Continuada Acreditado 2017;12:1483.e1-1483.e4. [DOI: 10.1016/j.med.2017.01.009] [Reference Citation Analysis]
453 Melchor Díaz S, de los Riscos M, Rabadán Rubio E. Protocolo de manejo terapéutico del lupus eritematoso sistémico. Medicine - Programa de Formación Médica Continuada Acreditado 2017;12:1467-1473. [DOI: 10.1016/j.med.2017.01.006] [Reference Citation Analysis]
454 Pattrakornkul N, Pruangprasert P, Chanthong P, Chawanasuntorapoj R, Pattaragarn A. Subclinical atherosclerosis in young Thai adults with juvenile-onset systemic lupus erythematosus. Asian Biomedicine 2017;10:139-46. [DOI: 10.5372/1905-7415.1002.475] [Reference Citation Analysis]
455 Aguiar R, Araújo C, Martins-coelho G, Isenberg D. Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years: Rituximab in SLE. Arthritis Care & Research 2017;69:257-62. [DOI: 10.1002/acr.22921] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
456 Aringer M, Leuchten N, Fischer-betz R. Ausschleichen und Beenden von immunsuppressiven Therapien: Systemischer Lupus erythematodes. Z Rheumatol 2017;76:27-32. [DOI: 10.1007/s00393-016-0258-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
457 Hanaoka H, Yamada H, Kiyokawa T, Iida H, Suzuki T, Yamasaki Y, Ooka S, Nagafuchi H, Okazaki T, Ichikawa D, Shirai S, Shibagaki Y, Koike J, Ozaki S. Lack of partial renal response by 12 weeks after induction therapy predicts poor renal response and systemic damage accrual in lupus nephritis class III or IV. Arthritis Res Ther 2017;19:4. [PMID: 28086993 DOI: 10.1186/s13075-016-1202-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
458 Moroni G, Ponticelli C. Synthetic pharmacotherapy for lupus nephritis. Expert Opinion on Pharmacotherapy 2016;18:175-86. [DOI: 10.1080/14656566.2016.1276563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
459 Anvari E, Ferreira Provenzano L, Nevares A, Herlitz L, Smith H. Lupus Nephritis (Including Antiphospholipid Antibody Syndrome), Adult. Glomerulonephritis 2017. [DOI: 10.1007/978-3-319-27334-1_14-1] [Reference Citation Analysis]
460 Kyttaris V. Lupus and Lupus Overlap Diseases: Emerging Therapies. Comprehensive Medicinal Chemistry III 2017. [DOI: 10.1016/b978-0-12-409547-2.12403-5] [Reference Citation Analysis]
461 Borgia RE, Bargman JM, Silverman ED. Pediatric Lupus Nephritis. Pediatric Rheumatology 2017. [DOI: 10.1007/978-981-10-1750-6_26] [Reference Citation Analysis]
462 Matos A, Junior AA, Mallmann L, Zarur E, Lima R, Neto ER, Mota G, Annunciato D. RECIDIVA DE NEFRITE LÚPICA EM PACIENTE COM LÚPUS ERITEMATOSO SISTÊMICO COM MANIFESTAÇÕES DE NEFRITE INTERSTICIAL AGUDA. A IMPORTÂNCIA DA BIÓPSIA RENAL. Revista Brasileira de Reumatologia 2017;57:S190-S191. [DOI: 10.1016/j.rbr.2017.07.210] [Reference Citation Analysis]
463 Medeiros A, Janes A, Mallmann L, Júnior AA, Martins L, Neto ER. CONCOMITÂNCIA DE NEFRITE LÚPICA MESANGIAL E MICROANGIOPATIA TROMBÓTICA EM PACIENTE COM LÚPUS ERITEMATOSO SISTÊMICO E SÍNDROME ANTIFOSFOLÍPIDE SECUNDÁRIA. Revista Brasileira de Reumatologia 2017;57:S149. [DOI: 10.1016/j.rbr.2017.07.138] [Reference Citation Analysis]
464 Bertsias G, Fanouriakis A, Boumpas DT. Treatment of Systemic Lupus Erythematosus. Kelley and Firestein's Textbook of Rheumatology. Elsevier; 2017. pp. 1368-1388.e5. [DOI: 10.1016/b978-0-323-31696-5.00081-4] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
465 Quittnat-pelletier FS, Bhasin A, Hladunewich MA. Glomerular Diseases in Pregnancy. Glomerulonephritis 2017. [DOI: 10.1007/978-3-319-27334-1_49-1] [Reference Citation Analysis]
466 Lazaro E, Scherlinger M, Truchetet M, Chiche L, Schaeverbeke T, Blanco P, Richez C. Biothérapies dans le lupus systémique : de nouvelles cibles. Revue du Rhumatisme 2017;84:23-30. [DOI: 10.1016/j.rhum.2016.06.002] [Reference Citation Analysis]
467 Ng Hoi-yan A, Mok CC. Therapeutic Drug Monitoring in Rheumatic Diseases. Hong Kong Bulletin on Rheumatic Diseases 2016;16:33-7. [DOI: 10.1515/hkbrd-2016-0009] [Reference Citation Analysis]
468 Kraaij T, Bredewold OW, Trompet S, Huizinga TW, Rabelink TJ, de Craen AJ, Teng YK. TAC-TIC use of tacrolimus-based regimens in lupus nephritis. Lupus Sci Med 2016;3:e000169. [PMID: 28123768 DOI: 10.1136/lupus-2016-000169] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
469 Thorbinson C, Oni L, Smith E, Midgley A, Beresford MW. Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus. Paediatr Drugs 2016;18:181-95. [PMID: 26971103 DOI: 10.1007/s40272-016-0170-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
470 Zakharova EV, Makarova TA, Zvonova EV, Anilina AM, Stolyarevich ES. Immunosuppressive Treatment for Lupus Nephritis: Long-Term Results in 178 Patients. Biomed Res Int 2016;2016:7407919. [PMID: 28050564 DOI: 10.1155/2016/7407919] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
471 Besouw MT, Vande Walle JG, Ilias MI, Raes AM, Prytula AA, Claeys L, Dehoorne JL. Pediatric lupus nephritis presenting with terminal renal failure. Acta Clin Belg 2016;71:455-7. [PMID: 27169353 DOI: 10.1080/17843286.2016.1159383] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
472 Ward F, Bargman JM. Membranous Lupus Nephritis: The Same, But Different. American Journal of Kidney Diseases 2016;68:954-66. [DOI: 10.1053/j.ajkd.2016.07.026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
473 Kuhn A, Bonsmann G, Anders HJ, Herzer P, Tenbrock K, Schneider M. The Diagnosis and Treatment of Systemic Lupus Erythematosus. Dtsch Arztebl Int 2015;112:423-32. [PMID: 26179016 DOI: 10.3238/arztebl.2015.0423] [Cited by in Crossref: 26] [Cited by in F6Publishing: 61] [Article Influence: 4.3] [Reference Citation Analysis]
474 Schneider M. Pitfalls in lupus. Autoimmunity Reviews 2016;15:1089-93. [DOI: 10.1016/j.autrev.2016.07.033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
475 Houssiau FA, Tamirou F, Nieuwland-husson S, Lauwerys BR. Ce que le rhumatologue doit savoir du lupus. Revue du Rhumatisme 2016;83:A13-A16. [DOI: 10.1016/s1169-8330(16)30198-3] [Reference Citation Analysis]
476 Kondo A, Takahashi K, Mizuno T, Kato A, Hirano D, Yamamoto N, Hayashi H, Koide S, Takahashi H, Hasegawa M, Hiki Y, Yoshida S, Miura K, Yuzawa Y. The Level of IgA Antibodies to Endothelial Cells Correlates with Histological Evidence of Disease Activity in Patients with Lupus Nephritis. PLoS One 2016;11:e0163085. [PMID: 27788140 DOI: 10.1371/journal.pone.0163085] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
477 Scheinberg MA, Hislop CM, Martin RS. Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser. Expert Opin Biol Ther 2016;16:723-33. [PMID: 27051973 DOI: 10.1517/14712598.2016.1169270] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
478 Szymanik-Grzelak H, Kuźma-Mroczkowska E, Małdyk J, Pańczyk-Tomaszewska M. Lupus nephritis in children - 10 years' experience. Cent Eur J Immunol 2016;41:248-54. [PMID: 27833441 DOI: 10.5114/ceji.2016.63123] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
479 Dörner T, Lipsky PE. Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE. Nat Rev Rheumatol 2016;12:645-57. [PMID: 27733759 DOI: 10.1038/nrrheum.2016.158] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 7.8] [Reference Citation Analysis]
480 Sigdel MR, Kafle MP, Shah DS. Outcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center study. BMC Nephrol 2016;17:145. [PMID: 27717323 DOI: 10.1186/s12882-016-0361-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
481 Thakral A, Klein-Gitelman MS. An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus. Rheumatol Ther 2016;3:209-19. [PMID: 27747587 DOI: 10.1007/s40744-016-0044-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
482 Mok CC. Opponent's comments. Nephrol Dial Transplant 2016;31:1571-2. [PMID: 27683731 DOI: 10.1093/ndt/gfw291a] [Reference Citation Analysis]
483 Schneider M, Carnarius H, Schlegl T. Partizipative Entscheidungsfindung auch bei komplexen systemischen Autoimmunerkrankungen wie dem systemischen Lupus erythematodes (SLE)? Z Rheumatol 2017;76:219-27. [DOI: 10.1007/s00393-016-0208-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
484 Coscia LA, Armenti DP, King RW, Sifontis NM, Constantinescu S, Moritz MJ. Update on the Teratogenicity of Maternal Mycophenolate Mofetil. J Pediatr Genet 2015;4:42-55. [PMID: 27617117 DOI: 10.1055/s-0035-1556743] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 8.7] [Reference Citation Analysis]
485 Mok CC. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis. Nephrol Dial Transplant 2016;31:1561-6. [PMID: 27591327 DOI: 10.1093/ndt/gfw289] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
486 Kattah AG, Garovic VD. Pregnancy and Lupus Nephritis. Semin Nephrol 2015;35:487-99. [PMID: 26573551 DOI: 10.1016/j.semnephrol.2015.08.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
487 Boneparth A, Wenderfer SE, Moorthy LN, Radhakrishna SM, Sagcal-Gironella AC, von Scheven E; CARRA Registry investigators. Clinical characteristics of children with membranous lupus nephritis: the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. Lupus 2017;26:299-306. [PMID: 27510603 DOI: 10.1177/0961203316662720] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
488 Tselios K, Gladman DD, Su J, Urowitz MB. Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? A Case-Control Study: ACE Inhibitors/ARBs and CV Protection in Lupus Nephritis. Arthritis Care & Research 2016;68:1497-504. [DOI: 10.1002/acr.22857] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
489 Rao D, Chaudhari NK, Moore RM, Jim B. HELLP syndrome: a diagnostic conundrum with severe complications. BMJ Case Rep 2016;2016:bcr2016216802. [PMID: 27535735 DOI: 10.1136/bcr-2016-216802] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
490 Ayna AB, Ermurat S, Coşkun BN, Harman H, Pehlivan Y. Neutrophil to Lymphocyte Ratio and Mean Platelet Volume as Inflammatory Indicators in Systemic Lupus Erythematosus Nephritis. Arch Rheumatol 2017;32:21-5. [PMID: 30375538 DOI: 10.5606/ArchRheumatol.2017.5886] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
491 Mejía-vilet JM, Córdova-sánchez BM, Uribe-uribe NO, Correa-rotter R. Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population. Clin Rheumatol 2016;35:2219-27. [DOI: 10.1007/s10067-016-3366-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
492 Medina-rosas J, Yap KS, Anderson M, Su J, Touma Z. Utility of Urinary Protein-Creatinine Ratio and Protein Content in a 24-Hour Urine Collection in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis: Assessment of Proteinuria in SLE. Arthritis Care & Research 2016;68:1310-9. [DOI: 10.1002/acr.22828] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
493 Mok CC, Penn HJ, Chan KL, Tse SM, Langman LJ, Jannetto PJ. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis. Arthritis Care Res (Hoboken) 2016;68:1295-302. [PMID: 26749299 DOI: 10.1002/acr.22837] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 9.8] [Reference Citation Analysis]
494 Mok CC. Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus. Expert Review of Clinical Immunology 2016;13:35-41. [DOI: 10.1080/1744666x.2016.1212659] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
495 Devarapu SK, Kumar Vr S, Rupanagudi KV, Kulkarni OP, Eulberg D, Klussmann S, Anders HJ. Dual blockade of the pro-inflammatory chemokine CCL2 and the homeostatic chemokine CXCL12 is as effective as high dose cyclophosphamide in murine proliferative lupus nephritis. Clin Immunol 2016;169:139-47. [PMID: 27392463 DOI: 10.1016/j.clim.2016.07.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
496 Floris A, Piga M, Cauli A, Mathieu A. Predictors of flares in Systemic Lupus Erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. Autoimmunity Reviews 2016;15:656-63. [DOI: 10.1016/j.autrev.2016.02.019] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
497 Martín-gómez MA, Rivera Hernández F, Frutos Sanz MÁ, Trujillo-martín MM. Hot topics in lupus nephropathy: Responses from a new 2015 Spanish guideline. Nefrología (English Edition) 2016;36:333-338. [DOI: 10.1016/j.nefroe.2016.10.004] [Reference Citation Analysis]
498 Martín-gómez MA, Rivera Hernández F, Frutos Sanz MÁ, Trujillo-martín MM. Recomendaciones y sugerencias a 4 preguntas clave en nefropatía lúpica: Extracto de la guía de práctica clínica 2015. Nefrología 2016;36:333-338. [DOI: 10.1016/j.nefro.2016.01.013] [Reference Citation Analysis]
499 Moroni G, Depetri F, Ponticelli C. Lupus nephritis: When and how often to biopsy and what does it mean? J Autoimmun 2016;74:27-40. [PMID: 27349351 DOI: 10.1016/j.jaut.2016.06.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 7.2] [Reference Citation Analysis]
500 Negrini S, Pappalardo F, Murdaca G, Indiveri F, Puppo F. The antiphospholipid syndrome: from pathophysiology to treatment. Clin Exp Med 2017;17:257-67. [PMID: 27334977 DOI: 10.1007/s10238-016-0430-5] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 9.8] [Reference Citation Analysis]
501 Muangchan C, van Vollenhoven RF, Bernatsky SR, Smith CD, Hudson M, Inanç M, Rothfield NF, Nash PT, Furie RA, Senécal JL, Chandran V, Burgos-Vargas R, Ramsey-Goldman R, Pope JE. Treatment Algorithms in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 2015;67:1237-45. [PMID: 25777803 DOI: 10.1002/acr.22589] [Cited by in Crossref: 74] [Cited by in F6Publishing: 76] [Article Influence: 12.3] [Reference Citation Analysis]
502 Parikh SV, Rovin BH. Current and Emerging Therapies for Lupus Nephritis. J Am Soc Nephrol 2016;27:2929-39. [PMID: 27283496 DOI: 10.1681/ASN.2016040415] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 9.5] [Reference Citation Analysis]
503 Haładyj E, Cervera R. Do we still need renal biopsy in lupus nephritis? Reumatologia 2016;54:61-6. [PMID: 27407281 DOI: 10.5114/reum.2016.60214] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
504 Wang Y, Huang X, Cai J, Xie L, Wang W, Tang S, Yin S, Gao X, Zhang J, Zhao J, Huang Y, Li Y, Zhang Y, Zhang J. Clinicopathologic Characteristics and Outcomes of Lupus Nephritis With Antineutrophil Cytoplasmic Antibody: A Retrospective Study. Medicine (Baltimore) 2016;95:e2580. [PMID: 26825903 DOI: 10.1097/MD.0000000000002580] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
505 Endo N, Tsuboi N, Furuhashi K, Shi Y, Du Q, Abe T, Hori M, Imaizumi T, Kim H, Katsuno T, Ozaki T, Kosugi T, Matsuo S, Maruyama S. Urinary soluble CD163 level reflects glomerular inflammation in human lupus nephritis. Nephrol Dial Transplant 2016;31:2023-33. [PMID: 27242373 DOI: 10.1093/ndt/gfw214] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 7.3] [Reference Citation Analysis]
506 Kallenberg CG. Pro: Cyclophosphamide in lupus nephritis. Nephrol Dial Transplant 2016;31:1047-52. [PMID: 27190359 DOI: 10.1093/ndt/gfw069] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
507 Mok CC. Con: Cyclophosphamide for the treatment of lupus nephritis. Nephrol Dial Transplant 2016;31:1053-7. [PMID: 27190358 DOI: 10.1093/ndt/gfw068] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
508 Velo-García A, Ntatsaki E, Isenberg D. The safety of pharmacological treatment options for lupus nephritis. Expert Opin Drug Saf 2016;15:1041-54. [PMID: 27159360 DOI: 10.1080/14740338.2016.1182496] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
509 Chen Y, Gao E, Yang L, Liu X, Li K, Liu Z, Zeng C, Zhang H, Liu Z, Hu W. Long-term outcome of mycophenolate mofetil treatment for patients with microscopic polyangiitis: an observational study in Chinese patients. Rheumatol Int. 2016;36:967-974. [PMID: 27169414 DOI: 10.1007/s00296-016-3492-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
510 Moroni G, Raffiotta F, Ponticelli C. Remission and withdrawal of therapy in lupus nephritis. J Nephrol 2016;29:559-65. [DOI: 10.1007/s40620-016-0313-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
511 Hara A, Furuichi K, Yamahana J, Yasuda H, Iwata Y, Sakai N, Shimizu M, Kaneko S, Wada T. Effect of Autoantibodies to Erythropoietin Receptor in Systemic Lupus Erythematosus with Biopsy-proven Lupus Nephritis. J Rheumatol 2016;43:1328-34. [PMID: 27134248 DOI: 10.3899/jrheum.151430] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
512 Ikeuchi H, Hiromura K, Kayakabe K, Tshilela KA, Uchiyama K, Hamatani H, Sakairi T, Kaneko Y, Maeshima A, Nojima Y. Renal outcomes in mixed proliferative and membranous lupus nephritis (Class III/IV + V): A long-term observational study. Modern Rheumatology 2016;26:908-13. [DOI: 10.3109/14397595.2016.1158896] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
513 Koga T, Ichinose K, Tsokos GC. T cells and IL-17 in lupus nephritis. Clin Immunol 2017;185:95-9. [PMID: 27109641 DOI: 10.1016/j.clim.2016.04.010] [Cited by in Crossref: 70] [Cited by in F6Publishing: 73] [Article Influence: 11.7] [Reference Citation Analysis]
514 Yang Z, Zhang Z, Qin B, Wu P, Zhong R, Zhou L, Liang Y. Human Epididymis Protein 4: A Novel Biomarker for Lupus Nephritis and Chronic Kidney Disease in Systemic Lupus Erythematosus. J Clin Lab Anal 2016;30:897-904. [PMID: 27075413 DOI: 10.1002/jcla.21954] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
515 Postal M, Sinicato NA, Appenzeller S, Niewold TB. Drugs in early clinical development for Systemic Lupus Erythematosus. Expert Opin Investig Drugs 2016;25:573-83. [PMID: 26950689 DOI: 10.1517/13543784.2016.1162291] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
516 Oliveira-Santos M, Verani JF, Camacho LA, de Andrade CA, Ferrante-Silva R, Klumb EM. Effectiveness of pharmaceutical care for drug treatment adherence in patients with systemic lupus erythematosus in Rio de Janeiro, Brazil: study protocol for a randomized controlled trial. Trials 2016;17:181. [PMID: 27038611 DOI: 10.1186/s13063-016-1317-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
517 Restrepo Escobar M, Vanegas-garcía AL, Muñoz Vahos CH, González Naranjo LA, Peñaranda Parada ÉA, Vásquez Duque GM. Study of the agreement between clinical opinion of rheumatologists regarding the need for immunosuppression and the result of renal biopsy in adult patients with lupus nephritis. Revista Colombiana de Reumatología (English Edition) 2016;23:73-78. [DOI: 10.1016/j.rcreue.2016.07.001] [Reference Citation Analysis]
518 Haladyj E, Mejía JC, Cervera R. ¿Sigue siendo necesaria la biopsia renal en la nefropatía lúpica? Revista Colombiana de Reumatología 2016;23:69-72. [DOI: 10.1016/j.rcreu.2016.04.001] [Reference Citation Analysis]
519 Restrepo Escobar M, Vanegas-garcía AL, Muñoz Vahos CH, González Naranjo LA, Peñaranda Parada ÉA, Vásquez Duque GM. Estudio de la concordancia entre la opinión clínica de los reumatólogos con respecto a la necesidad de inmunosupresión y el resultado de la biopsia renal en pacientes adultos con nefritis lúpica. Revista Colombiana de Reumatología 2016;23:73-78. [DOI: 10.1016/j.rcreu.2016.02.005] [Reference Citation Analysis]
520 Haladyj E, Mejía JC, Cervera R. Is the renal biopsy still necessary in lupus nephropathy? Revista Colombiana de Reumatología (English Edition) 2016;23:69-72. [DOI: 10.1016/j.rcreue.2016.04.007] [Reference Citation Analysis]
521 Ameh OI, Kengne AP, Jayne D, Bello AK, Hodkinson B, Gcelu A, Okpechi IG. Standard of treatment and outcomes of adults with lupus nephritis in Africa: a systematic review. Lupus 2016;25:1269-77. [PMID: 27013662 DOI: 10.1177/0961203316640915] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
522 Kim K, Bang S, Joo YB, Kim T, Lee H, Kang C, Bae S. Response to Intravenous Cyclophosphamide Treatment for Lupus Nephritis Associated with Polymorphisms in the FCGR2B-FCRLA Locus. J Rheumatol 2016;43:1045-9. [DOI: 10.3899/jrheum.150665] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
523 Jordan N, D'Cruz D. Current and emerging treatment options in the management of lupus. Immunotargets Ther. 2016;5:9-20. [PMID: 27529058 DOI: 10.2147/itt.s40675] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
524 Mok CC. Treat-to-target in systemic lupus erythematosus: are we there yet? Expert Review of Clinical Pharmacology 2016;9:675-80. [DOI: 10.1586/17512433.2016.1146589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
525 Vymetal J, Skacelova M, Smrzova A, Klicova A, Schubertova M, Horak P, Zadrazil J. Emergency situations in rheumatology with a focus on systemic autoimmune diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016;160:20-9. [PMID: 26868300 DOI: 10.5507/bp.2016.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
526 Tselios K, Gladman DD, Su J, Urowitz MB. Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study. J Rheumatol 2016;43:552-8. [DOI: 10.3899/jrheum.150779] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
527 Ding H, Kharboutli M, Saxena R, Wu T. Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis. Clin Exp Immunol 2016;184:11-8. [PMID: 26616478 DOI: 10.1111/cei.12743] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
528 Sawhney S. Childhood Lupus--Diagnosis and Management. Indian J Pediatr 2016;83:146-55. [PMID: 26729224 DOI: 10.1007/s12098-015-1962-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
529 Mok CC. Towards new avenues in the management of lupus glomerulonephritis. Nat Rev Rheumatol. 2016;12:221-234. [PMID: 26729459 DOI: 10.1038/nrrheum.2015.174] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 8.8] [Reference Citation Analysis]
530 Misra R, Gupta R. Biomarkers in lupus nephritis. Int J Rheum Dis 2015;18:219-32. [PMID: 25884459 DOI: 10.1111/1756-185X.12602] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
531 Marks SD, Tullus K. Lupus Nephritis. Pediatric Kidney Disease 2016. [DOI: 10.1007/978-3-662-52972-0_28] [Reference Citation Analysis]
532 Kyttaris VC. New Treatments for Systemic Lupus Erythematosus. Systemic Lupus Erythematosus. Elsevier; 2016. pp. 551-7. [DOI: 10.1016/b978-0-12-801917-7.00064-4] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
533 Pani A, Angioi A, Ferrario F. Lupus Nephritis. Connective Tissue Disease 2016. [DOI: 10.1007/978-3-319-24535-5_8] [Reference Citation Analysis]
534 Laxer RM, Sherry DD, Hashkes PJ. General Principles of Management. Pediatric Rheumatology in Clinical Practice 2016. [DOI: 10.1007/978-3-319-13099-6_2] [Reference Citation Analysis]
535 Houssiau FA. Moving East: the Euro–Lupus Nephritis regimen in Asia. Kidney International 2016;89:25-7. [DOI: 10.1016/j.kint.2015.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
536 Quattrocchio G, Fervenza F, Roccatello D. Conventional Treatment of Systemic Lupus Erythematosus. Connective Tissue Disease 2016. [DOI: 10.1007/978-3-319-24535-5_16] [Reference Citation Analysis]
537 Ünlü O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol 2016;3:75-84. [PMID: 27708976 DOI: 10.5152/eurjrheum.2015.0085] [Cited by in Crossref: 90] [Cited by in F6Publishing: 97] [Article Influence: 12.9] [Reference Citation Analysis]
538 Fanouriakis A, Pamfil C, Sidiropoulos P, Damian L, Flestea A, Gusetu G, Rednic S, Bertsias G, Boumpas DT. Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study. Lupus 2016;25:627-36. [DOI: 10.1177/0961203315622821] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
539 Silva CA, Aikawa NE, Pereira RMR, Campos LMA. Management considerations for childhood-onset systemic lupus erythematosus patients and implications on therapy. Expert Review of Clinical Immunology 2015;12:301-13. [DOI: 10.1586/1744666x.2016.1123621] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
540 Putterman C, Wu A, Reiner-Benaim A, Batty DS Jr, Sanz I, Oates J, Jakobi K, Petri M, Safer P, Gerwien R, Sorek R, Blumenstein Y, Cohen IR. SLE-key(®) rule-out serologic test for excluding the diagnosis of systemic lupus erythematosus: Developing the ImmunArray iCHIP(®). J Immunol Methods 2016;429:1-6. [PMID: 26678162 DOI: 10.1016/j.jim.2015.12.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
541 Mathian A, Jouenne R, Chader D, Cohen-Aubart F, Haroche J, Fadlallah J, Claër L, Musset L, Gorochov G, Amoura Z, Miyara M. Regulatory T Cell Responses to High-Dose Methylprednisolone in Active Systemic Lupus Erythematosus. PLoS One 2015;10:e0143689. [PMID: 26629828 DOI: 10.1371/journal.pone.0143689] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
542 Łuszczyńska P, Pawiński T. Therapeutic Drug Monitoring of Mycophenolic Acid in Lupus Nephritis: A Review of Current Literature. Therapeutic Drug Monitoring 2015;37:711-7. [DOI: 10.1097/ftd.0000000000000223] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
543 Cui L, Wang Y, Gao L, Hu L, Yan L, Wei Q, Du B. EDTA functionalized magnetic graphene oxide for removal of Pb(II), Hg(II) and Cu(II) in water treatment: Adsorption mechanism and separation property. Chemical Engineering Journal 2015;281:1-10. [DOI: 10.1016/j.cej.2015.06.043] [Cited by in Crossref: 457] [Cited by in F6Publishing: 464] [Article Influence: 65.3] [Reference Citation Analysis]
544 Oni L, Thorbinson C, Beresford MW. Juvenile-onset systemic lupus erythematosus: how to diagnose and manage. Paediatrics and Child Health 2015;25:555-560. [DOI: 10.1016/j.paed.2015.07.005] [Reference Citation Analysis]
545 Quintana LF, Jayne D. Sustained remission in lupus nephritis: still a hard road ahead. Nephrol Dial Transplant 2016;31:2011-8. [DOI: 10.1093/ndt/gfv381] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
546 Costa-Reis P, Russo PA, Zhang Z, Colonna L, Maurer K, Gallucci S, Schulz SW, Kiani AN, Petri M, Sullivan KE. The Role of MicroRNAs and Human Epidermal Growth Factor Receptor 2 in Proliferative Lupus Nephritis. Arthritis Rheumatol 2015;67:2415-26. [PMID: 26016809 DOI: 10.1002/art.39219] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
547 Medina-Rosas J, Gladman DD, Su J, Sabapathy A, Urowitz MB, Touma Z. Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus. Arthritis Res Ther 2015;17:296. [PMID: 26497948 DOI: 10.1186/s13075-015-0808-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
548 Tsang-A-Sjoe MW, Bultink IE. Systemic lupus erythematosus: review of synthetic drugs. Expert Opin Pharmacother 2015;16:2793-806. [PMID: 26479437 DOI: 10.1517/14656566.2015.1101448] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
549 Imran TF, Yick F, Verma S, Estiverne C, Ogbonnaya-Odor C, Thiruvarudsothy S, Reddi AS, Kothari N. Lupus nephritis: an update. Clin Exp Nephrol 2016;20:1-13. [PMID: 26471017 DOI: 10.1007/s10157-015-1179-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 5.9] [Reference Citation Analysis]
550 Hannah J, Casian A, D'Cruz D. Tacrolimus use in lupus nephritis: A systematic review and meta-analysis. Autoimmun Rev 2016;15:93-101. [PMID: 26427983 DOI: 10.1016/j.autrev.2015.09.006] [Cited by in Crossref: 88] [Cited by in F6Publishing: 94] [Article Influence: 12.6] [Reference Citation Analysis]
551 Tunnicliffe DJ, Singh-grewal D, Kim S, Craig JC, Tong A. Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus: A Systematic Review of Clinical Practice Guidelines: SLE Treatment Guidelines. Arthritis Care & Research 2015;67:1440-52. [DOI: 10.1002/acr.22591] [Cited by in Crossref: 89] [Cited by in F6Publishing: 95] [Article Influence: 12.7] [Reference Citation Analysis]
552 Mok CC. Mycophenolate mofetil for lupus nephritis: an update. Expert Review of Clinical Immunology 2015;11:1353-64. [DOI: 10.1586/1744666x.2015.1087314] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
553 Sánchez-Marcos C, Hoffman V, Prieto-González S, Hernández-Rodríguez J, Espinosa G. Renal tubular acidosis type IV as a complication of lupus nephritis. Lupus 2016;25:307-9. [PMID: 26345674 DOI: 10.1177/0961203315603143] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
554 Hanly JG, O'Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Fortin P, Gladman DD, Sanchez-Guerrero J, Petri M, Bruce IN, Dooley MA, Ramsey-Goldman R, Aranow C, Alarcón GS, Fessler BJ, Steinsson K, Nived O, Sturfelt GK, Manzi S, Khamashta MA, van Vollenhoven RF, Zoma AA, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Stoll T, Inanc M, Kalunian KC, Kamen DL, Maddison P, Peschken CA, Jacobsen S, Askanase A, Theriault C, Thompson K, Farewell V. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) 2016;55:252-62. [PMID: 26342222 DOI: 10.1093/rheumatology/kev311] [Cited by in Crossref: 241] [Cited by in F6Publishing: 252] [Article Influence: 34.4] [Reference Citation Analysis]
555 Kronbichler A, Brezina B, Quintana LF, Jayne DR. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review. Autoimmun Rev. 2016;15:38-49. [PMID: 26318215 DOI: 10.1016/j.autrev.2015.08.010] [Cited by in Crossref: 72] [Cited by in F6Publishing: 76] [Article Influence: 10.3] [Reference Citation Analysis]
556 Anders HJ, Weidenbusch M, Rovin B. Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicine. Clin Kidney J 2015;8:492-502. [PMID: 26413272 DOI: 10.1093/ckj/sfv072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
557 Watanabe H, Yamanaka R, Sada K, Zeggar S, Katsuyama E, Katsuyama T, Narazaki MT, Tatebe NT, Sugiyama K, Watanabe KS, Wakabayashi H, Kawabata T, Wada J, Makino H. The efficacy of add-on tacrolimus for minor flare in patients with systemic lupus erythematosus: a retrospective study. Lupus 2016;25:54-60. [DOI: 10.1177/0961203315600538] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
558 Schneider M, Haupt M. [Overcoming disease in systemic lupus erythematosus]. Z Rheumatol 2015;74:591-6. [PMID: 26286190 DOI: 10.1007/s00393-014-1556-z] [Reference Citation Analysis]
559 Tanaka Y, Takeuchi T, Miyasaka N, Sumida T, Mimori T, Koike T, Endo K, Mashino N, Yamamoto K. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Mod Rheumatol 2016;26:80-6. [PMID: 26054418 DOI: 10.3109/14397595.2015.1060665] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
560 Mavragani CP, Fragoulis GE, Somarakis G, Drosos A, Tzioufas AG, Moutsopoulos HM. Clinical and laboratory predictors of distinct histopathogical features of lupus nephritis. Medicine (Baltimore) 2015;94:e829. [PMID: 26020385 DOI: 10.1097/MD.0000000000000829] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
561 Selmi C, Generali E, Massarotti M, Bianchi G, Sciré CA. New treatments for inflammatory rheumatic disease. Immunol Res 2014;60:277-88. [PMID: 25381481 DOI: 10.1007/s12026-014-8565-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
562 Roccatello D, Sciascia S, Baldovino S, Rossi D, Alpa M, Naretto C, Di Simone D, Simoncini M, Menegatti E. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessment. Autoimmun Rev 2015;14:1123-30. [PMID: 26244817 DOI: 10.1016/j.autrev.2015.07.017] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 6.0] [Reference Citation Analysis]
563 Rabasco C, Cavero T, Román E, Rojas-Rivera J, Olea T, Espinosa M, Cabello V, Fernández-Juarez G, González F, Ávila A, Baltar JM, Díaz M, Alegre R, Elías S, Antón M, Frutos MA, Pobes A, Blasco M, Martín F, Bernis C, Macías M, Barroso S, de Lorenzo A, Ariceta G, López-Mendoza M, Rivas B, López-Revuelta K, Campistol JM, Mendizábal S, de Córdoba SR, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN). Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 2015;88:1153-60. [PMID: 26221755 DOI: 10.1038/ki.2015.227] [Cited by in Crossref: 97] [Cited by in F6Publishing: 99] [Article Influence: 13.9] [Reference Citation Analysis]
564 Zen M, Iaccarino L, Gatto M, Bettio S, Nalotto L, Ghirardello A, Punzi L, Doria A. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis 2015;74:2117-22. [DOI: 10.1136/annrheumdis-2015-207347] [Cited by in Crossref: 141] [Cited by in F6Publishing: 144] [Article Influence: 20.1] [Reference Citation Analysis]
565 Tselios K, Sarantopoulos A, Gkougkourelas I, Papagianni A, Boura P. Increase of peripheral T regulatory cells during remission induction with cyclophosphamide in active systemic lupus erythematosus. Int J Rheum Dis 2014;17:790-5. [PMID: 25430593 DOI: 10.1111/1756-185X.12500] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
566 Papagiannuli E, Rhodes B, Wallace GR, Gordon C, Murray PI, Denniston AK. Systemic lupus erythematosus: An update for ophthalmologists. Surv Ophthalmol 2016;61:65-82. [PMID: 26197421 DOI: 10.1016/j.survophthal.2015.06.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
567 Hanaoka H, Kuwana M, Takeuchi T. Glomerulomegaly in lupus nephritis: a prognostic marker for renal outcomes. Int J Rheum Dis 2015;18:768-75. [PMID: 26179413 DOI: 10.1111/1756-185X.12682] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
568 de Jesus GR, Mendoza-Pinto C, de Jesus NR, Dos Santos FC, Klumb EM, Carrasco MG, Levy RA. Understanding and Managing Pregnancy in Patients with Lupus. Autoimmune Dis 2015;2015:943490. [PMID: 26246905 DOI: 10.1155/2015/943490] [Cited by in Crossref: 17] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
569 Abd Rahman AN, Tett SE, Abdul Gafor HA, McWhinney BC, Staatz CE. Exposure-effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritis. Br J Clin Pharmacol 2015;80:1064-75. [PMID: 25959850 DOI: 10.1111/bcp.12678] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
570 Espinosa G, Cervera R. Current treatment of antiphospholipid syndrome: lights and shadows. Nat Rev Rheumatol 2015;11:586-96. [PMID: 26122952 DOI: 10.1038/nrrheum.2015.88] [Cited by in Crossref: 83] [Cited by in F6Publishing: 85] [Article Influence: 11.9] [Reference Citation Analysis]
571 Hanaoka H, Kaneko Y, Kuwana M, Takeuchi T. Early achievement of complete renal response predicts good long-term renal outcome and low systemic damage in newly diagnosed lupus nephritis class III or IV. Mod Rheumatol 2015;25:714-8. [PMID: 25563691 DOI: 10.3109/14397595.2014.1003172] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
572 Wenderfer SE, Lane JC, Shatat IF, von Scheven E, Ruth NM. Practice patterns and approach to kidney biopsy in lupus: a collaboration of the Midwest Pediatric Nephrology Consortium and the Childhood Arthritis and Rheumatology Research Alliance. Pediatr Rheumatol Online J 2015;13:26. [PMID: 26087651 DOI: 10.1186/s12969-015-0024-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
573 Tian SY, Feldman BM, Beyene J, Brown PE, Uleryk EM, Silverman ED. Immunosuppressive Therapies for the Maintenance Treatment of Proliferative Lupus Nephritis: A Systematic Review and Network Metaanalysis. J Rheumatol 2015;42:1392-400. [DOI: 10.3899/jrheum.141650] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
574 Morales E, Cánovas J, Cavero T, Auñón P, Gutiérrez E. Afectación renal en las vasculitis, el lupus eritematoso y las enfermedades sistémicas. Medicine - Programa de Formación Médica Continuada Acreditado 2015;11:4902-4913. [DOI: 10.1016/j.med.2015.06.012] [Reference Citation Analysis]
575 De Vriese AS, Fervenza FC. Con: Biomarkers in glomerular diseases: putting the cart before the wheel? Nephrology Dialysis Transplantation 2015;30:885-90. [DOI: 10.1093/ndt/gfv107] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
576 Schwartz N, Goilav B, Putterman C. The pathogenesis, diagnosis and treatment of lupus nephritis. Curr Opin Rheumatol 2014;26:502-9. [PMID: 25014039 DOI: 10.1097/BOR.0000000000000089] [Cited by in Crossref: 80] [Cited by in F6Publishing: 83] [Article Influence: 11.4] [Reference Citation Analysis]
577 Yasuda S, Atsumi T, Shimamura S, Ono K, Hiromura K, Sada K, Mori M, Takei S, Kawaguchi Y, Tamura N, Takasaki Y. Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan. Modern Rheumatology 2015;25:854-7. [DOI: 10.3109/14397595.2015.1031444] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
578 Hashkes PJ. 50 Years Ago in The Journal of Pediatrics: Teratogenic Effect of Azathioprine (Imuran). J Pediatr 2015;166:1139. [PMID: 25919723 DOI: 10.1016/j.jpeds.2014.11.007] [Reference Citation Analysis]
579 Wilhelmus S, Bajema IM, Bertsias GK, Boumpas DT, Gordon C, Lightstone L, Tesar V, Jayne DR. Lupus nephritis management guidelines compared. Nephrol Dial Transplant 2016;31:904-13. [PMID: 25920920 DOI: 10.1093/ndt/gfv102] [Cited by in Crossref: 73] [Cited by in F6Publishing: 82] [Article Influence: 10.4] [Reference Citation Analysis]
580 Schneider M. [Therapeutic strategies for systemic lupus erythematosus]. Z Rheumatol 2015;74:199-205. [PMID: 25854154 DOI: 10.1007/s00393-014-1457-1] [Reference Citation Analysis]
581 Fassbinder T, Saunders U, Mickholz E, Jung E, Becker H, Schlüter B, Jacobi AM. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus. Arthritis Res Ther 2015;17:92. [PMID: 25890338 DOI: 10.1186/s13075-015-0603-8] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 7.3] [Reference Citation Analysis]
582 Hu WX, Chen YH, Bao H, Liu ZZ, Wang SF, Zhang HT, Liu ZH. Glucocorticoid with or without additional immunosuppressant therapy for patients with lupus podocytopathy: a retrospective single-center study. Lupus 2015;24:1067-75. [PMID: 25819933 DOI: 10.1177/0961203315578766] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
583 Arıcı ZS, Batu ED, Ozen S. Reviewing the Recommendations for Lupus in Children. Curr Rheumatol Rep 2015;17. [DOI: 10.1007/s11926-014-0489-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
584 Tamirou F, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Fiehn C, Ayala Guttierez Mdel M, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R, Houssiau FA; MAINTAIN Nephritis Trial Group. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2016;75:526-531. [PMID: 25757867 DOI: 10.1136/annrheumdis-2014-206897] [Cited by in Crossref: 107] [Cited by in F6Publishing: 112] [Article Influence: 15.3] [Reference Citation Analysis]
585 Guettrot-imbert G, Le Guern V, Morel N, Vauthier D, Tsatsaris V, Pannier E, Piette J, Costedoat-chalumeau N. Lupus systémique et syndrome des antiphospholipides : comment prendre en charge la grossesse ? La Revue de Médecine Interne 2015;36:173-81. [DOI: 10.1016/j.revmed.2014.12.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
586 Sarbu MI, Salman-monte TC, Rubio Muñoz P, Lisbona MP, Bernabé MA, Carbonell J. Differences between clinical and laboratory findings in patients with recent diagnosis of SLE according to the positivity of anti-dsDNA by the Crithidia luciliae method. Lupus 2015;24:1198-203. [DOI: 10.1177/0961203315573852] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
587 Ekö SL, van Vollenhoven RF. Rituximab and lupus--a promising pair? Curr Rheumatol Rep 2014;16:444. [PMID: 25074032 DOI: 10.1007/s11926-014-0444-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
588 Carvalho C, Marinho A, Leal B, Bettencourt A, Boleixa D, Almeida I, Farinha F, Costa PP, Vasconcelos C, Silva BM. Association between vitamin D receptor ( VDR ) gene polymorphisms and systemic lupus erythematosus in Portuguese patients. Lupus 2015;24:846-53. [DOI: 10.1177/0961203314566636] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 7.6] [Reference Citation Analysis]
589 Lazaro E, Richez C, Seneschal J. Lupus eritematoso sistémico. EMC - Aparato Locomotor 2015;48:1-17. [DOI: 10.1016/s1286-935x(15)70082-1] [Reference Citation Analysis]
590 Al Maimouni H, Gladman DD, Ibañez D, Urowitz MB. Switching treatment between mycophenolate mofetil and azathioprine in lupus patients: indications and outcomes. Arthritis Care Res (Hoboken) 2014;66:1905-9. [PMID: 24821661 DOI: 10.1002/acr.22364] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
591 Maynard SI, Thadhani RE. Pregnancy and Chronic Kidney Disease. Chronic Renal Disease 2015. [DOI: 10.1016/b978-0-12-411602-3.00066-4] [Reference Citation Analysis]
592 Weinmann-menke J, Sollinger D. Immunsuppressive Therapie der Lupusnephritis. Nephrologe 2015;10:24-30. [DOI: 10.1007/s11560-014-0906-9] [Reference Citation Analysis]
593 Yang YS, Cheon BR, Shim JW, Kim DS, Jung HL, Park MS, Shim JY. Pulmonary hemorrhage as an unusual initial manifestation of systemic lupus erythematosus. Allergy Asthma Respir Dis 2015;3:370. [DOI: 10.4168/aard.2015.3.5.370] [Reference Citation Analysis]
594 Fischer-betz R, Späthling-mestekemper S. Schwangerschaft bei entzündlich rheumatischen Erkrankungen. Weiterbildung Gynäkologie und Geburtshilfe 2015. [DOI: 10.1007/978-3-662-44424-5_11] [Reference Citation Analysis]
595 Klumb EM, Silva CAA, Lanna CCD, Sato EI, Borba EF, Brenol JCT, de Albuquerque EMDN, Monticielo OA, Costallat LTL, Latorre LC, Sauma MDFLDC, Bonfá ESDDO, Ribeiro FM. Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis. Revista Brasileira de Reumatologia (English Edition) 2015;55:1-21. [DOI: 10.1016/j.rbre.2014.09.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
596 Klumb EM, Silva CAA, Lanna CCD, Sato EI, Borba EF, Brenol JCT, Albuquerque EMDND, Monticielo OA, Costallat LTL, Latorre LC, Sauma MDFLDC, Bonfá ESDDO, Ribeiro FM. Consenso da Sociedade Brasileira de Reumatologia para o diagnóstico, manejo e tratamento da nefrite lúpica. Revista Brasileira de Reumatologia 2015;55:1-21. [DOI: 10.1016/j.rbr.2014.09.008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
597 Bertsias G, Fanouriakis AC, Boumpas DT. Systemic lupus erythematosus. Rheumatology 2015. [DOI: 10.1016/b978-0-323-09138-1.00136-4] [Reference Citation Analysis]
598 Mok CC, Ying KY, Yim CW, Siu YP, Tong KH, To CH, Ng WL. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis 2015;75:30-6. [DOI: 10.1136/annrheumdis-2014-206456] [Cited by in Crossref: 131] [Cited by in F6Publishing: 139] [Article Influence: 16.4] [Reference Citation Analysis]
599 Braun S, Ferner M, Kronfeld K, Griese M. Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases. Pediatr Pulmonol 2015;50:410-9. [PMID: 25491573 DOI: 10.1002/ppul.23133] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
600 Moroni G, Ponticelli C. The multifaceted aspects of refractory lupus nephritis. Expert Rev Clin Immunol 2015;11:281-8. [PMID: 25487410 DOI: 10.1586/1744666X.2015.990883] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
601 Abd Rahman AN, Tett SE, Staatz CE. How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease? Clin Pharmacokinet 2014;53:227-45. [PMID: 24327238 DOI: 10.1007/s40262-013-0124-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
602 Aringer M, Smolen JS. Safety of off-label biologicals in systemic lupus erythematosus. Expert Opinion on Drug Safety 2014;14:243-51. [DOI: 10.1517/14740338.2015.986455] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
603 Karras A. [Lupus nephritis: up-to-date]. Rev Med Interne 2015;36:98-106. [PMID: 25443980 DOI: 10.1016/j.revmed.2014.09.006] [Reference Citation Analysis]
604 Chan TM. Treatment of severe lupus nephritis: the new horizon. Nat Rev Nephrol 2015;11:46-61. [DOI: 10.1038/nrneph.2014.215] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 8.5] [Reference Citation Analysis]
605 Karonitsch T, Aringer M. [Biologics in SLE]. Wien Med Wochenschr 2015;165:40-5. [PMID: 25411010 DOI: 10.1007/s10354-014-0322-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
606 Wilhelmus S, Cook HT, Noël LH, Ferrario F, Wolterbeek R, Bruijn JA, Bajema IM. Interobserver agreement on histopathological lesions in class III or IV lupus nephritis. Clin J Am Soc Nephrol 2015;10:47-53. [PMID: 25384443 DOI: 10.2215/CJN.03580414] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
607 Nørgaard JC, Stengaard-Pedersen K, Nørgaard M, de Thurah A. Antimalarials in the treatment of systemic lupus erythematosus: a registry-based cohort study in Denmark. Lupus 2015;24:299-306. [PMID: 25318969 DOI: 10.1177/0961203314555351] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
608 Mochizuki K, Kayakabe K, Hiromura K, Ando M, Sakurai N, Ikeuchi H, Sakairi T, Kaneko Y, Maeshima A, Nojima Y. Successful treatment of severe crescentic lupus nephritis by multi-target therapy using tacrolimus and mycophenolate mofetil. CEN Case Rep 2015;4:126-30. [PMID: 28509085 DOI: 10.1007/s13730-014-0151-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
609 Mackie FE, Kainer G, Adib N, Boros C, Elliott EJ, Fahy R, Munro J, Murray K, Rosenberg A, Wainstein B, Ziegler JB, Singh-grewal D. The national incidence and clinical picture of SLE in children in Australia – a report from the Australian Paediatric Surveillance Unit. Lupus 2015;24:66-73. [DOI: 10.1177/0961203314552118] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
610 Mok CC, Yap DY, Navarra SV, Liu ZH, Zhao MH, Lu L, Takeuchi T, Avihingsanon Y, Yu XQ, Lapid EA, Lugue-Lizardo LR, Sumethkul V, Shen N, Chen SL, Chan TM; Asian Lupus Nephritis Network (ALNN). Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology (Carlton) 2014;19:11-20. [PMID: 23876069 DOI: 10.1111/nep.12136] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 5.8] [Reference Citation Analysis]
611 Zabotti A, Baraldo M, Quartuccio L, Sacco S, De Marchi G, De Vita S. Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring. Clin Rheumatol 2015;34:171-4. [PMID: 25249327 DOI: 10.1007/s10067-014-2786-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
612 Chen TK, Gelber AC, Witter FR, Petri M, Fine DM. Renal biopsy in the management of lupus nephritis during pregnancy. Lupus 2015;24:147-54. [PMID: 25249595 DOI: 10.1177/0961203314551812] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
613 Tian SY, Feldman BM, Beyene J, Brown PE, Uleryk EM, Silverman ED. Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis. J Rheumatol 2014;41:1998-2007. [PMID: 25225281 DOI: 10.3899/jrheum.140050] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
614 Conti F, Ceccarelli F, Gigante A, Barbano B, Perricone C, Massaro L, Martinelli F, Spinelli FR, Giannakakis K, Valesini G, Cianci R. Ultrasonographic evaluation of renal resistive index in patients with lupus nephritis: correlation with histologic findings. Ultrasound Med Biol 2014;40:2573-80. [PMID: 25220271 DOI: 10.1016/j.ultrasmedbio.2014.06.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
615 Kraaij T, Huizinga TW, Rabelink TJ, Teng YK. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology (Oxford) 2014;53:2122-4. [PMID: 25205827 DOI: 10.1093/rheumatology/keu369] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 6.4] [Reference Citation Analysis]
616 Stokes MB. Classification Systems in Renal Pathology. Surgical Pathology Clinics 2014;7:427-41. [DOI: 10.1016/j.path.2014.04.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
617 Coppo R, Peruzzi L, Amore A, Martino S, Vergano L, Lastauka I, Schieppati A, Noris M, Tovo PA, Remuzzi G. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 2015;30:167-72. [PMID: 25173358 DOI: 10.1007/s00467-014-2944-y] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
618 Rivera F, Mérida E, Illescas ML, López-Rubio E, Frutos MA, García-Frías P, Ramos C, Sierra M, Baltar J, Lucas J, Oliet A, Vigil A, Fernández-Juárez G, Segarra A, Praga M; Glomerular Spanish Glomerular Study Group (GLOSEN). Mycophenolate in refractory and relapsing lupus nephritis. Am J Nephrol 2014;40:105-12. [PMID: 25096639 DOI: 10.1159/000365256] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
619 Zickert A, Sundelin B, Svenungsson E, Gunnarsson I. Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med 2014;1:e000018. [PMID: 25379188 DOI: 10.1136/lupus-2014-000018] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 9.4] [Reference Citation Analysis]
620 Zirkzee EJ, Ndosi ME, Vliet Vlieland TP, Meesters JJ. Measuring educational needs among patients with systemic lupus erythematosus (SLE) using the Dutch version of the Educational Needs Assessment Tool (D-ENAT). Lupus 2014;23:1370-6. [PMID: 25059487 DOI: 10.1177/0961203314544188] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
621 Menke J, Amann K, Cavagna L, Blettner M, Weinmann A, Schwarting A, Kelley VR. Colony-stimulating factor-1: a potential biomarker for lupus nephritis. J Am Soc Nephrol 2015;26:379-89. [PMID: 25012167 DOI: 10.1681/ASN.2013121356] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
622 Yap DY, Ma MK, Mok MM, Kwan LP, Chan GC, Chan TM. Long-term data on tacrolimus treatment in lupus nephritis. Rheumatology (Oxford) 2014;53:2232-7. [PMID: 24996908 DOI: 10.1093/rheumatology/keu265] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
623 Doria A, Gatto M, Zen M, Iaccarino L, Punzi L. Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmunity Reviews 2014;13:770-7. [DOI: 10.1016/j.autrev.2014.01.055] [Cited by in Crossref: 87] [Cited by in F6Publishing: 89] [Article Influence: 10.9] [Reference Citation Analysis]
624 Yap DYH, Chan TM. Treatment of lupus nephritis: practical issues in Asian countries. Int J Rheum Dis 2015;18:138-45. [DOI: 10.1111/1756-185x.12423] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
625 Aggarwal A, Srivastava P. Childhood onset systemic lupus erythematosus: how is it different from adult SLE? Int J Rheum Dis. 2014;Jun 26; Epub ahead of print. [PMID: 24965742 DOI: 10.1111/1756-185x.12419] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
626 Sthoeger Z, Sharabi A, Mozes E. Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus. J Autoimmun 2014;54:60-71. [PMID: 24958634 DOI: 10.1016/j.jaut.2014.06.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
627 Hiepe F. Where is lupus hidden? Presse Med 2014;43:e143-50. [PMID: 24908395 DOI: 10.1016/j.lpm.2014.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
628 Griffin B, Lightstone L. Renoprotective strategies in lupus nephritis: beyond immunosuppression. Lupus 2013;22:1267-73. [PMID: 24097999 DOI: 10.1177/0961203313505927] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
629 Jourde-chiche N, Chiche L, Mancini J, Daniel L, Bardin N, Burtey S, Gondouin B, Dussol B, Harlé J, Hamidou M, Meulders Q, Daugas É. Prise en charge des glomérulonéphrites lupiques prolifératives : enquête de pratique du Groupe coopératif sur le lupus rénal auprès des néphrologues et internistes français. Néphrologie & Thérapeutique 2014;10:170-6. [DOI: 10.1016/j.nephro.2013.11.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
630 Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384:1878-1888. [PMID: 24881804 DOI: 10.1016/s0140-6736(14)60128-8] [Cited by in Crossref: 447] [Cited by in F6Publishing: 472] [Article Influence: 55.9] [Reference Citation Analysis]
631 Kono M, Yasuda S, Kato M, Kanetsuka Y, Kurita T, Fujieda Y, Otomo K, Horita T, Oba K, Kondo M, Mukai M, Yanai M, Fukasawa Y, Atsumi T. Long-term outcome in Japanese patients with lupus nephritis. Lupus 2014;23:1124-32. [PMID: 24860121 DOI: 10.1177/0961203314536246] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
632 Tazi Mezalek Z, Bono W. Challenges for lupus management in emerging countries. Presse Med 2014;43:e209-20. [PMID: 24857588 DOI: 10.1016/j.lpm.2014.04.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
633 Costedoat-Chalumeau N, Dunogué B, Morel N, Le Guern V, Guettrot-Imbert G. Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med 2014;43:e167-80. [PMID: 24855048 DOI: 10.1016/j.lpm.2014.03.007] [Cited by in Crossref: 108] [Cited by in F6Publishing: 94] [Article Influence: 13.5] [Reference Citation Analysis]
634 Yazdany J, Feldman CH, Liu J, Ward MM, Fischer MA, Costenbader KH. Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States. Arthritis Care Res (Hoboken) 2014;66:617-24. [PMID: 24124011 DOI: 10.1002/acr.22182] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
635 van Gelder T, Berden JHM, Berger SP. To TDM or not to TDM in lupus nephritis patients treated with MMF? Nephrology Dialysis Transplantation 2015;30:560-4. [DOI: 10.1093/ndt/gfu184] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
636 Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. Current Opinion in Rheumatology 2014;26:334-40. [DOI: 10.1097/bor.0000000000000054] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 6.6] [Reference Citation Analysis]
637 Fischer-Betz R, Späthling-Mestekemper S. [Pregnancy and inflammatory rheumatic diseases]. Z Rheumatol 2013;72:669-82. [PMID: 23989692 DOI: 10.1007/s00393-013-1223-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
638 Torres-salido MT, Cortes-hernandez J, Vidal X, Pedrosa A, Vilardell-tarres M, Ordi-ros J. Neutrophil gelatinase-associated lipocalin as a biomarker for lupus nephritis. Nephrology Dialysis Transplantation 2014;29:1740-9. [DOI: 10.1093/ndt/gfu062] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
639 Janneck M, Velden J, Iking-Konert C. [Renal diseases in rheumatology]. Z Rheumatol 2013;72:555-68; quiz 569-70. [PMID: 23921983 DOI: 10.1007/s00393-013-1182-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
640 Aringer M, Fischer-Betz R, Hiepe F; Kommission Pharmakotherapie der DGRh., Germany Society of Rheumatology. [Statement on the use of mycophenolate mofetil for systemic lupus erythematosus]. Z Rheumatol 2013;72:575-80. [PMID: 23756593 DOI: 10.1007/s00393-013-1213-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
641 Haridasan S, Sharma A, Rathi M. Treatment of membranous lupus nephritis. Clinical Queries: Nephrology 2014;3:106-113. [DOI: 10.1016/j.cqn.2014.11.003] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
642 Fangtham M, Petri M. 2013 update: Hopkins lupus cohort. Curr Rheumatol Rep 2013;15:360. [PMID: 23888367 DOI: 10.1007/s11926-013-0360-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 5.9] [Reference Citation Analysis]
643 Gasparyan AY, Ayvazyan L, Akazhanov NA, Kitas GD. Conflicts of interest in biomedical publications: considerations for authors, peer reviewers, and editors. Croat Med J 2013;54:600-8. [PMID: 24382859 DOI: 10.3325/cmj.2013.54.600] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
644 Aringer M, Schneider M. Kochrezepte Systemischer Lupus erythematodes. Z Rheumatol 2014;73:496-500. [DOI: 10.1007/s00393-013-1324-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
645 Janneck M, Velden J, Iking-konert C. Renale Erkrankungen in der Rheumatologie. Nephrologe 2014;9:157-172. [DOI: 10.1007/s11560-014-0861-5] [Reference Citation Analysis]
646 Midgley A, Watson L, Beresford MW. New insights into the pathogenesis and management of lupus in children. Arch Dis Child 2014;99:563-7. [PMID: 24585754 DOI: 10.1136/archdischild-2013-304397] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
647 Yap DY, Yung S, Ma MK, Mok MM, Kwan LP, Chan GC, Chan TM. Serum immunoglobulin G level in patients with lupus nephritis and the effect of treatment with corticosteroids and mycophenolate mofetil. Lupus 2014;23:678-83. [PMID: 24554708 DOI: 10.1177/0961203314525248] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
648 Gatto M, Kiss E, Naparstek Y, Doria A. In-/off-label use of biologic therapy in systemic lupus erythematosus. BMC Med 2014;12:30. [PMID: 24528782 DOI: 10.1186/1741-7015-12-30] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
649 Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N, Meroni P, Messa P, Sinico AR. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology (Oxford) 2014;53:1570-7. [PMID: 24505125 DOI: 10.1093/rheumatology/ket462] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 7.5] [Reference Citation Analysis]
650 Tselios K, Koumaras C, Urowitz MB, Gladman DD. Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? A critical appraisal. Seminars in Arthritis and Rheumatism 2014;43:521-5. [DOI: 10.1016/j.semarthrit.2013.07.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
651 Rodriguez-garcia V, Sapeta Dias S, Isenberg D. Recent advances in the treatment of systemic lupus erythematosus. International Journal of Clinical Rheumatology 2014;9:89-100. [DOI: 10.2217/ijr.14.1] [Reference Citation Analysis]
652 Ruiz-irastorza G, Danza A, Perales I, Villar I, Garcia M, Delgado S, Khamashta M. Prednisone in lupus nephritis: How much is enough? Autoimmunity Reviews 2014;13:206-14. [DOI: 10.1016/j.autrev.2013.10.013] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
653 Malattia C, Martini A. Paediatric-onset systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2013;27:351-362. [PMID: 24238692 DOI: 10.1016/j.berh.2013.07.007] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 8.9] [Reference Citation Analysis]
654 Houssiau FA, Lauwerys BR. Current management of lupus nephritis. Best Pract Res Clin Rheumatol 2013;27:319-28. [PMID: 24238689 DOI: 10.1016/j.berh.2013.07.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
655 Rovin BH, Birmingham DJ, Nadasdy T. Systemic Lupus Erythematosus and the Kidney. Core Concepts in Parenchymal Kidney Disease 2014. [DOI: 10.1007/978-1-4614-8166-9_11] [Reference Citation Analysis]
656 Kyttaris VC. Systemic Lupus Erythematosus, Treatment. Encyclopedia of Medical Immunology 2014. [DOI: 10.1007/978-0-387-84828-0_373] [Reference Citation Analysis]
657 Becker MD, Chronopoulos A, Kötter I, Michels S, Pleyer U, Salchow DJ, Thurau S. Therapie: Grundkonzepte. Entzündliche Augenerkrankungen 2014. [DOI: 10.1007/978-3-642-38419-6_6] [Reference Citation Analysis]
658 Takasaki Y. Treatment for Rheumatic Diseases-present and Future. J Jpn Soc Intern Med 2014;103:2391-2394. [DOI: 10.2169/naika.103.2391] [Reference Citation Analysis]
659 Tamura N. 1. Systemic Lupus Erythematosus. J Jpn Soc Intern Med 2014;103:2465-2472. [DOI: 10.2169/naika.103.2465] [Reference Citation Analysis]
660 Atsumi T. 2. Systemic Lupus Erythematosus: Diagnosis and Treatment. J Jpn Soc Intern Med 2014;103:2236-2241. [DOI: 10.2169/naika.103.2236] [Reference Citation Analysis]
661 Marinaki S, Skalioti C, Boletis JN. B cell depletion: rituximab in glomerular disease and transplantation. Nephron Extra 2013;3:125-30. [PMID: 24550930 DOI: 10.1159/000356050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
662 Maneiro JR, Lopez-Canoa N, Salgado E, Gomez-Reino JJ. Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis. Rheumatology (Oxford) 2014;53:834-8. [PMID: 24369416 DOI: 10.1093/rheumatology/ket429] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
663 Mcrae M, Rousseau-gagnon M, Philibert D, Houde I, Riopel J, Latulippe E, De Serres SA. The interpretation of repeat renal biopsies in patients with lupus nephritis. Rheumatology 2014;53:1151-2. [DOI: 10.1093/rheumatology/ket420] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
664 Yap DY, Chan TM. An overview of current and future treatment methods for lupus nephritis. Expert Opinion on Orphan Drugs 2014;2:169-79. [DOI: 10.1517/21678707.2014.871201] [Reference Citation Analysis]
665 Nizard J. Prévention du RCIU vasculaire. Journal de Gynécologie Obstétrique et Biologie de la Reproduction 2013;42:1008-17. [DOI: 10.1016/j.jgyn.2013.09.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
666 Mina-Osorio P, LaStant J, Keirstead N, Whittard T, Ayala J, Stefanova S, Garrido R, Dimaano N, Hilton H, Giron M, Lau KY, Hang J, Postelnek J, Kim Y, Min S, Patel A, Woods J, Ramanujam M, DeMartino J, Narula S, Xu D. Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase. Arthritis Rheum 2013;65:2380-91. [PMID: 23754328 DOI: 10.1002/art.38047] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 6.3] [Reference Citation Analysis]
667 Parikh SV, Nagaraja HN, Hebert L, Rovin BH. Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis. Clin J Am Soc Nephrol 2014;9:279-84. [PMID: 24262502 DOI: 10.2215/CJN.05040513] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 7.3] [Reference Citation Analysis]
668 Du X, Wan X, Cao C. Cyclophosphamide versus mycophenolate mofetil for initial treatment of lupus nephritis. Kidney Int 2013;83:968-9. [PMID: 23633054 DOI: 10.1038/ki.2013.20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
669 Cavallasca JA, Costa CA, Maliandi MDR, Musuruana JL. Hot topics in lupus pregnancy. World J Rheumatol 2013; 3(3): 32-39 [DOI: 10.5499/wjr.v3.i3.32] [Reference Citation Analysis]
670 Kötter I, Henes JC. [Established medications : new areas of application]. Z Rheumatol 2013;72:853-66. [PMID: 24193188 DOI: 10.1007/s00393-013-1137-6] [Reference Citation Analysis]
671 Busch M, Wolf G. Was bringen nephropathologische Klassifikationen für den klinisch tätigen Nephrologen? Nephrologe 2013;8:468-473. [DOI: 10.1007/s11560-012-0723-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
672 Mok CC, Yap DYH, Navarra SV, Liu Z, Zhao M, Lu L, Takeuchi T, Avihingsanon Y, Yu X, Lapid EA, Lugue-lizardo LR, Sumethkul V, Shen N, Chen S, Chan TM; the Asian Lupus Nephritis Network (ALNN). Overview of lupus nephritis management guidelines and perspective from Asia. Int J Rheum Dis 2013;16:625-36. [DOI: 10.1111/1756-185x.12212] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
673 Ikeuchi H, Hiromura K, Takahashi S, Mishima K, Sakurai N, Sakairi T, Kaneko Y, Maeshima A, Kuroiwa T, Nojima Y. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis. Modern Rheumatology 2014;24:618-25. [DOI: 10.3109/14397595.2013.844397] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
674 Alsuwaida AO. The clinical significance of serial kidney biopsies in lupus nephritis. Modern Rheumatology 2013;24:453-6. [DOI: 10.3109/14397595.2013.844293] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
675 Duxbury B, Combescure C, Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus 2013;22:1489-503. [DOI: 10.1177/0961203313509295] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 7.9] [Reference Citation Analysis]
676 Morgan T, Watson L, Mccann L, Beresford M. Children and adolescents with SLE: not just little adults. Lupus 2013;22:1309-19. [DOI: 10.1177/0961203313502863] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
677 Tesar V. Rare transformation in repeat renal biopsies suggests a different pathogenesis of segmental and global lesions in proliferative lupus nephritis. Nephrology Dialysis Transplantation 2013;28:2929-32. [DOI: 10.1093/ndt/gft343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
678 Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Di Bona E, Fattizzo B, Consonni D, Cortelezzi A, Zanella A. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol 2013;91:546-51. [DOI: 10.1111/ejh.12199] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
679 Haas M, Rastaldi MP, Fervenza FC. Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification. Kidney Int. 2014;85:779-793. [PMID: 24088958 DOI: 10.1038/ki.2013.375] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
680 Ines L, Duarte C, Silva RS, Teixeira AS, Fonseca FP, da Silva JAP. Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study. Rheumatology 2013;53:85-9. [DOI: 10.1093/rheumatology/ket322] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
681 Harvey PR, Gordon C. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges. BioDrugs 2013;27:85-95. [PMID: 23456653 DOI: 10.1007/s40259-013-0015-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
682 Inda-Filho A, Neugarten J, Putterman C, Broder A. Improving outcomes in patients with lupus and end-stage renal disease. Semin Dial 2013;26:590-6. [PMID: 24004337 DOI: 10.1111/sdi.12122] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
683 Tedeschi B, Arnaud L, Hie M, Mathian A, Amoura Z. Successful treatment of combined proliferative and membranous lupus nephritis using a full corticosteroid-free regimen. Ann Rheum Dis 2013;73:474-5. [DOI: 10.1136/annrheumdis-2013-204385] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
684 Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, Houssiau FA, Drappa J, Close D, Maciuca R, Rao K, Shahdad S, Brunetta P. Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study: Ocrelizumab in Lupus Nephritis. Arthritis & Rheumatism 2013;65:2368-79. [DOI: 10.1002/art.38037] [Cited by in Crossref: 206] [Cited by in F6Publishing: 210] [Article Influence: 22.9] [Reference Citation Analysis]
685 Murphy G, Lisnevskaia L, Isenberg D. Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. Lancet 2013;382:809-18. [PMID: 23972423 DOI: 10.1016/S0140-6736(13)60889-2] [Cited by in Crossref: 81] [Cited by in F6Publishing: 85] [Article Influence: 9.0] [Reference Citation Analysis]
686 Wu JY, Yeh KW, Huang JL. Early predictors of outcomes in pediatric lupus nephritis: focus on proliferative lesions. Semin Arthritis Rheum 2014;43:513-20. [PMID: 23972330 DOI: 10.1016/j.semarthrit.2013.07.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
687 Mina R, Brunner HI. Update on differences between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Res Ther 2013;15:218. [PMID: 23998441 DOI: 10.1186/ar4256] [Cited by in Crossref: 85] [Cited by in F6Publishing: 90] [Article Influence: 9.4] [Reference Citation Analysis]
688 Bozzolo EP, Ramirez GA, Bonavida G, Lanzani C, Scotti R, Dell’antonio G, Baldissera E, Canti V, Manfredi AA, Rovere-querini P, Sabbadini MG. Efficacy and toxicity of treatments for nephritis in a series of consecutive lupus patients. Autoimmunity 2013;46:537-46. [DOI: 10.3109/08916934.2013.817560] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
689 Rao V, Bowman S. Latest advances in connective tissue disorders. Ther Adv Musculoskelet Dis. 2013;5:234-249. [PMID: 23904866 DOI: 10.1177/1759720x13480280] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
690 Ruiz-irastorza G, Petri M, Gordon C, Khamashta M. Managing Lupus Nephritis in Pregnant Women: Comment on the Article by Hahn et al. Arthritis Care & Research 2013;65:1391-1392. [DOI: 10.1002/acr.22004] [Reference Citation Analysis]
691 Bennett M, Brunner HI. Biomarkers and updates on pediatrics lupus nephritis. Rheum Dis Clin North Am 2013;39:833-53. [PMID: 24182857 DOI: 10.1016/j.rdc.2013.05.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
692 Korbet SM, Lewis EJ; for the Collaborative Study Group. Severe lupus nephritis: the predictive value of a >=50% reduction in proteinuria at 6 months. Nephrology Dialysis Transplantation 2013;28:2313-8. [DOI: 10.1093/ndt/gft201] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
693 Jourde-chiche N, Chiche L, Mancini J, Daniel L, Bardin N, Burtey S, Gondouin B, Dussol B, Harle J, Hamidou M, Meulders Q, Daugas E. Prise en charge des néphropathies lupiques prolifératives : enquête de pratique auprès des néphrologues et internistes français. La Revue de Médecine Interne 2013;34:A73-A74. [DOI: 10.1016/j.revmed.2013.03.304] [Reference Citation Analysis]
694 Schmaderer C, Heemann U, Moog P. [Update nephrology 2013]. MMW Fortschr Med 2013;155:56-9; quiz 60-1. [PMID: 23951664 DOI: 10.1007/s15006-013-0665-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
695 Rivera F, Illescas ML, López-Rubio E, Fulladosa J, Poveda R, Baltar J, Fernández-Juárez G, Ballarín J, Oliet A, Vigil A, Lucas J, Sierra M, Frutos MA, García-Frías P, Ramos C, Mérida E, Praga M, Segarra A. Mycophenolate as maintenance therapy for lupus nephritis with impaired renal function. Am J Nephrol 2013;37:509-17. [PMID: 23689615 DOI: 10.1159/000350756] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
696 Vachvanichsanong P, McNeil E. Pediatric lupus nephritis: more options, more chances? Lupus 2013;22:545-53. [PMID: 23629826 DOI: 10.1177/0961203313485490] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
697 Sangle SR, Lutalo PM, Davies RJ, Khamashta MA, D’Cruz DP. B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases. J Autoimmun. 2013;43:55-59. [PMID: 23608146 DOI: 10.1016/j.jaut.2013.03.001] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
698 Kronbichler A, Mayer G. Renal involvement in autoimmune connective tissue diseases. BMC Med 2013;11:95. [PMID: 23557013 DOI: 10.1186/1741-7015-11-95] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 7.2] [Reference Citation Analysis]
699 Brummaier T, Pohanka E, Studnicka-Benke A, Pieringer H. Using cyclophosphamide in inflammatory rheumatic diseases. Eur J Intern Med 2013;24:590-6. [PMID: 23528932 DOI: 10.1016/j.ejim.2013.02.008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
700 Tzavara V, Pamfil C, Boumpas DT, Bertsias GK. An update on the management of comorbid conditions in lupus nephritis. Clinical Investigation 2013;3:281-293. [DOI: 10.4155/cli.13.2] [Reference Citation Analysis]
701 Abud-mendoza C. Lupus Nephritis: Advances in the Knowledge of its Immunopathogenesis Without the Expected Therapeutic Success? Reumatología Clínica (English Edition) 2013;9:77-79. [DOI: 10.1016/j.reumae.2013.02.001] [Reference Citation Analysis]
702 Abud-mendoza C. Nefritis lúpica: ¿avances en el conocimiento de su inmunopatogénesis sin los esperables logros terapéuticos? Reumatología Clínica 2013;9:77-79. [DOI: 10.1016/j.reuma.2013.02.001] [Reference Citation Analysis]
703 Hogan J, Appel GB. Update on the treatment of lupus nephritis: . Current Opinion in Nephrology and Hypertension 2013;22:224-30. [DOI: 10.1097/mnh.0b013e32835d921c] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
704 Upadhyaya S. Treatment of lupus nephritis in adult patients. Apollo Medicine 2013;10:85-86. [DOI: 10.1016/j.apme.2013.01.010] [Reference Citation Analysis]
705 Lee S. Survey Results on Diagnosis and Treatment of Lupus Nephritis. J Rheum Dis 2013;20:205. [DOI: 10.4078/jrd.2013.20.4.205] [Reference Citation Analysis]
706 Gómez-Puerta JA, Waikar SS, Solomon DH, Liu J, Alarcón GS, Winkelmayer WC, Costenbader KH. Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal Disease. J Clin Cell Immunol 2013;4:179. [PMID: 24672742 DOI: 10.4172/2155-9899.1000179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
707 Pérez Gómez A, Ruiz Gutiérrez L, Moruno Cruz H, Albarrán Hernández F. Lupus eritematoso sistémico (II). Medicine - Programa de Formación Médica Continuada Acreditado 2013;11:1966-1974. [DOI: 10.1016/s0304-5412(13)70564-x] [Reference Citation Analysis]
708 Bertsias GK, Boumpas DT. WITHDRAWN: Use of mycophenolic acid in lupus nephritis. Clinical Immunology 2013. [DOI: 10.1016/j.clim.2012.12.010] [Reference Citation Analysis]
709 Joo YB, Sung Y, Park Y, Suh C, Shim S, Lee YH, Lee J, Lee H, Cha H, Bae S. Diagnosis and Treatment of Lupus Nephritis: Survey Results on Four Important Issues. J Rheum Dis 2013;20:156. [DOI: 10.4078/jrd.2013.20.3.156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
710 Punaro MG. The treatment of systemic lupus proliferative nephritis. Pediatr Nephrol 2013;28:2069-78. [DOI: 10.1007/s00467-012-2327-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
711 Hiepe F. Lupus nephritis: Transatlantic management recommendations compared. Nat Rev Rheumatol 2012;8:697-8. [PMID: 23147901 DOI: 10.1038/nrrheum.2012.192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
712 Miettunen PM, Pistorio A, Palmisani E, Ravelli A, Silverman E, Oliveira S, Alessio M, Cuttica R, Mihaylova D, Espada G, Pasic S, Insalaco A, Ozen S, Porras O, Sztajnbok F, Lazarevic D, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study. Ann Rheum Dis 2013;72:1503-9. [PMID: 23100607 DOI: 10.1136/annrheumdis-2012-201937] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
713 Rovin BH. Lupus nephritis: guidelines for lupus nephritis--more recommendations than data? Nat Rev Nephrol 2012;8:620-1. [PMID: 23007619 DOI: 10.1038/nrneph.2012.215] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
714 Espinosa G. Guías de práctica clínica en lupus eritematoso sistémico: importancia de su implementación en los sistemas de salud. Revista Colombiana de Reumatología 2012;19:121-123. [DOI: 10.1016/s0121-8123(12)70020-8] [Reference Citation Analysis]